Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

Indicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ☒ No ☐

As of ~~November 9, 2020,~~January 4, 2022, the registrant had ~~133,526,319~~466,522,611 shares of ~~Class 2 Common Stock,~~common stock, $0.0001 par value per share, issued and outstanding.

This Quarterly Report on Form 10-Q for the quarter ended November 30, 2021 (the “Form 10-Q”) contains forward-looking statements within the meaning of safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve risks, uncertainties and assumptions. If the risks or uncertainties ever materialize or the assumptions prove incorrect, our results may differ materially from those expressed or implied by such forward-looking statements. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,”” might,” “plan,” “project,” “will,” “would” ”seek,” or “should,” or the negative or plural of these words or similar expressions or variations are intended to identify such forward-looking statements. Forward-looking statements include, among other things, our beliefs or expectations relating to our future performance, results of operations and financial condition; our strategic initiatives, business strategy, supply chain, brand portfolio and product performance; the COVID-19 pandemic; current or future macroeconomic trends; and future corporate acquisitions and strategic transactions.

Risks and uncertainties that may cause actual results to differ materially from forward-looking statements include: our ability to successfully complete the integration of the businesses of Tilray and Aphria; challenges and uncertainty resulting from the COVID-19 pandemic; the highly regulated environment in which we operate and our dependence on regulatory approvals and licenses; our ability to manage our supply chain effectively; disruption of operations at our cultivation and manufacturing facilities; challenges and uncertainty resulting from the impact of competition; our ability to manage risks associated with our international sales and operations; our ability to successfully develop and commercialize new products; our ability to execute our strategic plan and other initiatives, including our ability to achieve $4 billion of revenue by the end of our fiscal year 2024; our dependency on significant customers, which generate a significant amount of our revenue; input cost inflation; disruptions to information technology systems; pending and future litigation; volatility in our stock; our ability to raise funds; and other risks and matters described in our most recent Annual Report on Form 10-K, this Form 10-Q and our other filings from time to time with the U.S. Securities and Exchange Commission and in our Canadian securities filings.

Forward looking statements are based on information available to us as of the date of this Quarterly Report on Form 10-Q and, while we believe that information provides a reasonable basis for these statements, these statements are inherently uncertain, and investors are cautioned not to unduly rely on these statements. You should not rely upon forward-looking statements or forward-looking information as predictions of future events.

We undertake no obligation to update forward-looking statements to reflect actual results or changes in assumptions or circumstances, except as required by applicable law.

(in thousands of United States dollars, ~~except for share and par value data~~, unaudited)

The accompanying notes are an integral part of these ~~condensed~~ consolidated financial statements.

~~Condensed~~ Consolidated Statements of ~~Net Loss~~Income (Loss) and Comprehensive Loss

(in thousands of United States dollars, except for share and per share data,, unaudited)

Three months ended September 30,

Nine months ended September 30,

2020

2019

2020

2019

Revenue

$
51,406

$
51,101

$
153,922

$
120,043

Cost of sales

Product costs

34,224

35,047

108,616

85,806

Inventory valuation adjustments

13,443

201

36,116

726

Gross profit

3,739

15,853

9,190

33,511

General and administrative expenses

12,665

20,122

49,030

49,618

Sales and marketing expenses

10,000

16,974

40,709

39,161

Research and development expenses

921

2,315

2,831

4,891

Stock-based compensation expenses

8,080

8,644

23,404

22,303

Depreciation and amortization expenses

3,425

3,200

10,353

7,457

Impairment of assets

—

—

58,210

—

Acquisition-related expenses (income), net

—

(13,454
)

—

(6,566
)
Loss from equity method investments

1,420

1,837

4,495

1,837

Operating loss

(32,772
)

(23,785
)

(179,842
)

(85,190
)
Foreign exchange (gain) loss, net

(9,319
)

2,585

5,424

1,153

Change in fair value of warrant liability

(31,913
)

—

51,275

—

Interest expenses, net

10,437

8,680

30,147

26,005

Finance income from ABG

—

(210
)

—

(557
)
Other expense (income), net

(38
)

(1,116
)

4,944

(6,185
)
Loss before income taxes

(1,939
)

(33,724
)

(271,632
)

(105,606
)
Deferred income tax expenses (recoveries)

134

2,432

(4,013
)

(3,987
)
Current income tax expenses (benefit)

243

195

505

402

Net loss

$
(2,316
)

$
(36,351
)

$
(268,124
)

$
(102,021
)
Net loss per share - basic and diluted

(0.02
)

(0.37
)

(2.23
)

(1.05
)
Weighted average shares used in computation of net loss per
share - basic and diluted

129,100,909

98,130,507

120,128,856

96,742,626

Net loss

$
(2,316
)

$
(36,351
)

$
(268,124
)

$
(102,021
)
Foreign currency translation gain (loss), net

2,265

(4,863
)

(7,184
)

(2,414
)
Unrealized gain on available-for-sale debt securities

193

11

154

80

Other comprehensive income (loss)

2,458

(4,852
)

(7,030
)

(2,334
)
Comprehensive income (loss)

$
142

$
(41,203
)

$
(275,154
)

$
(104,355
)

	Three months ended November 30,						Six months ended November 30,
	2021			2020			2021			2020
Net revenue	$	155,153		$	129,459		$	323,176		$	246,949
Cost of goods sold		122,387			94,176			239,455			176,721
Gross profit		32,766			35,283			83,721			70,228
Operating expenses:
General and administrative		33,469			28,273			82,956			54,245
Selling		9,210			6,079			16,642			11,896
Amortization		29,016			4,208			59,755			8,335
Marketing and promotion		7,120			4,252			12,585			9,177
Research and development		515			225			1,300			345
Transaction costs		8,120			18,206			33,699			20,664
Total operating expenses		87,450			61,243			206,937			104,662
Operating loss		(54,684	)		(25,960	)		(123,216	)		(34,434	)
Interest expense, net		(9,940	)		(4,832	)		(20,110	)		(10,568	)
Non-operating income (expense), net		64,750			(72,649	)		113,610			(86,008	)
Income (loss) before income taxes		126			(103,441	)		(29,716	)		(131,010	)
Income taxes (recovery)		(5,671	)		(14,192	)		(909	)		(20,017	)
Net income (loss)	$	5,797		$	(89,249	)	$	(28,807	)	$	(110,993	)
Total net income (loss) attributable to:
Shareholders of Tilray Inc.		(201	)		(99,900	)		(41,850	)		(134,243	)
Non-controlling interests		5,998			10,651			13,043			23,250
Other comprehensive (loss) income, net of tax
Foreign currency translation (loss) gain		(32,367	)		(910	)		(133,139	)		475
Unrealized loss on convertible notes receivable		52			—			(597	)		—
Change in fair value of long-term investments		(16,357	)		—			(16,357	)		—
Total other comprehensive (loss) income, net of tax		(48,672	)		(910	)		(150,093	)		475
Comprehensive loss		(42,875	)		(90,159	)		(178,900	)		(110,518	)
Total comprehensive income (loss) attributable to:
Shareholders of Tilray Inc.		(41,853	)		(100,810	)		(184,923	)		(133,768	)
Non-controlling interests		(1,022	)		10,651			6,023			23,250
Weighted average number of common shares - basic		460,254,275			243,477,655			454,797,598			242,207,388
Weighted average number of common shares - diluted		460,254,275			243,477,655			454,797,598			242,207,388
Net income (loss) per share - basic	$	(0.00	)	$	(0.41	)	$	(0.09	)	$	(0.55	)
Net income (loss) per share - diluted	$	(0.00	)	$	(0.41	)	$	(0.09	)	$	(0.55	)

The accompanying notes are an integral part of these ~~condensed~~ consolidated financial statements.

Common stock

Additional

Accumulated other

Total

Number of
shares

Amount

paid-in
capital

comprehensive (loss)
income

Accumulated
deficit

stockholders' equity
(deficit)

Balance as of December 31, 2018

93,170,867

$
10

$
302,057

$
3,763

$
(108,177
)

$
197,653

Cumulative effect adjustment from transition to ASU 2016-01

—

—

—

803

(803
)

—

Cumulative effect adjustment from transition to ASC 842

—

—

—

—

19

19

Shares issued for Natura acquisition

180,332

—

15,100

—

—

15,100

Shares issued for Manitoba Harvest acquisition

1,209,946

—

96,844

—

—

96,844

Shares issued for ABG Profit Participation Agreement

1,680,214

—

125,097

—

—

125,097

ABG finance receivable, net of finance income of $2,700

—

—

(30,292
)

—

—

(30,292
)
Shares issued under stock-based compensation plans

545,000

—

931

—

—

931

Shares issued for employee compensation

11,868

—

649

—

—

649

Stock-based compensation expenses

—

—

5,736

—

—

5,736

Other comprehensive loss

—

—

—

(456
)

—

(456
)
Net loss

—

—

—

—

(29,369
)

(29,369
)
Balance as of March 31, 2019

96,798,227

$
10

$
516,122

$
4,110

$
(138,330
)

$
381,912

Shares issued under stock-based compensation plans

530,943

—

3,483

—

—

3,483

Shares issued for investment acquisition

28,361

—

70

—

—

70

Stock-based compensation expenses

—

—

7,923

—

—

7,923

Other comprehensive income

—

—

—

2,974

—

2,974

Net loss

—

—

—

—

(36,301
)

(36,301
)
Balance at June 30, 2019

97,357,531

$
10

$
527,598

$
7,084

$
(174,631
)

$
360,061

Shares issued for common stock at-the-market, net of issuance costs

1,344,166

—

37,445

—

—

37,445

Shares issued for Manitoba Harvest acquisition

899,306

—

31,866

—

—

31,866

Shares issued for investments and S&S acquisition

433,338

—

14,438

—

—

14,438

Finance income for receivable for ABG Profit Participation Arrangement

—

—

1,393

—

—

1,393

Shares issued under stock-based compensation plans

237,402

—

2,967

—

—

2,967

Stock-based compensation expense

—

—

8,644

—

—

8,644

Other comprehensive loss

—

—

—

(4,852
)

—

(4,852
)
Net loss

—

—

—

—

(36,351
)

(36,351
)
Balance as of September 30, 2019

100,271,743

$
10

$
624,351

$
2,232

$
(210,982
)

$
415,611

Balance at December 31, 2019

102,781,225

$
11

$
705,671

$
9,719

$
(430,130
)

$
285,271

Proceeds from ABG Profit Participation Arrangement

—

—

1,353

—

—

1,353

Write-off of ABG finance receivable

—

—

28,900

—

(28,900
)

—

Escrow shares released from downstream merger

(7,659
)

—

(151
)

—

—

(151
)
Shares issued for common stock at-the-market, net of issuance costs

2,265,115

—

27,027

—

—

27,027

Shares issued for investments

6,934

—

—

—

—

—

Shares issued under stock-based compensation plans

597,868

—

1,079

—

—

1,079

Stock-based compensation expenses

—

—

7,677

—

—

7,677

Shares issued under registered offering, net of issuance costs

7,250,000

1

19,827

—

—

19,828

Shares issued for exercise of pre-funded warrants

11,750,000

1

49,053

—

—

49,054

Other comprehensive loss

—

—

—

(16,707
)

—

(16,707
)
Net loss

—

—

—

—

(184,123
)

(184,123
)
Balance at March 31, 2020

124,643,483

$
13

$
840,436

$
(6,988
)

$
(643,153
)

$
190,308

Escrow shares released from downstream merger

(42,785
)

—

(378
)

—

—

(378
)
Shares issued for common stock at-the-market, net of issuance costs

447,289

—

3,842

—

—

3,842

Shares issued under stock-based compensation plans

883,425

—

4,536

—

—

4,536

Stock-based compensation expenses

—

—

7,647

—

—

7,647

Other comprehensive income

—

—

—

7,219

—

7,219

Net loss

—

—

—

—

(81,687
)

(81,687
)
Balance at June 30, 2020

125,931,412

13

856,083

231

(724,840
)

131,487

Shares issued for common stock at-the-market, net of issuance costs

6,781,090

—

45,230

—

—

45,230

Shares issued under stock-based compensation plans

375,218

—

286

—

—

286

Stock-based compensation expenses

—

—

8,080

—

—

8,080

Shares issued for contract settlement

202,224

—

1,492

—

—

1,492

Other comprehensive income

—

—

—

2,458

—

2,458

Net loss

—

—

��

—

(2,316
)

(2,316
)
Balance at September 30, 2020

133,289,944

13

911,171

2,689

(727,156
)

186,717

	Number of common shares		Common stock		Additional paid-in capital			Accumulated other comprehensive income (loss)			Accumulated Deficit			Non- controlling interests			Total
Balance at May 31, 2020		240,132,635	$	24	$	1,366,736		$	(5,434	)	$	(113,352	)	$	26,957		$	1,274,931
Share issuance - legal settlement		1,389,884		—		7,018			—			—			—			7,018
Share issuance - options exercised		41,065		—		4			—			—			—			4
Share issuance - RSUs exercised		429,280		—		2,246			—			—			—			2,246
Share-based payments		—		—		1,233			—			—			—			1,233
Comprehensive income (loss) for the period		—		—		—			1,385			(34,343	)		12,599			(20,359	)
Balance at August 31, 2020		241,992,864	$	24	$	1,377,237		$	(4,049	)	$	(147,695	)	$	39,556		$	1,265,073
Share issuance - legal settlement		503,974		—		3,436			—			—			—			3,436
Share issuance - equity financing		14,610,496		2		103,594			—			—			—			103,596
Share issuance - SweetWater acquisition		8,232,810		1		69,189			—			—			—			69,190
Share issuance - options exercised		74,337		—		86			—			—			—			86
Share issuance - RSUs exercised		8,823		—		306			—			—			—			306
Share-based payments		—		—		1,017			—			—			—			1,017
Comprehensive income (loss) for the period		—		—		—			(910	)		(99,900	)		10,651			(90,159	)
Balance at November 30, 2020		265,423,304	$	27	$	1,554,865		$	(4,959	)	$	(247,595	)	$	50,207		$	1,352,545

Balance at May 31, 2021		446,440,641	$	46	$	4,792,406		$	152,668		$	(486,050	)	$	6,243		$	4,465,313
Third party contribution to Superhero Acquisition LP		—		—		—			—			—			52,995			52,995
Share issuance - options exercised		417,489		—		2,756			—			—			—			2,756
Share issuance - RSUs exercised		3,665,337		—		6,661			—			—			—			6,661
Share-based payments, net		—		—		(5,944	)		—			—			—			(5,944	)
Comprehensive income (loss) for the period		—		—		—			(101,421	)		(41,649	)		7,045			(136,025	)
Balance at August 31, 2021		450,523,467	$	46	$	4,795,879		$	51,247		$	(527,699	)	$	66,283		$	4,385,756
Share issuance - Superhero Acquisition LP		9,817,061		—		117,804			—			—			—			117,804
Share issuance - DDH note		2,677,596		—		28,560			—			—			(28,560	)		—
Share issuance - options exercised		98,044		—		1,939			—			—			—			1,939
Share issuance - RSUs exercised		470,324		—		6,314			—			—			—			6,314
Share-based payments, net		215,901		—		4,051			—			—			—			4,051
Comprehensive income (loss) for the period		—		—		—			(41,652	)		(201	)		(1,022	)		(42,875	)
Balance at November 30, 2021		463,802,393	$	46	$	4,954,547		$	9,595		$	(527,900	)	$	36,701		$	4,472,989

The accompanying notes are an integral part of these ~~condensed~~ consolidated financial statements.

Nine months ended September 30,

2020

2019

Operating activities

Net loss

$
(268,124
)

$
(102,021
)
Adjusted for the following items:

Inventory valuation adjustments

36,116

—

Depreciation and amortization expenses

14,232

10,460

Impairment of assets

58,210

—

Stock-based compensation expenses

23,404

22,303

Change in fair value of warrant liability

51,275

—

Loss from equity method investments

4,495

—

Change in fair value of contingent consideration

—

(17,019
)
Loss from equity investments measured at fair value

1,272

1,572

Loss from sale of investment

65

—

Interest on debt securities

(601
)

—

Deferred taxes

(4,013
)

(3,987
)
Amortization of discount on convertible notes

7,944

7,616

Amortization of transaction costs on Senior Facility

943

—

Foreign currency loss

5,424

—

Accretion related to obligations under finance leases

394

138

Issuance costs on registered offering recorded to net loss

3,953

—

Credit loss expenses

288

—

Provision for sales returns

(188
)

—

Loss on disposal of property and equipment

885

—

Other non-cash items

88

1,755

Changes in non-cash working capital:

Accounts receivable

11,072

(15,019
)
Inventory

(25,476
)

(73,758
)
Prepayments and other current assets

4,263

(54,607
)
Accounts payable

(12,544
)

38,773

Accrued expenses and other current liabilities

(17,863
)

16,539

Net cash used in operating activities

(104,486
)

(167,255
)
Investing activities

Business combinations, net of cash acquired

—

(166,086
)
Investment in ABG Profit Participation Arrangement

—

(33,333
)
Investment in equity method investees and S&S acquisition

—

(14,302
)
Interest receipts on debt securities

146

—

Investment in joint venture with AB InBev

(2,323
)

—

Change in deposits and other assets

(3,148
)

85

Purchases of short-term and other investments

—

(8,486
)
Proceeds from the sale of other investments

437

8,640

Purchases of property and equipment

(39,366
)

(50,421
)
Proceeds from disposal of property and equipment

2,371

—

Purchases of intangible assets

—

(941
)
Net cash used in investing activities

(41,883
)

(264,844
)
Financing activities

Proceeds from at-the-market equity offering, net of costs

75,459

37,445

Proceeds from ABG Profit Participation Arrangement

1,353

3,333

Proceeds from issuance of registered offering, net of issuance costs

85,465

—

Payment of ABG finance liability

(1,500
)

—

Proceeds from exercise of stock options

6,007

4,885

Payment of obligations under finance lease

(309
)

(565
)
Payment on the settlement of stock options

(1,144
)

—

Proceeds from issuance of Senior Facility, net of transaction costs

46,395

—

Repayment of Senior Facility

(1,605
)

—

Net cash provided by financing activities

210,121

45,098

Effect of foreign currency translation on cash and cash equivalents

(5,338
)

(95
)
Cash and cash equivalents

Increase (decrease) in cash and cash equivalents

58,414

(387,096
)
Cash and cash equivalents, beginning of period

96,791

487,255

Cash and cash equivalents, end of period

$
155,205

$
100,159

	For the six months ended November 30,
	2021			2020
Cash used in operating activities:
Net loss	$	(28,807	)	$	(110,993	)
Adjustments for:
Deferred income tax recovery		(11,228	)		(36,175	)
Unrealized foreign exchange (gain) loss		(6,530	)		6,648
Amortization		76,804			23,010
Loss on sale of capital assets		230			—
Inventory valuation write down		12,000			—
Other non-cash items		3,739			(134	)
Stock-based compensation		17,670			8,339
Loss on long-term investments & equity investments		2,197			1,519
Loss (gain) on derivative instruments		(133,436	)		70,342
Loss on contingent consideration		1,682			—
Transaction costs associated with business acquisitions		—			13,897
Change in non-cash working capital:
Accounts receivable		2,734			(28,570	)
Prepaids and other current assets		(6,299	)		(4,019	)
Inventory		3,409			(18,352	)
Accounts payable and accrued liabilities		(44,513	)		20,827
Net cash used in operating activities		(110,348	)		(53,662	)
Cash used in investing activities:
Investment in capital and intangible assets		(23,856	)		(29,863	)
Proceeds from disposal of capital and intangible assets		8,264			6,607
Promissory notes advances		—			(2,419	)
Repayment of notes receivable		—			4,032
Proceeds from disposal of long-term investments and equity investees		—			2,676
Net cash paid on business acquisitions		—			(275,603	)
Net cash used in investing activities		(15,592	)		(294,570	)
Cash (used in) provided by financing activities:
Share capital issued, net of cash issuance costs		—			102,559
Proceeds (payment) from warrants and options exercised		(3,927	)		90
Proceeds from long-term debt		—			1,881
Repayment of long-term debt		(20,779	)		(2,210	)
Repayment of lease liabilities		(3,360	)		(71	)
Increase in bank indebtedness		19			3,689
Net cash (used in) provided by financing activities		(28,047	)		105,938
Effect of foreign exchange on cash and cash equivalents		(2,696	)		29,853
Net decrease in cash and cash equivalents		(156,683	)		(212,441	)
Cash and cash equivalents, beginning of period		488,466			360,646
Cash and cash equivalents, end of period	$	331,783		$	148,205

The accompanying notes are an integral part of these ~~condensed~~ consolidated financial statements.

~~(in thousands of United States dollars, except for shares, warrants, per share amounts and per warrant amounts, unaudited)~~

Tilray, Inc., and its wholly owned subsidiaries (collectively “Tilray”, the “Company”, “we”, ~~“our”,~~ or “us”) is a leading global ~~medical~~cannabis-lifestyle and consumer packaged goods company headquartered in New York, with operations in Canada, the United States, Europe, Australia, New Zealand and Latin America that is changing people’s lives for the better – one person at a time – by inspiring and empowering the worldwide community to live their very best life by providing them with products that meet the needs of their mind, body, and soul and invoke a sense of wellbeing. Tilray’s mission is to be the trusted partner for its patients and consumers by providing them with a cultivated experience and health and wellbeing through high-quality, differentiated brands and innovative products. A pioneer in cannabis research, cultivation ~~processing~~ and distribution, ~~organization,~~Tilray’s production platform supports over 20 brands in over 20 countries, including comprehensive cannabis offerings, hemp-based foods, and ~~is one~~alcoholic beverages.

On April 30, 2021, Tilray acquired all of the ~~leading suppliers~~issued and outstanding common shares of ~~adult-use cannabis~~Aphria Inc. (“Aphria”), an international organization focused on building a global cannabis-lifestyle consumer packaged goods company in ~~Canada. The Company also markets~~addition to its businesses in the marketing and ~~distributes food~~manufacturing beverage alcohol products ~~from hemp seed~~in the United States, and ~~offers~~in the distribution of (non-Cannabis) pharmaceutical products in Germany and Argentina, pursuant to a ~~broad range~~plan of ~~natural and organic hemp based food products and ingredients that are sold through retailers and websites globally.~~arrangement (the “Arrangement”) under the Business Corporations Act (Ontario).

Note 2. Basis of presentation and ~~going concern~~summary of significant accounting policies

The accompanying unaudited ~~condensed~~ consolidated financial statements (the “financial statements”) reflect the accounts of the Company. The financial statements were prepared in accordance with generally accepted accounting principles in the United States of America (“~~U.S.~~ GAAP”) and pursuant to the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information. The information included in this Form 10-Q should be read in conjunction with the audited consolidated financial statements included in the Company’s ~~annual report~~Annual Report on Form 10-K for the year ended ~~December~~May 31, ~~2019~~2021 (the “Annual Financial Statements”). These financial statements reflect all adjustments, which, in the opinion of management, are necessary for a fair presentation of the results for the interim periods presented. Interim results are not necessarily indicative of results for a full year. The Company’s balance sheet in these interim financial statements was derived from the audited Annual Financial Statements but does not contain all of the footnote disclosures from the Annual Financial Statements.

These consolidated financial statements have been prepared on athe going concern basis which assumes that the Company will continue in operation for the foreseeable future and, accordingly, will be able to realize its assets and discharge its liabilities in the normal course of operations as they come ~~due.~~due, under the historical cost convention except for certain financial instruments that are measured at fair value, as detailed in the Company’s accounting policies.

~~For~~As a result of the ~~three~~April 30, 2021 business combination with Aphria, the reported results do not include the results of operations of Tilray and ~~nine months ended September~~its subsidiaries on and prior to April 30, ~~2020,~~2021, in accordance with the ~~Company reported a consolidated net loss of $2,316 and $268,124, and a net loss of $36,351 and $102,021~~accounting treatment applicable to the Arrangement. Accordingly, comparisons between the Company's results for the three and ~~nine months ending September 30, 2019.~~

~~For the nine~~six months ended ~~September~~November 30, ~~2020,~~2021 and prior periods may not be meaningful.

Information about the accounting treatment of the Arrangement including details of the transaction, determination of the total fair value consideration, and allocation of the purchase price, are included in the Company's Annual Report for the year ended May 31, 2021 filed in Form 10-K with the U.S. Securities and Exchange Commission on July 28, 2021 (“Annual Report”).

The purchase price allocation for the Arrangement is open for adjustments and has been allocated based on estimated fair values of the assets acquired and liabilities assumed at the acquisition date. In the event that more information is obtained, the purchase price allocation may change. Any future adjustments to the purchase price allocation, including changes within identifiable intangible assets or estimation uncertainty impacted by market conditions, may impact future net earnings. The purchase price allocation adjustments can be made through the end of the measurement period, which is not to exceed one year from the acquisition date.

Subsidiaries are entities controlled by the Company. Control exists when the Company ~~had cash flows used~~either has a controlling voting interest or is the primary beneficiary of a variable interest entity. The financial statements of subsidiaries are included in ~~operating activities of $104,486 and cash flows used in operating activities of $167,255 for~~ the ~~nine months ended September 30, 2019.~~

~~As at September 30, 2020 and December 31, 2019 the Company had working capital of $171,349 and $166,600, respectively.~~

Current management forecasts and related assumptions support the view that the Company can adequately manage the operational needs of the business with the current cash on hand for the next twelve monthsconsolidated financial statements from the date that control commences until the date that control ceases. A complete list of our subsidiaries that existed prior to our most recent year end is included in the Company's Annual Report for the year ended May 31, 2021 filed in Form 10-K with the U.S. Securities and Exchange Commission on July 28, 2021 (“Annual Report”).

On August 13, 2021, the Company and other unrelated persons formed Superhero Acquisition L.P., a Delaware limited partnership (“SH Acquisition”), for the purpose of acquiring certain senior secured convertible notes in the principal amount of approximately $165.8 million (the “MM Notes”) originally issued by MedMen Enterprises Inc. (“MedMen”) together with certain associated warrants (the “MM Warrants”) to acquire Class B subordinate voting shares of Medmen (the “MedMen Shares”) fromcertain funds affiliated with Gotham Green Partners (the “MM Transaction”). The MM Notes mature onAugust 17, 2028. On August 17, 2021, SH Acquisition completed the MM Transaction and issued 9,817,061 shares of its common stock as partial consideration for the MM Transaction. The balance of the consideration for the MM Transaction was paid in cash by the other unrelated investors of SH Acquisition.

In connection with its issuance of ~~these financial statements.~~9,817,061 shares of its common stock, the Company’s received an interest in SH Acquisition equal to approximately 68% of the interests in SH Acquisition and, therefore, indirectly acquired a right to 68% of the MM Notes and related MM Warrants, which were convertible into approximately 21% of the MedMen Shares outstanding (if such MM Notes and MM Warrants were converted and exercised upon closing the MM Transaction). In addition, interest on the principal amount of the MM Notes shall accrue at an interest rate of LIBOR plus 6%, with a LIBOR floor of 2.5% and, any accrued interest shall be pay-in-kind at a price equal to the trailing 30-day volume weighted average price of the MedMen Shares, as and when such pay-in-kind interest becomes due and payable. SH Acquisition was also granted “top-up” rights enabling it (and its limited partners) to maintain its percentage ownership (on an “as-converted” basis) in the event that MedMen issues equity securities upon conversion of convertible securities that may be issued by MedMen. Tilray’s ability to convert the Notes and exercise the Warrants is dependent upon U.S. federal legalization of cannabis (a “Triggering Event”) or Tilray’s waiver of such requirement as well as any additional regulatory approvals.

Under the SH Acquisition partnership agreement, certain material events described therein require the approval of the Company, received net proceeds of $85,289 ($90,439 of gross proceeds) from its registered equity offering (refer to Note 14). 19,000,000 warrants were issued as part of the offering. All the warrants remain outstanding as of September 30, 2020. The warrants issued contain an anti-dilution provision that was approved byand, upon a ~~vote of the Company’s stockholders at its Annual Meeting held on May 28, 2020. While~~Triggering Event, the Company has the ability to issue securities under its at-the-market program, because warrants from the equity offering remain outstanding as of September 30, 2020, the Company may only issue up to $20,000 in aggregate gross proceeds under its at-the-market offering program at prices less than the exercise priceappoint two of the ~~warrants (currently $5.95 per share)~~three members of the board of directors of the general partner of SH Acquisition. As a result, we consolidated SH Acquisition as a subsidiary of Tilray beginning on August 17, 2021. Additional information about the MM Transaction is included in Note 7 Long-term investments.

Debt securities are classified as available-for-sale and are recorded at fair value and are subject to impairment testing. Other than impairment losses, unrealized gains and losses during the period, net of the related tax effect, are excluded from income and reflected in other comprehensive income (loss), and ~~in no event more than $6,000 per quarter at prices below~~ the exercise price of the warrants, without triggering the warrant’s anti-dilution price protection feature. During the three months ended September 30, 2020, the Company received gross proceeds of $46,153 from shares sold under its at-the-market offering program. All shares were sold at share prices above $5.95 per share.

On February 28, 2020, the Company completed a debt financing under its Senior Facility with maximum aggregate principal amount of $59,600 and borrowed an aggregate principal amount of $49,700. The Senior Facility provided for an additional draw of $9,900. On June 5, 2020, as a result of COVID-19 related financial markets conditions that affected the lender and not because of any material changes to the business of Tilray or its subsidiaries, the lender requested that Tilray withdraw its then outstanding request for the additional draw of $9,900 and entered into an amendment to its Senior Facility which provides for, among other things, interest-only payments for the remainder of its term with all outstanding principal payments due at February 28, 2022 (refer to Note 13).

As of September 30, 2020, the Company had cash and cash equivalents of $155,205. During the last nine months management has implemented a series of cost reduction strategies including headcount reductions and the closure of certain facilities. Currently, management’s forecasts and related assumptions indicate that the Company will remain in compliance with all its debt covenants and, over the next twelve months from the date of issuance of these financial statements, will be able to satisfy all its contractual obligations such as payment of interest on the 5% convertible notes (refer to Note 12 and Note 18), interest-only payments on the Senior Facility (refer to Note 13 and Note 18), non-cancelable minimum purchase commitments for inventory (refer to Note 18), payment of the ABG finance liability (refer to Note 18), payment of the Company’s lease commitments (refer to Note 18) and payment of the Company’s Portugal construction commitments (refer to Note 18). Due to uncertainties the Company may face in raising additional equity financing in the future, which may be further impacted by the economic downturn and unprecedented

~~conditions due to COVID-19, there remains uncertainty about the impact this may have on management’s assumptions used to develop these forecasts.~~ ~~Accordingly, the Company has concluded it~~cumulative effect is probable that it can implement plans that would effectively mitigate the conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern for the next twelve months.

These financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from uncertainty related to the Company’s ability to successfully implement its initiatives. Any such adjustments could be material.

~~The Company lost its emerging growth company status effective December 31, 2019 and therefore~~ reported as a ~~large accelerated filer~~separate component of shareholders’ equity until realized. Upon sale, realized gain and losses are reported in ~~the Annual Financial Statements. As~~net income. Debt securities are impaired when a result, the Company complies with new and revised accounting standards applicable to public companies. In the fourth quarter of 2019, the Company adopted the following accounting pronouncements issued by FASB: ASU 2016-01, Financial Instruments – Overall (Subtopic 825-10): Recognition and Measurement of Financial Assets and Financial Liabilities (“ASU 2016-01”); ASU 2016-02, Leases, codified as ASC 842 (“ASC 842”); ASU 2014-09 Revenue from Contracts with Customers and all subsequent amendments to the ASU, codified as ASC 606 (“ASC 606”); and ASU 2018-07, Compensation – Stock Compensation (Topic 718): Improvements to Nonemployee Share-Based Payment Accounting (“ASU 2018-07”), as described in the Annual Financial Statements, with an effective date of January 1, 2019. The comparative three and nine months ended September 30, 2019 included in the financial statements reflect the new and revised accounting standards and therefore does not mirror the September 30, 2019 interim period condensed consolidated financial statements previously filed. The impact to the statements of net loss and comprehensive loss for the three and nine months ended September 30, 2019 is as follows:

The statement of net loss and comprehensive loss for the three and nine months ended September 30, 2019 was reclassified to conform to the current period’s presentation. In addition, unrelated to the impact of adoption of accounting standards, cost of sales, which was formerly presented as a single line item, is separated between product costs and inventory valuation adjustments. Loss on disposal of property and equipment, formerly presented in other expenses (income) is now presented in general and administrative expenses.

In May 2020, the Company announced its decision to close the High Park Gardens facility in response to its anticipated future product needs and the current economic climate. As a result, the Company adopted an accounting policy for assets held for sale. Assets held for sale are accounted for in accordance with applicable accounting guidance provided in ASC Topic 360, Property, Plant and Equipment.

The Company classifies its assets as held for sale if, among other criteria, the carrying amount will be recovered principally through a sale transaction rather than continued use and a sale is considered probable and within one year. Assets classified as held for sale are measured at the lower of the carrying amount and fair value less costs to sell.

An impairment loss is recognized in impairment of assets through the statements of net loss and comprehensive loss for any initial or subsequent write-down of the asset to fair value less costs to sell. A gain is recognized for any subsequent increasesdecline in fair value ~~less costs~~is determined to ~~sell~~be other-than-temporary. If the cost of an asset, but not in excess of any cumulative impairment loss previously recognized. A gain or loss not previously recognized by the date of the sale of the asset is recognized at the date of derecognition. Assets are not depreciated or amortized while they are classified as held for sale. Interest and other expenses attributable to the liabilities classified as held for sale continue to be recognized.

~~Assets classified as held for sale are combined and presented separately from the other assets in the balance sheets.~~

In June 2016, the FASB issued ASU 2016-13, Financial Instruments - Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. This guidance was subsequently amended by ASU 2018-19, Codification Improvements, ASU 2019-

04, Codification Improvements, ASU 2019-05, Targeted Transition Relief, ASU 2019-10, Effective Dates, and ASU 2019-11, Codification Improvements. These ASUs are referred to collectively as the new guidance on current expected credit loss (“CECL”). As a result of the adoption of the new CECL guidance on January 1, 2020,investment exceeds its fair value, the Company ~~has changed its accounting policy for the allowance for~~evaluates, among other factors, general market conditions, credit ~~losses, as it relates to accounts receivable and available-for-sale~~quality of debt ~~securities. The adoption of the CECL guidance did not have a material impact on the consolidated financial statements at January 1, 2020.~~

Accounts receivable – The Company maintains an allowance for credit losses at an amount sufficient to absorb losses inherent in its accounts receivable portfolio as of the reporting dates based on the projection of expected credit losses.

The Company applies the aging method to estimate the allowance for expected credit losses. The aging method is applied to accounts receivables at the business unit level to reflect shared risk characteristics, such as receivable type, customer type and geographical location. The aging method assigns accounts receivables to a level of delinquency and applies loss rates to each class based on historical loss experience. The Company also considers relevant qualitative and quantitative factors to assess whether historical loss experience should be adjusted to better reflect the risk characteristics of the current classesinstrument issuers, and the ~~expected future loss. This assessment incorporates all available information relevant~~duration and extent to considering the collectability of its current classes, including considering economic and business conditions, default trends, changes in its class composition, among other internal and external factors. The expected credit loss estimates are adjusted for current conditions and reasonable supportable forecasts.

As part of the Company’s analysis of expected credit losses, it may analyze contracts on an individual basis in situations where such accounts receivables exhibit unique risk characteristics and are not expected to experience similar losses to the rest of their class.

~~Available-for-sale debt securities– The Company assesses its available-for-sale debt securities for impairment at each measurement date. When~~which the fair value is less than the amortized cost, the Company assesses whether it intends to sell the security. When it is assessed that the Company will sell the security or the Company will be required to sell before recovery, the difference between thecost. Once a decline in fair value ~~and amortized cost~~is determined to be other-than-temporary, an impairment charge is recorded ~~as an impairment of assets~~ in the statements of net loss and ~~comprehensive loss. When~~a new cost basis for the investment is established. The Company ~~does not intend~~also evaluates whether there is a plan to sell ~~and~~the security or it is ~~not~~ more likely than not that the Company will be required to sell the security before ~~recovery,~~recovery. If neither of the ~~Company assesses whether a~~conditions exist, then only the portion of the ~~unrealized~~impairment loss ~~is a result of a credit loss. The Company recognizes the portion related~~attributable to credit loss ~~as credit loss expenses~~is recorded in ~~general and administrative expenses within~~ the statements of net loss and ~~comprehensive loss and~~ the ~~portion of unrealized loss related to factors other than credit losses~~remaining amount is recorded in other comprehensive ~~loss. The~~income (loss).

Investments in equity securities of entities over which the Company ~~determines~~does not have a controlling financial interest or significant influence are accounted for at fair value. Equity investments without readily determinable fair values are measured at cost with adjustments for observable changes in price or impairments (referred to as the ~~best estimate of~~“measurement alternative”). In applying the ~~present value of cash flows expected to be collected from~~measurement alternative, the ~~available-for-sale debt securities~~Company performs a qualitative assessment on a quarterly basis and recognizes an ~~individual basis based on past events, current conditions and forecasts relevant to the individual securities.~~

In August 2018, the FASB issued ASU 2018-13, Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement (Topic 820) (“ASU 2018-13”). ASU 2018-13 removes (a) the prior requirement to disclose the amount and reason for transfers between Level 1 and Level 2 ofimpairment if there are sufficient indicators that the fair value ~~hierarchy contained~~of the equity investments are less than carrying values. Changes in ~~ASC Topic 820, (b)~~value are recorded in the ~~policy for timing~~statement of ~~transfers between levels,~~net loss and ~~(c)~~comprehensive loss, within the ~~valuation process used for Level 3 fair value measurements. ASU 2018-13 also adds, among other items, a requirement to disclose~~line, “Non-operating income (expense)”.

Investments in entities over which the ~~range and weighted average of significant unobservable inputs used in Level 3 fair value measurements. The~~ Company ~~adopted ASU 2018-13 effective January 1, 2020 and such adoption did~~does not have a ~~material effect on its~~controlling financial ~~statements.~~

~~In March 2020, the Company closed on a registered offering including Class 2 common stock, warrants, and pre-funded warrants (refer to Note 14). Warrants~~interest but has significant influence, are accounted for using the equity method, with the Company’s share of earnings or losses reported in ~~accordance with applicable accounting guidance provided in ASC Topic 815, Derivatives and Hedging – Contracts in Entity's Own Equity (“ASC 815”), as either liabilities~~earnings or aslosses from equity ~~instruments depending~~method investments on the specific terms of the warrant agreement. The Company's warrants are classified as liabilities and are recorded at fair value. The warrants are subject to remeasurement at each balance sheet date until settlement and any change in fair value is recognized as a component of change in fair value of warrant liability in the statements of net loss and comprehensive loss. ~~Transaction costs allocated to warrants that~~Equity method investments are ~~presented as a liability are expensed immediately~~recorded at cost, plus the Company’s share of undistributed earnings or losses, and impairment, if any, within ~~other expenses (income)~~“Interest in equity investees” on the ~~statements of net loss and comprehensive loss.~~

~~Assets held for sale –~~balance sheets. The Company ~~uses a third party real estate agent to assist management~~assesses investments in ~~its determination~~equity method investments when events or circumstances indicate that the carrying amount of the investment may be impaired. If it is determined that the current fair value of an equity method investment is less than the ~~assets held for sale. The Company estimates the fair value by reviewing market data from recent sales of similar properties and determining an implied sale price per acre of land and greenhouse space.~~

Allowance for credit losses – The Company’s projections of expected credit losses are inherently uncertain, and as a result the Company cannot predict with certainty the amount of such losses. Changes in economic conditions, the risk characteristics and composition of the portfolio, bankruptcy laws, and other factors could impact the actual and projected expected credit losses and the

related allowance for credit losses. Actual losses may vary from current estimates. Due to potential COVID-19 disruptions in the marketplace it is possible the Company may experience unforeseen and greater credit losses than anticipated or experienced historically.

~~Warrant liability – The Company estimates the fair~~carrying value of the ~~warrant liability using~~investment, the Company will assess if the shortfall is other than temporary (OTTI). Evidence of a ~~Monte Carlo pricing model. The Company~~loss in value might include, but would not necessarily be limited to, absence of an ability to recover the carrying amount of the investment or inability of the equity investee to sustain an earnings capacity that would justify the carrying amount of the investment. Once a determination is ~~required~~made that an OTTI exists, the investment is written down to ~~make assumptions and estimates in determining an appropriate risk-free interest rate, volatility, term, dividend yield and discount due to exercise restrictions and~~its fair value ~~of common stock.~~

Basic net loss per share is computed by dividing reported net loss by the weighted average number of common shares outstanding for the reported period. Diluted net loss per share reflects the potential dilution that could occur if securities or other contracts to issue common stock were exercised or converted into common stock of the Company duringin accordance with ASC 820 at the reporting period. Diluted net loss per share is computed by dividing net loss by the sum of the weighted average number of common shares and the number of potential dilutive common share equivalents outstanding during the period. Potential dilutive common share equivalents consist of the incremental common shares issuable upon the exercise of vested share options and the incremental shares issuable upon conversion of the convertible notes. Potential additional dilutive common share equivalents consist of warrants, stock options, restricted stock units (“RSUs”) and restricted stock awards.

~~In computing diluted earnings per share, common share equivalents are not considered in periods in~~date, which establishes a net loss is reported, as the inclusion of the common share equivalents would be anti-dilutive. As of September 30, 2020, there were 13,141,298 common share equivalents with potential dilutive impact (September 30, 2019 – 8,043,920). Because the Company is in a net loss for all periods presented in these financial statements, there is no difference between the Company’s basic and diluted net loss per share for the periods presented.new cost basis.

In August 2020, the FASB issued ASU 2020-06, Debt—Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which amends and simplifies existing guidance in an effort to reduce the complexity of accounting for convertible instruments and to provide financial statement users with more meaningful information. ASU 2020-06 is effective for the Company beginning June 1, 2022. This update may be applied retrospectively or on a modified retrospective basis with the cumulative effect recognized as an adjustment to the opening balance of retained earnings on the date of adoption. The Company is currently evaluating the effect of adopting this ASU.

In May 2021, the FASB issued ASU 2021-04, Modifications and Extinguishments (Subtopic 470-50), Compensation—Stock Compensation (Topic 718), and Derivatives and Hedging—Contracts in Entity’s Own Equity (Subtopic 815-40) (“ASU 2021-04”), which amends existing guidance for earnings per share (EPS) in accordance with Topic 260. ASU 2021-04 is effective for the Company beginning June 1, 2022. This update should be applied prospectively on or after the effective date of the amendments. The Company is currently evaluating the effect of adopting this ASU.

In October 2021, the FASB issued ASU 2021-08, Business Combinations (Subtopic 805), Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”), which is intended to improve the accounting for acquired revenue contracts with customers in a business combination by addressing diversity in practice and inconsistency. ASU 2021-08 is effective for the Company beginning June 1, 2023. This update should be applied prospectively on or after the effective date of the amendments. The Company is currently evaluating the effect of adopting this ASU.

In December 2019, the FASB issued ASU 2019-12, Income Taxes (Topic 740) -– Simplifying the Accounting for Income Taxes (“ASU 2019-12”), which is intended to simplify various aspects related to accounting for income taxes. ASU 2019-12 removes certain exceptions to the general principles in Topic 740 and also clarifies and amends existing guidance to improve consistent application. ~~ASU 2019-12~~The standard is effective for ~~the Company~~annual reporting periods beginning ~~January 1, 2021.~~after December 15, 2020 and including interim periods within those fiscal years. The Company ~~is currently evaluating~~adopted the ~~effect~~ASU beginning June 1, 2021 and the adoption of ~~adopting this ASU.~~ASU 2019-12 did not have a material impact on our consolidated financial statements.

In January 2020, the FASB issued ASU 2020-01, Investments -– Equity Securities (Topic 321), Investments - Equity Method and Joint Ventures (Topic 323), and Derivatives and Hedging (Topic 815) (“ASU 2020-01”), which is intended to clarify the interaction of the accounting for equity securities under Topic 321 and investments accounted for under the equity method of accounting in Topic 323 and the accounting for certain forward contracts and purchased options accounted for under Topic 815. The Company adopted the ASU beginning June 1, 2021 and the adoption of ASU 2020-01 ~~is effective for~~did not have a material impact on our consolidated financial statements.

During the three and six months ended November 30, 2021, the Company ~~beginning January 1, 2021. The Company is currently evaluating the effect~~recorded $12,000 and $12,000 in our cannabis segment of ~~adopting this ASU.~~

Capital assets consisted of the complexity associated with applying generally accepted accounting principles (GAAP) for certain financial instruments with characteristics of liabilities and equity. ASU 2020-06 is effective for the Company beginning January 1, 2022. The Company is currently evaluating the effect of adopting this ASU.following:

~~On May 26, 2020, the Company announced its decision to close its High Park Gardens facility, a wholly-owned subsidiary~~Note 5. Intangible Assets

As of November 30, 2021, included in ~~Leamington, Ontario in response to its anticipated~~Licenses, permits & applications is $383,445 of indefinite-lived intangible assets (May 31, 2021 - $412,000).

Expected future ~~product needs and the current economic climate. The Company concluded that the~~amortization expense for intangible assets ~~attributable to High Park Gardens, which are expected to be sold to a third-party within twelve months, met the criteria for classification as assets held for sale~~ as of ~~September~~November 30, ~~2020.~~2021 are as follows:

~~As a result of~~The following table shows the Company’s decision to close this facility, the Company recognized impairment charges of $25,051 recorded to impairment of assets within the statements of net loss and comprehensive loss to adjust the fair value, less costs to sell, of the assets classified as held for sale. This included impairment charges of $13,616 relating to land and buildings (refer to Note 8), $10,239 relating to the write-down to nil of its cultivation license (refer to Note 10) and $1,196 relating to foreign currency translation adjustments.

~~The disposal group is included in the Company’s cannabis segment. The~~ carrying amount of ~~major classes of assets comprising the disposal group classified as held for sale are as follows:~~

~~The following table provides summary pretax (loss) income for the High Park Gardens facility, which are included in continuing operations for their respective periods:~~

~~Pretax loss for the nine months ended September 30, 2020 includes impairment charges of~~ ~~$25,051.~~goodwill:

~~The Company entered into a Profit Participation Arrangement (“ABG Arrangement”) with ABG Intermediate Holdings 2, LLC (“ABG”) on January 14, 2019~~ as described in ~~the~~ ~~Annual Financial Statements~~.

On January 24, 2020, the Company entered into (i) an Amended and Restated Profit Participation Agreement (the “A&R Profit Participation Agreement”) with ABG, which amended and restated in its entirety the Profit Participation Agreement, dated January 14, 2019, and (ii) the First Amendment to Payment Agreement with ABG (the “Payment Agreement Amendment”), which amends the Payment Agreement, dated January 14, 2019. The Company and ABG agreed that Tilray no longer has any obligation to pay the additional consideration with an aggregate value of $83,333 in cash or in shares of Class 2 common stock. In addition,Note 1, the Company is ~~not entitled~~within the measurement period of the business acquisition. As of November 30, 2021, the fair values of assets and liabilities acquired have been prepared on a provisional basis and are subject to ~~any guaranteed minimum participation rights and beginning January 1, 2020 through December 31, 2028,~~further adjustments as the Company agreed that it is not entitled to any participation rights until such participation rights with respect to each contract year exceeds $10,000, and in the event the participation rights thresholds are achieved, the Company is entitled to the full 49% participation rights.

As a result of entering into the A&R Profit Participation Agreement and the Payment Agreement Amendment, the Company derecognized the ABG finance receivable, $7,011 of which was recorded to impairment of assets through the statements of net loss and comprehensive loss and $28,900 of which was recorded through accumulated deficit in January 2020.

completes its analysis. The Company ~~entered into a Trademark License Agreement with ABG on~~will finalize the amounts recognized by April 1, 2019 for the use of the Prince trademark (“ABG Prince Agreement”). Under the ABG Prince Agreement, the Company pays a royalty on actual product sales in addition to a guaranteed minimum royalty payment (“GMR”) of $500 on April 1, 2019, October 1, 2019, January 1, 2020 and July 1, 2020, with subsequent quarterly payments of $375 commencing January 1, 2021 until the maturity date of December 31, 2025.

~~Inventory is written down for any obsolescence, spoilage and excess inventory or when the net realizable~~30, 2022. The fair value ~~of inventory is less than the carrying value. Inventory valuation~~ adjustments ~~included in cost of sales on the statements of net loss and comprehensive loss is comprised of the following:~~

For the three and nine months ended September 30, 2020, cannabis products were written down by $13,318 and $31,626 (2019 – $124 and $610) and hemp products were written down by $125 and $4,490 (2019 – $77 and $116). In the three and nine months ended September 30, 2020, included in inventory valuation adjustments in cost of sales, $5,157 and $10,090 related to termination of a supply agreement; $4,934 relating to a loss on deposit payments for future purchases of inventory to secure supply (refer to Note 5) and $5,157 of additional termination penalties due to the same supplier. Also included in inventory valuation adjustments in cost of sales for the nine months ended September 30, 2020 is $1,800, relating to the destruction of unharvested flower as a result of the closure of the High Park Gardens facility (refer to Note 2).

Deposits include advance payments on future purchases of inventory to secure supply. During the nine months ended September 30, 2020, the Company reached agreement with certain suppliers to terminate supply agreements. As a result, deposits have been written down by $4,934 in the Cannabis segment and were recorded in inventory valuation adjustments in the statements of net loss and comprehensive loss (refer to Note 4).

~~Unrealized gains and losses recognized in other expense (income)~~made during the three and ~~nine~~six months ended ~~September~~November 30, ~~2020 on equity investments still held at September 30, 2020~~2021 are ~~losses of $506~~not significant and ~~$1,272 (2019 – loss of $274 and gain of $264). There were 0 impairments or adjustments to equity investments under~~are reflected in the ~~measurement alternative for the three and nine months ended September 30, 2020 and September 30, 2019.~~table below:

As of November 30, 2021, the Company’s debt securities ~~accounted for~~ under ~~the~~ available-for-sale method ~~consist~~include the MM Notes, described in Note 2 Basis of ~~convertible debt instruments~~presentation and summary of significant accounting policies. Interest on the principal amount of the MM Notes shall accrue at an interest rate of LIBOR plus 6%, with ~~contractual maturities~~a LIBOR floor of 2.5% and, any accrued interest shall be pay-in-kind at a price equal to the trailing 30-day volume weighted average price of the MedMen Shares, as and when such pay-in-kind interest becomes due and payable. The MM Notes, which mature in ~~2022. Total~~2028, are indirectly held by the Company through its majority-owned subsidiary, SH Acquisition. The Company has the ability, in its sole discretion, to transfer its partnership interest in SH Acquisition and/or the pro rata portion of the MM Notes and the corresponding portion of accrued and unpaid pay-in-kind interest, and/or cause the redemption of the partnership interest and/or the pro rata portion of the MM Notes held by the minority interest in SH Acquisition at any time. The total unrealized loss of ~~$148~~$16,357 in accumulated other comprehensive income at ~~September~~November 30, ~~2020 (December 31, 2019 - $302)~~2021 relates to the long-term available-for-sale debt securities. The Company’s allowance for credit losses on debt securities classified as available-for-sale is $0 at ~~September~~November 30, ~~2020 (December 31, 2019 – $0)~~2021 and 0 related credit loss expenses were recorded during the three and ~~nine~~six months ended ~~September~~November 30, ~~2020 (2019 – $0 and $0).~~

~~Equity method investments~~2021. Comparisons are comprised of the Company’s joint venture with Anheuser-Busch InBev (“AB InBev”) in Plain Vanilla Research Limited Partnership (“Fluent”) and the Company’s joint venture with Cannfections Group Inc. (“Cannfections”). As of September 30, 2020, there are no changes to the status of the Company’s assessment of its joint ventures.

During the nine months ended September 30, 2020, the Company contributed $2,323 to Fluent (2019 - $10,090). The Company provides production support services to Fluent on a cost recovery basis. For the nine months ended September 30, 2020, total fees charged were $3,109 (2019 - $0). Total amounts included in accounts payable is $441 at September 30, 2020 (December 31, 2019 – accounts receivable of $388). At September 30, 2020, the maximum exposure to loss is limited to the Company’s equity investment in Fluent.

During the nine months ended September 30, 2020, the Company made 0 capital contributions to Cannfections (2019 - $3,600). At September 30, 2020, the maximum exposure to loss is limited to the Company’s equity investment in Cannfections.

~~The Company’s ownership interests in its equity method investments as of September 30, 2020 and December 31, 2019 and (loss) gain from equity method investments~~not provided for the ~~nine months ended September 30, 2020 were as follows:~~

~~Summary financial information for~~comparable prior year periods given the ~~Company’s equity method investments on an aggregate basis is as follows:~~

The Company ~~maintains an allowance for credit losses at an amount sufficient to absorb losses inherent in~~values debt securities under available-for-sale method using the ~~existing accounts receivable portfolio as of~~Black-Scholes model (Level 3) with the ~~reporting dates based on the estimate of expected net credit losses. The~~ following ~~table provides activity in the allowance for credit losses for the nine months ended September 30, 2020:~~weighted-average assumptions:

The ~~Company holds~~Company’s equity investments ~~in 2 available-for-sale debt securities, 1~~at fair value consist of which is in an unrealized loss position. The unrealized loss relates to an investment in the convertible debentures of a recreational cannabis company. This investment is deemed not to have a credit loss. The unrealized loss primarily reflects an extended period of general volatility in the cannabis industry, as well

~~as the more recent volatility in the overall economy due to COVID-19. The Company expects to recover the entire amortized cost basis of the security. The Company does not intend to sell the investment~~publicly traded shares and ~~it is not more likely than not that~~warrants held by the Company, ~~will be required to sell~~including certain warrants acquired with the MM Notes and exercisable for equity securities of MedMen’s Class B subordinate voting shares. The Company’s equity investment ~~before recovery of its amortized cost basis. The following table provides~~under measurement alternative includes equity investments without readily determinable fair values.

Unrealized gains and losses recognized in non-operating income (expense) during the ~~fair value~~three and ~~unrealized~~six months ended November 30, 2021 on equity investments still held at November 30, 2021 are a loss of ~~the investment at September 30, 2020~~$1,806 and ~~December 31, 2019:~~

~~Property~~a loss of $3,883 (2020 – loss of $399 and ~~equipment, net consists~~loss of ~~the following:~~

In connection with the Company’s closure of its High Park Gardens facility, the Company determined that the fair value of the land and buildings at the High Park Gardens facility (Level 2) was below its carrying value. The decline in fair value of the land and buildings at the High Park Gardens facility is primarily due$1,326). There were 0 impairments or adjustments to recent sales of similar properties resulting in a lower implied sale price per acre of land and greenhouse space. As a result, the Company incurred non-cash impairment charges of $13,616 presented in impairment of assets in the statements of net loss and comprehensive loss (refer to Note 2).

~~Refer to Note 18 for contractual commitments related to construction-in-process.~~

Goodwill is tested for impairment annually, or more frequently when events or circumstances indicate that impairment may have occurred. At the end of the first quarter of 2020, the Company determined the hemp reporting unit, representing $130,343 of the $159,595 total goodwill, was at risk of having a carrying value exceeding the fair value. As a result, a quantitative test was performed to determine if impairment exists. In performing the Company’s impairment analysis, the fair value of the hemp reporting unit was determined primarily by discounting estimated future cash flows, which were determined based on revenue and expense growth assumptions ranging from 9% to 38%, at a weighted average cost of capital (discount rate) ranging from 10% to 12%. The discounted future cash flow model also made the key assumption that Cannabidiol (“CBD”) revenue will commence to build in the third quarter of 2021. The fair value of the hemp reporting unit was determined to exceed the carrying value by $76,998, or 26%, and 0 impairment was recorded. No triggers have been identified in subsequent quarters to perform additional quantitative tests.

A relatively small change in the underlying assumptions, including a 1% change in the weighted average cost of capital, continued lack of clarity from the Food and Drug Administration regarding approval of CBD, or the financial performance of the reporting unit in future years, may cause a change in the results of the impairment assessment in future periods and, as such, could result in an impairment of goodwill.

September 30,

December 31,

2020

2019

Cost

Accumulated
Amortization

Impairment

Net

Cost

Accumulated
Amortization

Impairment

Net

Definite-lived intangible assets:

Patent

$
669

$
131

$
538

$
—

$
716

$
99

$
—

$
617

Customer relationships

132,837

13,241

—

119,596

135,953

7,132

—

128,821

Developed technology

6,912

1,094

—

5,818

7,074

590

—

6,484

Websites

5,126

3,921

—

1,205

5,157

3,331

—

1,826

Trademarks and licenses

9,052

1,293

7,650

109

9,135

925

—

8,210

Total

154,596

19,680

8,188

126,728

158,035

12,077

—

145,958

Indefinite-lived intangible
   assets:

Cultivation license

10,239

—

10,239

—

10,689

—

—

10,689

Alef license

—

—

—

—

4,086

—

4,086

—

Trademarks

54,125

—

—

54,125

55,416

—

—

55,416

Rights under ABG Profit
   Participation
   Arrangement

16,765

—

16,765

—

119,366

—

102,601

16,765

Total

81,129

—

27,004

54,125

189,557

—

106,687

82,870

Total intangible assets

235,725

19,680

35,192

180,853

$
347,592

$
12,077

$
106,687

$
228,828

In connection with the Company’s closure of its High Park Gardens facility, the Company determined that the fair value of the indefinite-lived cultivation license was below carrying value. As a result, the Company incurred non-cash impairment charges of $10,239, representing the full net book value of the cultivation license, presented in impairment of assets in the statements of net loss and comprehensive loss (refer to Note 2).

In connection with the decreased demand projections of CBD products in the United States resulting in a reduced estimate of future cash flows, during the first quarter of 2020 the Company determined that the fair value of indefinite-lived rightsequity investments under the ABG Profit Participation Arrangement and definite-lived trademarks under the Trademark and License Agreement with ABG for the use of the Prince trademark (“ABG Prince Agreement”) were below the carrying value. As a result, the Company incurred non-cash impairment charges of $16,765 and $6,063 representing the full net book values of the intangible assets relating to the ABG Profit Participation Agreement and ABG Prince Agreement respectively, presented in impairment of assets in the statements of net loss and comprehensive loss (refer to Note 3). In June 2020, the Company completed the separation from Smith & Sinclair and recognized additional non-cash impairment charges of $3,320 presented in impairment of assets in the statement of net loss and comprehensive loss, of which $2,126 related to other CBD trademarks and patents.

~~Amortization expenses for intangibles was $2,765 and $7,603~~measurement alternative for the three and ~~nine~~six months ended ~~September~~November 30, ~~2020 (2019 – $2,529~~2021 and ~~$6,131). Expected future amortization expenses for intangible assets as at September~~November 30, ~~2020 are as follows:~~2020.

~~Accrued expenses~~Note 8. Accounts payable and ~~other current~~accrued liabilities

Accounts payable and accrued liabilities are comprised ~~of the following items:~~of:

During the nine months ended September 30, 2020, the Company reduced its employee headcount in portions of its global organization to meet the needs of the current industry environment. During the three and nine months ended September 30, 2020, the Company incurred $239 and $3,576, respectively (2019 – $0 and $0), in severance costs, of which $133 and $3,128 is included in salaries within general and administrative expenses and $106 and $448 is included in cost of sales. During the three and nine months ended September 30, 2020, severance costs of $239 and $2,432 are allocated to the cannabis reportable segment and $0 and $1,144 are allocated to the hemp reportable segment. Management continues to evaluate its cost structure and may take further actions in the future and incur additional related costs. The following table shows the reconciliation of the severance costs included within the accrued payroll and employment related withholding taxes balance above, relating to scheduled benefit payments which were communicated to employees prior to September 30, 2020:

The Company has ~~convertible senior notes with a face value~~an operating line of ~~$475,000.~~credit in the amount of C$1,000 which bears interest at the lender’s prime rate plus 75 basis points. As of ~~September~~November 30, ~~2020, the convertible notes are not yet convertible and~~2021, the Company has 0t drawn on the line of credit. The operating line of credit is secured by a security interest on that certain real property at 265 Talbot St. West, Leamington, Ontario.

CC Pharma GmbH, a subsidiary of the Company, has 3 operating lines of credit for €8,000, €3,500, and €500 each, which bear interest at Euro Over Night Index Average plus 1.79% and Euro Interbank Offered Rate plus 3.682% respectively. As of November 30, 2021, a total of €7,353 ($8,264) was drawn down from the available credit of €12,000. The operating lines of credit are secured by a security interest in on the inventory held by CC Pharma GmbH.

Four Twenty Corporation (“420”), a subsidiary of the Company, has a revolving credit facility of $20,000 which bears interest at EURIBOR plus an applicable margin. As of November 30, 2021, the Company has 0t drawn any amount on the revolving line of credit. The revolving credit facility is secured by all of 420 and SweetWater’s assets and includes a corporate guarantee by a subsidiary of the Company.

The following table sets forth the net carrying amount of long-term debt instruments:

As of November 30, 2021, the Company was in compliance with all the long-term debt covenants.

The following table sets forth the net carrying amount of the convertible ~~notes:~~debentures:

~~The following table sets forth total interest expense recognized related to the convertible notes:~~

On February 28, 2020, High Park Holdings Ltd., a wholly owned subsidiary of the Company (the “Borrower”) entered into a credit agreement, denominated in Canadian dollars (“C$”), for a senior secured credit facility in a maximum aggregate principal amount of $59,600 (C$79,800) (the “Senior Facility”). An aggregate principal amount equal to $49,700 (C$66,500) was drawn on February 28, 2020 (the “Closing Date Draw”) and the Company submitted an irrevocable 30 day notice on May 4, 2020 to draw an additional $9,900 (C$13,300) (the “Additional Draw”).

~~On June 5, 2020, a~~s a result of COVID-19 related financial markets conditions that affected the lender of the Senior Facility, and not because of any material changes to the business of Tilray or its subsidiaries, the lender requested that Tilray withdraw its outstanding request for the Additional Draw of $9,900 (C$13,300) under the Senior Facility. In exchange for the Company’s accommodation of the lender’s request to withdraw its funding request, the lender agreed to enter into the First Amendment of the Senior Facility (the “Amendment”). The Amendment provides for interest-only payments for the remainder of its term with all outstanding principal payments due at February 28, 2022. This will result in an aggregate balance of $47,355 (C$64,283) due at February 28, 2022. Additionally, and at such time as the lender’s business may allow, the lender may make the additional proceeds of $9,900 (C$13,300) available, at its sole discretion.

Concurrently, with the Amendment, the lender also approved the Company’s ability to sell the High Park Gardens facility, which is classified as assets held for sale (refer to Note 2), if and when Tilray so desires. As part of any sale of the High Park Gardens facility, the lender has agreed that the Company may retain 60% of any sales proceeds (net of all expenses, fees and taxes), and that the lender will receive 40% of all sales proceeds (net of all expenses, fees and taxes). All sales proceeds to the lender will be applied as a repayment of principal on the Senior Facility without any prepayment penalties or fees. The sale of the High Park Gardens facility is expected to be completed within the next twelve months. ~~The Amendment did not meet the accounting criteria for debt extinguishment.~~

The Senior Facility bears interest on the outstanding principal balance at an annual rate equal to the Canadian prime rate plus 8.05%, calculated based on the daily outstanding balance of the Senior Facility calculated and compounded monthly in arrears and with no deemed reinvestment of monthly payments. Interest is due monthly throughout the term. The Company has the option to voluntarily prepay, without penalty, the outstanding amounts, in full or in part, at any time starting 6 months from the closing date subsequent to providing 75 days’ notice.

Transaction costs incurred on the Closing Date Draw were $3,306 (C$4,425). There were no fees incurred associated with the Amendment. Transaction costs are deferred and amortized as a component of interest expense over the estimated term using the effective interest rate method. On June 29, 2020, the lender notified the Company that it had exercised its unilateral right to syndicate $19,153 (C$26,000) of the Company’s Senior Facility in the aggregate principal amount of $59,600 (C$79,800). The Senior Facility’s terms otherwise remain unchanged.

The Senior Facility has first priority claims on all North American assets of the Company and contains certain affirmative and negative covenants. The operational covenant includes a minimum unrestricted cash threshold of $29,466 (C$40,000) in order for the Company to make additional capital expenditures and investments. The Senior Facility is collateralized against all real and personal property owned, leased and operated by the Company in North America, and any and all other property of the Company now existing and acquired in North America after the closing date. As of September 30, 2020, the Company was in compliance with all covenants set forth under the Senior Facility.

~~The following table sets forth the net carrying amount of the Senior Facility:~~

~~The following table sets forth total interest expense recognized related to the Senior Facility:~~

Holders of the APHA 24 may convert all or any portion of their Notes, in multiples of $1 principal amount, at their option at any time between December 1, 2023 to the maturity date. The initial conversion rate for the APHA 24 will be 89.31162364 shares of common stock, par value $0.0001 per share, of Tilray, Inc. per $1,000 principal amount of Notes, which will be settled in cash, common shares of Aphria or a combination thereof, at Tilray’s election. This is equivalent to an initial conversion price of approximately $11.20 per common share, subject to adjustments in certain events. In addition, holders of the APHA 24 may convert all or any portion of their Notes, in multiples of $1 principal amount, at their option at any time preceding December 1, 2023, if:

The Company may not redeem the APHA 24 prior to June 6, 2022, except upon the occurrence of certain changes in tax laws. On ~~March 17, 2020,~~or after June 6, 2022, the Company ~~closed a registered offering~~may redeem for cash all or part of ~~7,250,000 shares~~the Notes, at its option, if the last reported sale price of the Company’s ~~Class 2~~ common stock for $4.76 per share with an equal number of accompanying warrants and 11,750,000 pre-funded warrants for $4.7599 (the “pre-funded warrants”) with an equal number of accompanying warrants. The pre-funded warrants had an exercise price per share of Class 2 common stock of $0.0001 and were exercisableshares has been at any time after their original issuance and expire on the fifth anniversary date of issuance. As of September 30, 2020, all pre-funded warrants have been exercised. The 19,000,000 total accompanying warrants (the “warrants”) allow the holders to purchase an aggregate of 19,000,000 sharesleast 130% of the ~~Company’s Class 2 common stock. The warrants have an exercise~~conversion price ~~per share of Class 2 common stock of $5.95 and are exercisable~~then in effect for at least 20 trading days during any ~~time after the first~~30 consecutive trading day ~~following~~period ending on and including trading day immediately preceding the ~~six-month~~ ~~anniversary~~date on which the Company provides notice of redemption. The redemption of the ~~issuance and~~APHA 24 will ~~expire on the fifth anniversary date from the date they become exercisable. As of September 30, 2020, the warrants remain outstanding.~~

~~The total gross proceeds~~be equal to 100% of the ~~registered offering were $90,439, of which $21,025 was allocated~~principal amount plus accrued and unpaid interest to, but excluding, the Class 2 common stock at the offering close and $69,414 was allocated to the warrant liability. Issuance costs incurred on the registered offering were $5,150, of which $3,953 was recorded to other expenses (income) in the statements of net loss and comprehensive loss and $1,197 was allocated to the Class 2 common stock and recorded net against the allocated gross proceeds in additional paid-in-capital.redemption date.

The warrants contain anti-dilution price protection features, which adjust the exercise price of the warrants if the Company subsequently issues Class 2 common stock at a price lower than the exercise price of the warrants. In the event additional warrants or convertible debt are issued with a lower and/or variable exercise price, the exercise price of the warrants will be adjusted accordingly. There were no triggering events during the three and nine months ended September 30, 2020. The Company received stockholder approval of the anti-dilution price protection feature at the Company’s Annual Meeting on May 28, 2020.

The Company's warrants are classified as liabilities as they are to be settled in registered shares, and the registration statement is required to be active, unless such shares may be subject to an applicable exemption from registration requirements. The holders, at their sole discretion, may elect to effect a cashless exercise, and be issued exempt securities in accordance with Section 3(a)(9) of the 1933 Act. In the event the Company does not maintain an effective registration statement, the Company may be required to pay a daily cash penalty equal to 1% of the number of shares of Class 2 common stock due to be issued multiplied by any trading price of the Class 2 common stock between the exercise date and the share delivery date, as selected by the holder. Alternatively, the Company may deliver registered Class 2 common stock purchased by the Company in the open market. The Company may also be required to pay cash if it does not have sufficient authorized shares to deliver to the holders upon exercise.

Pre-funded warrants and warrants outstanding at September 30, 2020, and related activity for the nine months ended September 30, 2020 is as follows (reflects the number of shares of Class 2 common stock as if the warrants were converted to Class 2 common stock):

The Company estimated the fair value of the ~~Warrant liability~~APHA 24 convertible debenture at ~~September~~November 30, ~~2020~~2021 at ~~$3.76~~$1,098 per ~~warrant~~convertible debenture using the ~~Monte Carlo pricing~~Black-Scholes model (Level 3) with the following weighted-average assumptions:

Expected volatility is based on the historical volatility of the Company's common ~~stock since its initial public offering in 2018.~~stock.

The Company’s certificate of incorporation authorized the Company to issue the following classes of shares with the following par value and voting rights as of September 30, 2020. The liquidation and dividend rights are identical among Class 1 common stock and Class 2 common stock, and all classes of common stock share equally in the Company’s earnings and losses.

On March 17, 2020, the Company closed the registered offering, issuing 7,250,000 shares of the Company’s Class 2 common stock along with pre-funded warrants and warrants (refer to Note 14). During the period from the close of the registered offering and March 31, 2020, all pre-funded warrants were exercised at a price per share of $0.0001 and the Company issued 11,750,000 shares of Class 2 common stock (refer to Note 14).

During the three and nine months ended September 30, 2020, the Company issued 6,781,090 and 9,493,494 shares of Class 2 common stock for gross proceeds of $46,153 and $76,999, respectively, under the at-the-market equity offering. Transaction costs of $1,540 were recorded net against the allocated gross proceeds in additional paid-in-capital. The warrants’ anti-dilution price protection features allow, for the period the warrants are outstanding, the Company to only issue up to $20,000 in aggregate gross proceeds under the Company’s at-the-market offering program at prices less than the exercise price of the warrants, and in no event more than $6,000 per quarter, at prices below the exercise price of the warrants, without triggering the warrant’s anti-dilution price protection features.

~~The Company’s future ability to pay cash dividends on Class 2 common stock is limited by the terms of the Senior Facility and cannot be paid without the consent of the lender.~~

On September 30, 2020, 13,159,762 shares of Class 1 common stock, constituting all of the shares of Class 1 common stock that were issued and outstanding, were automatically converted into shares of Class 2 common stock, as the Class 1 common stock ceased to represent at least 10% of the outstanding common stock. Prior to theUpon conversion, the Company ~~had authorized 250,000,000~~will pay or deliver, as the case may be, cash, shares of ~~Class 1 common stock. Upon conversion, 16,666,667 were retired, leaving 233,333,333 shares authorized, par value $0.0001 per share. There are 0 shares of Class 1~~our common stock ~~outstanding as~~or a combination of ~~September 30, 2020.~~

~~Certain employees of the Company participated in the equity-based compensation plan of Privateer Holdings, Inc. (the “Original Plan”) under the terms~~cash and valuation method detailed in the Company’s annual financial statements. For the three and nine months ended September 30, 2020, the total stock-based compensation expense associated with the Original Plan was $114 and $410 (2019 – $143 and $411). As of September 30, 2020, the total remaining unrecognized stock-based compensation expense related to non-vested stock options under the Original Plan amounted to $375 which will be recognized over the weighted-average remaining requisite service period of approximately 0.8 years.

NaN stock options were granted under the Original Plan during the nine months ended September 30, 2020 and September 30, 2019. The total fair value of stock options vested as of September 30, 2020 was $118 (December 31, 2019 – $2,789).

The number of shares of Class 2 common stock reserved for issuance under the 2018 Equity Incentive Plan (the “2018 EIP”) automatically increases on January 1 of each calendar year, for a period of not more than ten years, starting on January 1, 2019 and ending on and including January 1, 2027, in an amount equal to 4% of the total number of shares of the Company’s common stock,

at the Company’s election (the “cash conversion option”). The initial conversion rate for the convertible notes is 5.9735 shares of common stock per one thousand dollar principal amount of notes, which is equivalent to an initial conversion price of approximately $167.41 per share of common stock, which represents approximately 1,659,737 shares of common stock, based on the $277,856 aggregate principal amount of convertible notes outstanding ~~on December~~as of May 31, 2021 (2020 - $nil). Throughout the term of the ~~prior calendar year, or a lesser number~~TLRY 23, the conversion rate may be adjusted upon the occurrence of ~~shares determined by~~certain events.

Prior to the ~~Company’s Board~~close of ~~Directors. The shares reserved include~~business on the business day immediately preceding April 1, 2023, the TLRY 23 will be convertible only ~~the outstanding shares related to stock options and RSUs and excludes stock options outstanding~~ under the ~~Original Plan.~~ specified circumstances. On or after April 1, 2023 until the close of business on the business day immediately preceding the maturity date, holders may convert all or any portion of their TLRY 23, in multiples of $1 principal amount, at the option of the holder regardless of the aforementioned circumstances.

The ~~number~~Company estimated the fair value of ~~shares reserved for issuance under~~ the ~~2018 EIP is 17,037,421, effective~~Warrant liability at November 30, 2021 at $6.51 per warrant using the Black-Scholes pricing model (Level 3) with the following weighted-average assumptions:

The Company operates stock-based compensation plans as ~~of January 1, 2020 (December 31, 2019 – 12,926,172).~~disclosed in our Annual Report. For the three and ~~nine~~six months ended ~~September~~November 30, ~~2020,~~2021, the total stock-based compensation was $8,253 and $17,670 (2020 - $5,489 and $8,339).

During the three and six months ended November 30, 2021, the Company did 0t grant any further stock options or RSUs out of Aphria’s predecessor plan. The Company's total stock-based compensation expense ~~associated~~recognized is as follows:

For the three and six months ended November 30, 2021, the Company granted 69,508 and 1,414,666 performance-based RSUs, with NaN vesting in the period (2020 – NaN and NaN). During the three and six months ended November 30, 2021, the Company accelerated the vesting of NaN and 679,000 RSUs to fully vested (2020 – NaN and NaN)

The following tables summarize the information relating to the Company’s subsidiaries, Superhero LP, CC Pharma Nordic ApS, Aphria Diamond, and ColCanna S.A.S. before intercompany eliminations. During the three and six months ended November 30, 2021, the Company made contributions to Superhero LP of $0 and $117,804 in the form of Tilray Class 2 common shares, the Company paid dividends of C$70,000 and C$70,000 (USD$56,630) to the shareholders of Aphria Diamond (“DDH note”), with the ~~2018 EIP was $7,966~~portion allocated to the non-controlling partner settled via issuance of Tilray Class 2 common shares. There were no other contributions or distributions during the period.

The determination of the Company’s overall effective tax rate requires significant judgment, the use of estimates, and ~~$22,994 (2019 - $8,501~~the interpretation and ~~$21,892). As~~application of ~~September 30, 2020,~~complex tax laws. The effective tax rate reflects the ~~total~~ ~~remaining unrecognized stock-based~~income earned and taxed in various United States federal, state, and foreign jurisdictions. Tax law changes, increases and decreases in temporary and permanent differences between book and tax items, valuation allowances against the deferred tax assets, stock-based compensation, ~~expense~~and the Company’s change in income in each jurisdiction all affect the overall effective tax rate. It is the Company’s practice to recognize interest and penalties related to ~~non-vested stock options~~uncertain tax positions in income tax expense.

The Company reported income tax benefit of $(5,671) and ~~restricted stock units (“RSUs”) under~~$(909) for the ~~2018 EIP amounted~~three and six months ended November 30, 2021 and income tax benefit of $(14,192) and $(20,017) for the three and six months ended November 30, 2020. The income tax expense (benefit) in the current period varies from the US statutory income tax rate and prior period primarily due to ~~$40,805 which will be recognized over~~ the ~~weighted average remaining requisite service period~~geographical mix of ~~approximately~~ ~~1.03 years~~earnings and losses with no tax benefit resulting from valuation allowances in certain jurisdictions.

~~Stock option~~Note 17. Commitments and ~~RSU activity under the 2018 EIP are as follows:~~contingencies

~~During the nine months ended September 30, 2020~~, 0 time-based stock options were granted under the 2018 EIP (2019 – 10,000). The weighted-average fair values of stock options granted during the nine months ended September 30, 2020 was $0 per share (2019 – $12.01). ~~The total fair value of stock options vested as of September 30, 2020 was $31,299 (December 31, 2019 – $16,708).~~

NaN performance-based stock options were granted under the 2018 EIP during the nine months ended September 30, 2020 and September 30, 2019. The total fair value of stock options vested as of September 30, 2020 was $0 (December 31, 2019– $1,246).

During the nine months ended September 30, 2020, 2,024,334 (2019 – 944,616) time-based RSUs were granted. During the nine months ended September 30, 2020, 396,051 (2019 – 54,635) time-based RSUs vested.

448,230 performance-based RSUs were granted during the nine months ended September 30, 2020 (2019 – 0ne). During the nine months ended September 30, 2020, 159,375 (2019 – 731,250) performance-based RSUs vested.

In the normal course of business, the Company may become involved in legal disputes regarding various litigation matters. The Company records a loss contingency if the information available indicates that it is probable that a liability has been incurred at the date of the financial statements and the amount of loss can be reasonably estimated. As of September 30, 2020, in the opinion of management, no claims meet the criteria to record a loss contingency.

~~The Company leases various facilities, under non-cancelable finance and operating leases, which expire at various dates through September 2027.~~

~~The following table reflects the Company’s future non-cancellable minimum purchase commitments for inventory as of September 30, 2020:~~

In 2018, the Company signed an agreement with Rose Lifescience Inc. (“Rose”) for distribution and marketing of product in Quebec in exchange for a minimum fee of $384 per annum for an initial term of five years, and agreed to purchase the lesser of 2,000 Kg per year or 40% of the production of Cannabis at a rate of 115% of cost of goods sold from the Rose facility. In September 2020, the Company signed an amendment to this agreement and the estimated compensation fee is approximately $10,350 through 2023. As there is no firm commision fee commitment, it is excluded from the above schedule. Compensation fee expense is recorded as incurred.

In 2018, the Company entered into a Product and Trademark License Agreement with Docklight LLC, a related party (refer to Note 22), to use certain intellectual property rights in exchange for payment of royalty depending upon specified percentage of licensed product net sales. As the purchase commitment is an undeterminable variable amount, it is excluded from the above schedule.

The Company has payments on ~~the ABG finance liability~~long-term debt (refer to Note ~~11)~~10 Long-term debt), convertible notes (refer to Note ~~12)~~11 Convertible Debentures), material purchase commitments and ~~the Senior Facility (refer to Note 13)~~construction commitments as follows:

20Effective November 10, 2021, the Company entered into a termination and settlement agreement with ABG Intermediate Holdings 2, LLC (“ABG”) and certain of its affiliates.  Pursuant to this settlement agreement, the Company terminated $6,600 in remaining guaranteed royalty payments owed to ABG in exchange for the payment of $3,925 as a termination fee. The termination fee was comprised of a $1,500 cash payment plus the issuance of 215,901 Class 2 common shares.

The following table presents the future undiscounted payment associated with lease liabilities as of November 30, 2021:

The Company reports 2its net revenue in 4 reporting segments: cannabis, distribution, beverage alcohol and ~~hemp,~~wellness, in accordance with ASC 280 Segment Reporting. The Company generates revenues from ~~the cannabis and hemp~~these segments through contracts and purchase orders with customers, each with a single performance obligation, being the sale of products. ~~The Company determines that~~

Net revenue information disclosed in business segment information in Note 25 disaggregates revenue into categories that depict how the nature, amount, timing and uncertainty of revenue and cash flows are affected by economic factors.

For certain long-term arrangements, the Company has performance obligations for goods it has not yet delivered. For these arrangements, the Company does not have a right to bill for the undelivered goods. The Company has determined that any unbilled consideration relates entirely to the value of undelivered goods. Accordingly, the Company has not recognized revenue, and has elected not to disclose amounts, related to these undelivered goods. As of September 30, 2020 and December 31, 2019, other than accounts receivable, net of allowance for credit losses and provision for sales returns, the Company has 0 contract balances in the balance sheets.is comprised of:

General and administrative expenses are comprised ~~of the following items:~~of:

The Company ~~enters into related party transactions with certain entities under common control and joint ventures~~ has classified its financial instruments as described in ~~the~~Note 3 Significant accounting policies in our Annual ~~Financial Statements and detailed below.~~

The Company has an agreement with Leafly providing for data licensing activities. During the three and nine months ended September 30, 2020, operational expenses of $5 and $134 was recorded within general and administrative expenses in the statements of net loss and comprehensive loss (2019 - $130 and $149).

The ~~Company pays Docklight a royalty fee pursuant~~carrying values of accounts receivable, bank indebtedness and accounts payable and accrued liabilities approximate their fair values due to ~~a brand licensing agreement which provides~~their short periods to maturity.

At November 30, 2021 the ~~Company~~Company’s long-term debt of $18,305 (May 31, 2021 - $20,358) is subject to fixed interest rates. The Company’s long-term debt is valued based on discounting the future cash outflows associated with ~~exclusive rights in Canada for~~ the use of certain adult-use brands. During the three and nine months ended September 30, 2020, royalty fees of $331 and $748 were recorded within general and administrative expenses in the statements of net loss and comprehensive loss (2019 - $44 and $176). Refer to Note 18 for purchase commitments with Docklight.

In January 2020, the Company entered into a corporate services agreement with Ten Eleven Management LLC (“Ten Eleven”), pursuant to which Ten Eleven provides the Company with certain general administrative and corporate services for a service fee. This agreement was terminated in April 2020. In August 2020, the Company entered into a corporate services agreement with Ten Eleven pursuant to which Ten Eleven provides the Company with certain accounting services for a service fee. This agreement was terminated in October 2020. During the three and nine months ended September 30, 2020, management services of $- and $71 was recorded within general and administrative expenses in the statements of net loss and comprehensive loss (2019 - $75 and $200).

long-term debt. The ~~Company sub-leases a portion of certain office space to Ten Eleven. Ten Eleven’s lease payments are~~discount rate is based on the ~~pro-rata share of space that they occupy, with annual lease payments of $470. The sub-lease was terminated in~~ ~~May 2020. For the three and nine months ended September 30, 2020, $- and $196 of sublease income is recorded in other income, net (2019 - $115 and $192).~~

The Company has joint venture arrangements with a 50% ownership and voting interest in each of Fluent and Cannfections. Refer to Note 6 for details over transactions with these entities for the nine months ended September 30, 2020.

The Company had entered into an aircraft time-share agreement and a lease consent and subordination agreement with Brendan Kennedy, our Chief Executive Officer, whereby the Company had access to and use of an aircraft owned by Mr. Kennedy on an as-needed basis for business purposes. Pursuant to this arrangement, the Company reimbursed Mr. Kennedy for certain related aircraft expenses. During the three and nine months ended September 30, 2020, the Company incurred $0 and $261 of fees which is included in general and administrative expenses (2019 – $0 and $0).

~~At September 30, 2020, the Company has accounts payable due to related parties of $141 (December 31, 2019 - $68).~~

Credit risk is the risk of financial loss to the Company if a customer or counterparty to a financial instrument fails to meet its contractual obligations, and arises principally from the Company’s cash and cash equivalents and accounts receivable.

The Company’s cash and cash equivalents are deposited in major financial institutions in Canada, Australia, Portugal, Germany and the United States. To date, the Company has not experienced any losses on its cash deposits. Accounts receivable are unsecured and the Company does not require collateral from its customers.

~~The Company is also exposed to credit risk from the potential default by any of its counterparties on its financial assets.~~

~~The Company evaluates the collectability of its accounts receivable and provides an allowance for credit losses as necessary (refer to Note 7).~~

Due to the uncertainties associated with COVID-19, the Company may be unable to accurately predict the creditworthiness of its counterparties and their ability to meet their obligations. This may result in unforeseen additional credit losses.

The Company conducts its business in several countries and in a variety of currencies, the most significant of which are the Canadian dollar and Euro. Consequently, the Company is exposed to foreign currency risk. A significant portion of the Company’s assets, liabilities, revenue, and expenses are denominated in Canadian dollars. A 10% change in the exchangeincremental premium above market rates for Government of Canada securities of similar duration. In each period thereafter, the ~~Canadian dollar would affect~~incremental premium is held constant while the ~~carrying value~~Government of ~~net assets by approximately $23,578 as of September 30, 2020, with a corresponding impact to accumulated other comprehensive income (loss). The Company~~Canada security is ~~also exposed to risk related to changes in the value of the Euro due to its construction commitment in Portugal.~~

The Company’s exposure to changes in interest rates relates primarily to the Company’s outsanding debt. The Company is exposed to changes to the Canadian prime rate as the Senior Facility bears interest based on the ~~Canadian prime rate plus 8.05%. The convertible notes bear interest at a fixed rate of 5% and are not publicly traded and, therefore, are not affected by changes in~~then current market value to derive the market interest rates. A 1% change in the Canadian prime rate would have an impact of $127 and $295 to the statements of net loss and comprehensive loss for the three and nine months ended September 30, 2020.

The Company’s objective is to have sufficient liquidity to meet its liabilities when due. The Company monitors its cash balances and cash flows generated from operations to meet its requirements. As of September 30, 2020, the most significant financial liabilities are accounts payable, accrued expenses and other current liabilities, convertible notes and the Senior Facility.

The Company complies with ASC 820, Fair Value Measurements, for its financial assets and liabilities that are re-measured and reported at fair value at each reporting period, and non-financial assets and liabilities that are re-measured and reported at fair value at least annually. In general, fair values determined by Level 1 inputs utilize quoted prices (unadjusted) in active markets for identical assets or liabilities. Fair values determined by Level 2 inputs utilize data points that are observable such as quoted prices, interest rates and yield curves. Fair values determined by Level 3 inputs are unobservable data points for the asset or liability, and includes situations where there is little, if any, market activity for the asset or liability.discount rate.

The following tables present information about the Company’s assets and liabilities that are measured at fair value on a recurring basis as of ~~September~~November 30, ~~2020~~2021 and ~~December~~May 31, ~~2019~~2021 and indicates the fair value hierarchy of the valuation techniques the Company utilized to determine such fair value:

TheCompany’s financial assets and liabilities required to be measured on a recurring basis are its equity investments measured at fair value, debt securities classified as available-for-sale, acquisition-related contingent consideration, and warrant liability.

~~Debt securities classified as available-for-sale~~Convertible notes receivable, and equity investments recorded at fair ~~value:~~value. The estimated fair value is determined using quoted market prices, broker or dealer quotations or discounted cash ~~flows.~~flows and is classified as Level 2. Certain equity investments recorded at fair value have quoted prices in active markets for identical assets and are classified as Level 1.

~~Warrant liability:~~ Debt securities classified as available-for sale are recorded at fair value. The estimated fair value is determined using the Black-Scholes option pricing model and is classified as Level 3. The Company classified these securities as level 2 in the period of acquisition, when the valuation was determined to reflect the recent market transaction.

The warrants associated with the warrant liability are classified as Level 3 derivatives. Consequently, the estimated fair value of the warrant liability is determined using the ~~Monte Carlo~~Black-Scholes pricing ~~model (refer to Note 14).~~model. Until the warrants are exercised, expire, or other facts and circumstances lead the warrant liability to be reclassified to stockholders’ equity, the warrant liability (which relates to warrants to purchase shares of ~~Class 2~~ common stock) is marked-to-market each reporting period with the change in fair value recorded in change in fair value of warrant ~~liability,.~~ liability. Any significant adjustments to the unobservable inputs disclosed in the table below would have a direct impact on the fair value of the warrant liability.

The ~~opening~~ contingent consideration from the acquisition of SweetWater, first due in December 2023 and payable in cash, is determined by discounting future expected cash outflows at a discount rate of 5%. The inputs into the future expected cash outflows are classified as Level 3.

The APHA 24 Convertible debentures are recorded at fair value. The estimated fair value is determined using the Black-Scholes option pricing model and is classified as Level 3.

The balances of assets and liabilities categorized within Level 3 of the fair value hierarchy measured at fair value on a recurring basis are reconciled, ~~to the closing balances~~ as follows:

The unrealized gain (loss) on fair value for the convertible debenture, the warrant liability, contingent consideration, and debt securities classified under available-for-sale method is recognized in non-operating income (loss) using the following inputs:

The Company's ~~prepayments~~ prepaids and other current assets, long lived assets, including property and equipment, goodwill and intangible assets are measured at fair value when there is an indicator of impairment and are recorded at fair value only when an impairment charge is recognized.

Management~~Land~~ reviews its capital management approach on an ongoing basis and ~~buildings (held for sale):~~believes that this approach, given the relative size of the Company, is reasonable. There have been no changes to the Company’s capital management approach in the period. The Company ~~used a third-party real estate agent to assist management in~~considers its determination of the fair value of the assets held for sale at the High Park Gardens facility. Management, in its determination of the fair value of the assets held for sale reviewed market data from recent sales of similar properties to determine an implied sale price per acre of land and greenhouse space and wrote-down the carrying value of the land and greenhouse space held for sale to the estimated fair value less selling costs.

In connection with an evaluation of such assets during the nine months ended September 30, 2020, the carrying values of the land and buildings at the High Park Gardens facility (Level 2), ABG finance receivable and certain intangible assets (Level 3) were concluded to exceed their fair values. As a result, the Company recorded impairment charges that incorporates fair value measurements based on Level 2 (refer to Note 2) and Level 3 inputs (refer to Note 3, Note 8 and Note 10).

~~The estimated fair value of~~ cash and cash equivalents ~~accounts receivable, net, accounts payable, accrued expenses~~ and other current liabilities, convertible notes and Senior Facility at September 30, 2020 (December 31, 2019 – the fair value of all aforementioned, except the Senior Facility which was entered into in 2020) approximate their carrying value.marketable securities as capital.

The Company ~~has 2 operating segments based on major product categories:~~operates in 4 reporting segments. 1) cannabis operations, which encompasses the production, distribution and ~~hemp. These operating segments are also the Company’s reportable segments.~~

~~The cannabis segment cultivates, processes and distributes~~sale of both medical and adult-use cannabis, 2) beverage alcohol operations, which encompasses the production, marketing and sale of beverage alcohol products, ~~in a variety~~3) distribution operations, which encompasses the purchase and resale of ~~formats, as well as related accessories, on a global basis. The hemp segment processes~~pharmaceuticals products to customers, and ~~distributes a diverse portfolio of hemp-based natural and organic food and~~4) wellness products, ~~on a global basis.~~which encompasses hemp foods and cannabidiol (“CBD”) products. This structure is in line with how our Chief Operating Decision Maker (“CODM”) assesses our performance and allocates resources.

~~The results of each segment are regularly reviewed by the Company’s Chief Executive Officer, who is the Company’s chief operating decision maker, to assess the performance of the segment~~Operating segments have not been aggregated and make decisions regarding the allocation of resources. The Company’s chief operating decision maker uses revenue and gross profit as the measure of segment profit or loss. The accounting policies of each segment are the same as those set out under the summary of significant accounting policies in Note 1. There are 0 intersegment sales or transfers.

~~The comparative three and nine months ended September 30, 2019 have been recast to reflect to the current segment structure.~~

Nono asset information is provided for the segments because the Company’s ~~chief operating decision maker~~CODM does not ~~review this~~receive asset information by segment on a regular basis. While the Company reported “business under development” as a fifth segment in its previous Annual Report, management determined that this no longer met the definition of a reporting segment.

Segment gross profit ~~for the reportable segments is equal to the Company’s consolidated revenue and gross profit.~~from external customers:

~~Revenue attributed to geographic region based on the location of the customer was as follows:~~

~~Revenue includes excise duties of $4,213 and $13,325 for the three and nine months ended September 30, 2020 (2019: $2,931 and $8,707).~~

~~Long-lived assets consisting of property and equipment, net of accumulated depreciation, attributed to geographic regions based on their physical location~~ were as follows:

Two customers accounted for 21% and 19% of revenue, respectively, for the three months ended September 30, 2020. Three customers accounted for 20%, 18% and 11% of revenue, respectively, for the nine months ended September 30, 2020. Three customers accounted for 20%, 14%, and 10% of revenue, respectively, for the three months ended September 30, 2019. Two customers accounted for 12% and 11%, of revenue, respectively, for the nine months ended September 30, 2019.Geographic net revenue:

Major customers ~~accounted~~are defined as customers that each individually account for ~~20% and 11%, respectively,~~greater than 10% of the Company’s ~~accounts receivable balance, as~~annual revenues. For the three and six months ended November 30, 2021 and 2020, there were 0 major customers representing greater than 10% of ~~September 30, 2020. Two customers accounted for 20% and 10%, respectively, of the Company’s accounts receivable balance as of December 31, 2019.~~our annual revenues.

On December 1, 2021, the Company acquired all the membership interests in Cheese Grits, LLC, a Georgia limited liability company that owns the SweetWater Brewing Company brewery and taproom in Atlanta, Georgia (the “SW Acquisition”), which facility was previously leased to the Company. As consideration for the SW Acquisition, the Company paid a purchase price at closing equal to $30,665, which purchase price was satisfied through the assumption of ~~September 30, 2020, Tilray holds 8,532,243~~outstanding debt as well as the issuance of 843,687 shares of Tilray’s Class 2 common stock with a fair value of $8,741. On December 17, 2021, the Company issued an additional 82,224 Class 2 common shares with a fair value at issuance of $776 to satisfy its contractual obligations under the SW Acquisition.

On December 7, 2021, the Company acquired all the membership interests in ~~Kiaro Brands Inc. (Kiaro) at~~ of Double Diamond Distillery LLC (d/b/a ~~balance~~Breckenridge Distillery), a Colorado limited liability company and a leading distilled spirits brand located in Breckenridge, Colorado, widely known for its award-winning bourbon whiskey collection and innovative craft spirits portfolio (the “Breckenridge Acquisition”). As consideration for the Breckenridge Acquisition, the Company paid a purchase price in an aggregate amount equal to $102,900, which purchase price was satisfied through the issuance of ~~$3,600 within Other Investments. Effective October 13, 2020, Kiaro went public as Kiaro Holdings Corp. (Ticker: KO)~~11,245,511 shares of Tilray’s Class 2 common shares.

On December 7, 2021, the Company entered into the Second Amendment to Credit Agreement (the “Amendment”) with the Bank of Montreal (as amended, the “Credit Agreement”). The Amendment reduced our total outstanding long-term debt under the Credit Agreement to $79,375 and increased our current line of credit to $30,000. On December 7, 2021, the Company drew $10,000 borrowed on the ~~TSX Venture Exchange at a price~~line of ~~CAD $0.17 per share. The completion of this transaction will impact the manner~~credit.

On December 17, 2021, the Company ~~assesses~~acquired certain assets from WC IPA LLC, consisting of certain intellectual property, inventory and other assets relating to the Alpine and Green Flash brands (the “Alpine Acquisition”). As consideration for the Alpine Acquisition, the Company paid a purchase price in an aggregate amount equal to $5,133, which purchase price was satisfied through the payment of cash and the issuance of 366,308 shares of Tilray’s Class 2 common shares with a fair value ~~reporting~~ of ~~its investment, which will continue to be presented within Other Investments.~~$3,000.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

~~You~~This Management’s Discussion and Analysis of Financial Condition and Results of Operations should be read ~~the following discussion and analysis of our financial condition and results of operations together~~in conjunction with the ~~unaudited financial information~~Consolidated Financial Statements and the ~~notes~~related Notes thereto ~~included elsewhere~~for the period ended November 30, 2021 contained in this Quarterly Report on Form 10-Q and our Annual Report on Form 10-K for the fiscal year ended ~~December~~May 31, ~~2019 (“Annual Report”). Some~~2021. Forward looking statements in this Form 10-Q are qualified by the cautionary statement included in this Form 10-Q under the sub-heading “Cautionary Note Regarding Forward-Looking Statements” in the introduction of this Form 10-Q.

We are a leading global cannabis-lifestyle and consumer packaged goods company headquartered in New York, New York with the largest global geographic footprint in the industry; including operations in Canada, the United States, Europe, Australia, New Zealand and Latin America that is changing people’s lives for the better – one person at a time – by inspiring and empowering the worldwide community to live their very best life by providing them with products that meet the needs of their mind, body, and soul and invoke a sense of wellbeing. Tilray’s mission is to be the trusted partner for its patients and consumers by providing them with a cultivated experience and health and wellbeing through high-quality, differentiated brands and innovative products.

In the pursuit of our strategic vision and mission, we continue to leverage our scale, expertise and capabilities to drive brand awareness and market share in Canada, Europe, the United States and the rest of world, achieve industry-leading, profitable growth and build sustainable, long-term stockholder value. In order to ensure the long-term sustainable growth of our Company, we continue to focus on developing strong capabilities, including in consumer and patient insights, drive category management leadership and assess growth opportunities with the introduction of innovative new products and the entry into new markets. In addition, we are relentlessly focused on managing our cost of goods and expenses in order to maintain our strong financial position and expand our profit margins.

On April 30, 2021, upon consummation of the ~~information contained~~arrangement with Aphria Inc. (“Aphria”) pursuant to a plan of arrangement under the Business Corporations Act (Ontario) (the “Arrangement”), Aphria stockholders and Tilray stockholders owned approximately 61.2% and 38.8%, respectively, of the post-closing outstanding Tilray common stock resulting in the reverse acquisition of Tilray, whereby Tilray is the legal acquirer and Aphria is the acquirer for accounting purposes. Accordingly, as reported in our Annual Report and in this ~~discussion~~Form 10-Q, the assets and ~~analysis or set forth elsewhere~~liabilities of Aphria are presented at their historical carrying values and the assets and liabilities of Tilray are recognized on the effective date of the business combination transaction and measured at fair value. The operating results for the comparable period, the three and six months ended November 30, 2020, are of those of Aphria. In conjunction with the reverse acquisition, the Company elected to adopt Aphria’s fiscal year of June 1 to May 31.

Prior to the completion of the Arrangement, our condensed consolidated financial statements were presented under International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board and in Canadian Dollars (C$). All prior periods have been recast and are shown in this ~~Quarterly Report on~~ Form 10-Q ~~including information with respect~~under GAAP and in United States Dollars ($).

Our cannabis business reporting segment operates in an industry that is still in its early stages of development. In Canada, the industry celebrated its third year of adult-use legalization in October 2021. As the industry continues to our plans and strategy for our business and related financing, includes “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or “forward-looking information” within the meaning of Canadian securities laws. These statementsmature, there are often identified by the use of words such as “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “project,” “will,” “would” or the negative or plural of these words or similar expressions or variations. Such forward-looking statements and forward-looking information are subject to a number of ~~risks, uncertainties, assumptions~~new entrants into the industry, which has led to increased competition. This competitive environment in the Canadian cannabis industry subjects us to the risk of loss of market share, price discounting by competitors, and to the challenge of acquiring new customers amidst the evolving market changes. The number of licenses granted, and the number of licensed producers ultimately authorized by Health Canada could have an adverse impact on our ability to compete for market share in Canada. During the three months ended November 30, 2021, we maintained our market leadership within Canada but experienced a decline in market share percent to 12.8% from the 15.7% market share we maintained at May 31, 2021. Prior to the end of our fiscal second quarter, the Company was primarily focused on margin maintenance in Canada. With the current market dynamics and the Company’s cost advantages, the Company adjusted its focus to be more price competitive in the value, mainstream and premium plus market categories, particularly, in vape and pre-rolled products. Management continues to explore key partnerships and acquisitions as a strategy to maintain and expand our market share position.

The cannabis industry in Europe is also in its early stages of development whereby countries within Europe are at different stages of legalization of medical and adult-use cannabis as some countries have expressed a clear political ambition to broadly legalize adult-use cannabis (Germany, Portugal, Luxembourg and Malta), some are engaging in an experiment for adult-use (Netherlands, Switzerland) and some are debating regulations for cannabinoid-based medicine (France, Spain, Italy, and the United Kingdom). In Europe, we believe that, despite continuing COVID-19 pressure, cannabis legalization (both medicinal and adult-use) will continue to gain traction, especially following actions of the Maltese and German governments. We also continue to believe that Tilray remains uniquely positioned to win in these markets with its infrastructure being the only company with EU-GMP cultivation facilities in two countries within Europe and our demonstrated commitment to the consistency, quality and safety of our products. Today, Germany remains the largest medical cannabis market in Europe. We are the market leader in medical cannabis within Germany with a market share of approximately 19.7% with our dried flower, extracts and Dronabinol products.

Germany. The new coalition government led by chancellor Olaf Schulz declared its intention to legalize adult-use cannabis use, which aims to regulate the sale of adult-use cannabis.

Malta. In December 2021, Malta now allows its citizens to grow up to six plants at home, possess up to seven grams for personal use, establish a dedicated government authority, and allows the creation of social cannabis clubs. Although commercial sales are still forbidden, such achievement marks an important cornerstone for the cannabis industry in Europe.

Luxemburg. The government stated intentions to legalize adult-use cannabis in October 2021, thereby allowing cultivation, possession, and sale of seeds. However, legislation delays are due to the COVID-19 pandemic. The Luxemburg government has refined its draft bill, which we believe will be enacted in calendar year 2022.

Italy. Cannabis activists successfully set up a referendum to decriminalize domestic cannabis cultivation and remove penalties for cannabis possession through the amendment of several articles of narcotics law, which may come to a vote in calendar year 2022.

Portugal. There are currently two draft bills to allow for the consumption, cultivation, and possession of cannabis for adult use.

Switzerland. In October 2021, Switzerland announced its intention to legalize cannabis by allowing production, cultivation, trade, and consumption. In the meantime, Zurich, Switzerland's largest city, will be the location of a three-year pilot project starting in the Fall 2022 to conduct scientific studies on the cannabis market and its impact on Swiss society.

The Netherlands. The Dutch government aims to initiate an experiment involving the cultivation of cannabis for adult use to determine whether and how regulated cannabis can be legally supplied to coffee shops and what the resulting effects.

Spain. A subcommittee on cannabis was recently created and will commence its work in early February 2022 on a report leading the way for a government sponsored bill on medical cannabis.

France. France launched a two-year pilot experiment to supply approximately 3,000 patients with medical cannabis. To date, approximately 1,000 patients are enrolled in the experiment.

United Kingdom. Medical cannabis is legal in the United Kingdom, however, there is a need to maximize both clinical research and patient benefit in a safe, cautious and ethical manner so that those patients for whom medical cannabis is shown to be effective can access it. Currently, a new piece of legislation is in discussion, which aims to improve access to cannabinoid-based medicine through two measures: (1) expanding the ability to prescribe these products to General Practitioners (GPs) who are registered with the General Medical Council and (2) establishing a commission for the assessment of cannabinoid-based medicinal products.

We have grown, and expect to continue to grow, our business through a combination of organic growth and acquisition. While we continue to execute against our strategic initiatives that we believe will result in long-term, sustainable growth, we also evaluate potential acquisitions and other ~~factors~~strategic transactions of businesses that ~~could cause actual results~~we believe complement our existing businesses or provide us with the opportunity to enter attractive new geographic markets and/or expand our products portfolio and capabilities. We incur transaction costs in connection with identifying and completing acquisitions as well as ongoing integration costs as we integrate acquired companies and seek to achieve synergies. For the ~~timing~~six months ended November 30, 2021, we incurred $33.7 million of ~~certain events~~transaction costs.

In connection with the Arrangement, we committed to ~~differ materially from future results expressed or implied by~~achieving at least $80 million of synergies in connection with the ~~forward-looking statements or forward-looking information. Factors that could cause or contribute~~integration of Tilray and Aphria and developed a robust plan and timeline to achieve such ~~differences include, but are not limited~~synergies. In connection with the development of our integration plan, we evaluated and optimized the organizational structure, evaluated and retained the talent and capabilities we identified as necessary to ~~those identified in this Quarterly Report~~achieve our longer-term growth plan and vision, evaluated contracts and arrangements, and evaluated our supply chain and our strategic partnerships. During the six months ended November 30, 2021, we have executed on ~~Form 10-Q and those discussed in the section titled “Risk Factors” set forth in Part II, Item 1A~~a series of this Quarterly Report on Form 10-Q, subsequent quarterly and annual reports, and in our other SEC and Canadian public filings. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based on information available to us assynergistic actions which included:

As of the date of this ~~Quarterly Report~~filing, we have achieved $70 million in cost-savings on a run-rate basis and $36 million in actual cash-savings.

During the six months ended November 30, 2021, we also executed on other strategic transactions, which completed after the end of our fiscal quarter ended November 30, 2021 but before the filing of this Form 10-Q, ~~and while we believe that information provides a reasonable basis for these statements, that information may be limited or incomplete. Our statements should not be read~~as follows (Refer to ~~indicate that we have conducted an exhaustive inquiry into, or review of, all relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely~~Part I, Financial Information, Note 24 Subsequent Events):

The Coronavirus ("COVID-19") Pandemic, Its Impact on these statements. You should not rely upon forward-looking statements or forward-looking information as predictions of future events. Furthermore, such forward-looking statements or forward-looking information speak only asUs

We continuously address the effects of the ~~date~~COVID-19 pandemic, a discussion of ~~this report. Except as required by law, we undertake no obligation to update any forward-looking statements or forward-looking information to reflect events or circumstances after the date~~which is available in sections entitled "Risk Factors" in Item 1A of ~~such statements.~~

~~Amounts are presented~~ Part I and “The Coronavirus ("COVID-19") Pandemic, Its Impact on Us” in ~~thousands~~Item 7 of United States dollars, except for shares, warrants, per share amounts and per warrant amounts or as otherwise noted. The Canadian dollar (“C$”) equivalents presented are derived using the average exchange rate during the reporting period. Amounts are individually converted by multiplying the United States dollar to Canadian dollar rate to determine the Canadian dollar amount.

~~We lost our emerging growth company status effective December 31, 2019 and therefore reported as a large accelerated filer in the audited consolidated financial statements included in~~ our Annual Report on Form 10-K for the fiscal year ended ~~December~~May 31, ~~2019 (the “Annual Financial Statements”). As a result, we comply with new and revised accounting standards applicable to public companies. The comparative~~2021.

During the three and ~~nine~~six months ended ~~September~~November 30, ~~2019 included in Item 2. Management’s Discussion and Analysis~~2021, our business operations experienced the following as result of ~~Financial Condition and Results of Operation reflects~~ the ~~new and revised accounting standards and therefore does not mirror the September 30, 2019 interim period condensed consolidated financial statements previously filed.~~COVID-19 pandemic:

Our ~~vision is to build the world’s most trusted and valuable cannabis and hemp company. We are pioneering the future of medical, wellness and~~Canadian adult-use cannabis ~~and hemp research, cultivation, processing and distribution globally, and we are one~~business continued to experience the effect of the ~~leading suppliers~~changes in consumer demand that were established during the onset of ~~adult-use~~COVID-19 pandemic and periods of lockdown. As we have previously reported, consumers shifted their demand behavior to purchasing elections based primarily on pricing. This consumer model of purchasing eroded the sales of our higher quality, higher priced brands resulting in our market share reduction during the period. Our Canadian medical cannabis business experienced a slight uptick in ~~Canada and medical use~~patient demand. Our international cannabis ~~in Germany, and a leading supplier of hemp products in North America.~~

~~We have supplied high-quality cannabis products~~business continued to tens of thousands of patients in fifteen countries spanning five continents through our subsidiaries in Australia, Canada, Germany, Latin America and Portugal, and through agreements with established pharmaceutical distributors. We cultivate medical and adult-use cannabis in Canada andexperience delays from regulatory authorities overseeing access to medical cannabis in ~~Portugal. We operate only~~several European jurisdictions. In accessible markets, the access to physician practices remains limited due to protective measures in ~~countries where~~place throughout Germany, slowing down the adoption of cannabis ~~or hemp-derived cannabinoids are legal,~~as an innovative treatment option. Our distribution business experienced slight improvement in the global supply chain disrupted by ~~which we mean~~ the ~~activities~~COVID-19 pandemic resulting in ~~those countries are permitted under all applicable federal and state or provincial and territory laws.~~

~~We are witnessing~~ a global paradigm shift for cannabis and hemp and, as a result of this shift, the transformation of a multibillion dollar industry from a state of prohibition to a state of legalization. Medical cannabis is now authorized at the national or federal levelmodest increase in ~~forty-one countries. The legal market for medical cannabis is still~~net revenue in its ~~early stages~~base currency but due to the weakening of the US dollar against the Euro resulted in a decrease in sales from the prior year’s comparable period. Our beer and alcohol business continues to see a decline in on-premise business primarily as the on-premise industry dealt with a lack of staffing and a change demand pattern related to after work alcohol consumption. The continued impact of the COVID-19 pandemic has hampered revenue growth in our main consumer facing markets. Within the hemp food segment of our business, we ~~believe~~continue to navigate the ~~number~~changes with growth in ecommerce and “click + pickup” channels offsetting declines in traditional retailer channels as consumer shopping behaviors shift.

Our business and operating results for the three and six months ended November 30, 2021 continue to be impacted by the COVID-19 pandemic,including Delta and Omicron variants. The COVID-19 pandemic remains highly volatile, and the responses of ~~countries with legalized regimes~~local governments based on numbers of new cases, disease severity, risk of reinfection, and vaccine performance continue are unpredictable. We cannot accurately predict the duration or extent of the impact of the COVID-19 virus. We will continue to ~~increase. As this transformation occurs, we believe companies with trusted global brands~~assess our operations and ~~multinational supply chains~~ will ~~become market leaders by earning the confidence of patients, doctors, governments and adult consumers around the world.~~

We are a leader in the Canadian adult-use market. We have entered into agreements to supply certain provinces and territories with our adult-use products for sale through the distribution systems they have established. Adult-use legalization occurred in Canada on October 17, 2018 and on October 17, 2019, the Canadian adult-use regulations were amended to permit the sale of new class of cannabis products including edibles, beverages and vape products.

During the nine months ended September 30, 2020, and in an effort to better align our cost structure with the current business environment we reduced headcount in different areas of the organization. A total of 482 positions were eliminated with an expected annualized savings impact, net of severance costs, of $38.0 million. In addition to headcount reductions, we have undertaken other efforts to increase operating efficiencies which will result in future additional cost savings of approximately $17.0 million, totaling approximately $55.0 million in overall cost savings annually versus our Q4 2019 annualized run rate cost structure. We continue to ~~evaluate~~consider the guidance of local governments throughout the world. If economic conditions caused by the pandemic do not recover as currently estimated by management or market factors currently in place change, there could be a further impact on our ~~cost structure in light of business conditions and COVID-19 and may take additional actions during the remaining of the year~~.

~~During the nine months ended September 30, 2020, we~~ ~~issued 9,493,494~~ ~~shares of Class 2 common stock for gross proceeds of approximately $77.0 million under the at-the-market equity offering program.~~

On February 28, 2020, we entered into a credit agreement for a senior secured credit facility, denominated in Canadian dollars, for a maximum aggregate principal amount of $59.6 million (C$79.8 million) (the “Senior Facility”). An aggregate principal amount equal to $49.7 million (C$66.5 million) was drawn on February 28, 2020.

As a result of COVID-19 related financial market conditions that affected the lender, and not because of any material changes to the business of Tilray or its subsidiaries, the lender requested that we withdraw our then outstanding request for the additional draw of $9.9 million made on May 4, 2020. We agreed and, as a result, on June 5, 2020, we entered into the First Amendment to the Senior Facility (“the First Amendment”). The First Amendment provides that the Senior Facility will only require interest payments for the remainder of its term and all outstanding principal payments will be due at maturity, February 28, 2022. We have been, and currently are, in full compliance with all terms of the Senior Facility and did not incur any fees or penalties in connection with the First Amendment.

Additionally, and at such time as the lender’s business may allow, the lender may make the additional proceeds of $9.9 million available during the term of the Credit Agreement, at its sole discretion. Concurrently with the First Amendment, the lender also approved our ability to sell the High Park Gardens facility, if and when we desire. As part of any sale of the High Park Gardens facility, the lender has agreed that we may retain 60% of any sales proceeds (net of all expenses, fees and taxes), and that the lender shall receive 40% of all sales proceeds (net of all expenses, fees and taxes). All sales proceeds to the lender will be applied as a repayment of principal on the Senior Facility, without any prepayment penalties or fees. As of September 30, 2020, we have not completed the sale of the High Park Gardens facility.

On March 17, 2020, we closed an underwritten registered offering of 7,250,000 shares of Class 2 common stock for $4.76 per share and 11,750,000 pre-funded warrants for $4.7599 (the “pre-funded warrants”) accompanied by 19,000,000 warrants with an exercise price of $5.95. The pre-funded warrants have an exercise price per share of Class 2 common stock of $0.0001 and were exercisable at any time after their original issuance and expire on the fifth anniversary date of issuance. The pre-funded warrants were exercised in full during March 2020. The 19,000,000 warrants (the “warrants”) have an exercise price of $5.95 and allow the holder to purchase 19,000,000 shares of the Company’s Class 2 common stock. All 19,000,000 warrants remain outstanding as of September 30, 2020, and are exercisable at any time after the first trading day following the six-month anniversary of the issuance and will expire on the fifth anniversary date from the date they become exercisable. Our net proceeds from this offering was $85.3 million (gross proceeds of $90.4 million).

On May 26, 2020, we announced that we would permanently shut down our facility at High Park Gardens, a licensed cannabis facility in Leamington, Ontario, operated through its wholly-owned subsidiary Natura Naturals Inc. (“High Park Gardens”). This is a result of changing industry dynamics and evolving business needs. As a result of the closure, we expect to realize annualized net savings of approximately $6.0 million and avoid significant ongoing capital expenditures.

Due to the closure of High Park Gardens in June 2020, we incurred termination costs of $0.3 million related to severance, which are included within general and administrative expenses, recorded total non-cash charges of $25.5 million, which included of $13.6 million related to the write down of land and buildings upon placing these assets for sale and valuing such at their fair value less normal selling costs, $1.8 million of inventory valuation adjustments related to the destruction of unharvested flower and $10.2 million related to write down of the acquired cultivation license. We expect to recognize additional cash charges of $0.3 million in real estate transaction fees upon final sale of the Leamington facility.

~~On June 30, 2020, we completed the separation from Smith & Sinclair, a previously consolidated entity, which develops and distributes CBD-infused edibles.~~

As COVID-19 continues to spread around the world, and governments and businesses take unprecedented measures in response, the actions taken, or that may be taken, have or may materially adversely affect our business, results of operations, financial condition and stock price. Due to COVID-19, governments have imposed restrictions on travel and business operations, temporarily closed businesses, and implemented quarantines and shelter-in-place orders. Consequently, the COVID-19 pandemic has negatively impacted global economic activity, caused significant volatility and disruptioncash flows from operations.

Our consolidated results, in ~~global financial markets, and generally introduced significant uncertainty and unpredictability throughout the world.~~thousands except for per share data, are as follows:

Our business has likely been negatively impacted during 2020, due to the restrictions on, or temporary closure of, retail outlets, and the challenges faced by patients accessing clinics and doctors for prescriptions for our products and due to the vast majority of the Company’s employees working remotely. We continue to operate its manufacturing facilities at normal production levels while its administrative offices remain closed. We have taken all recommended actions to protect public health and the health and safety of employees and it continues to work on safely re-opening its offices subject to local rules and regulations.

	For the three months November 30,						Change			% Change			For the six months November 30,						Change			% Change
(in thousands of U.S. dollars)	2021			2020			2021 vs. 2020						2021			2020			2021 vs. 2020
Net revenue	$	1,55,153		$	1,29,459		$	25,694			20	%	$	3,23,176		$	2,46,949		$	76,227			31	%
Cost of goods sold		1,22,387			94,176			28,211			30	%		2,39,455			1,76,721			62,734			35	%
Gross profit		32,766			35,283			(2,517	)		(7	%)		83,721			70,228			13,493			19	%
Operating expenses:
General and administrative		33,469			28,273			5,196			18	%		82,956			54,245			28,711			53	%
Selling		9,210			6,079			3,131			52	%		16,642			11,896			4,746			40	%
Amortization		29,016			4,208			24,808			590	%		59,755			8,335			51,420			617	%
Marketing and promotion		7,120			4,252			2,868			67	%		12,585			9,177			3,408			37	%
Research and development		515			225			290			129	%		1,300			345			955			277	%
Transaction costs		8,120			18,206			(10,086	)		(55	%)		33,699			20,664			13,035			63	%
Total operating expenses		87,450			61,243			26,207			43	%		2,06,937			1,04,662			1,02,275			98	%
Operating loss		(54,684	)		(25,960	)		(28,724	)		111	%		(1,23,216	)		(34,434	)		(88,782	)		258	%
Interest expense, net		(9,940	)		(4,832	)		(5,108	)		106	%		(20,110	)		(10,568	)		(9,542	)		90	%
Non-operating (expense) income, net		64,750			(72,649	)		1,37,399			(189	%)		1,13,610			(86,008	)		1,99,618			(232	%)
Income (loss) before income taxes		126			(1,03,441	)		1,03,567			(100	%)		(29,716	)		(1,31,010	)		1,01,294			(77	%)
Income taxes (recovery)		(5,671	)		(14,192	)		8,521			(60	%)		(909	)		(20,017	)		19,108			(95	%)
Net income (loss)		5,797			(89,249	)		95,046			(106	%)		(28,807	)		(1,10,993	)		82,186			(74	%)

We are unable to predict the future impacts of COVID-19 on our operational and financial performance. The nature and extent of any impacts are very uncertain and depend on many factors outside our control, including, the timing, extent, and duration of the pandemic, the development and availability of effective treatments and vaccines, the imposition of protective public safety measures, and the impact of the pandemic on the global economy and demand for our products. We believe our cash balances and access to cash through our at-the-market program will be sufficient to satisfy our working capital needs, debt payments, and general liquidity requirements.

We use the following key operating metrics to evaluate our business and operations, measure our performance, identify trends affecting our business, project our future performance, and make strategic decisions.

Other companies, including companies in our industry, may calculate key operating metrics with similar names differently which may reduce their usefulness as comparative measures. Certain variances are labeled as not meaningful ("NM") throughout management's discussion and analysis.

Three months ended September 30,

Nine months ended September 30,

2020

2019

Change

% Change

2020

2019

Change

% Change

Kilograms equivalents sold - cannabis

5,107

10,848

(5,741
)

(53
)%

22,331

19,448

2,883

15
%
Kilograms harvested - cannabis

8,903

15,498

(6,595
)

(43
)%

25,216

35,366

(10,150
)

(29
)%
Thousand units sold - hemp products

2,431

1,946

485

25
%

7,681

5,645

2,036

36
%
Average net selling price per gram - cannabis

$
6.15

$
3.25

$
2.90

89
%

$
3.53

$
4.03

$
(0.50
)

(12
)%
Average cost per gram sold - cannabis

$
4.23

$
2.28

$
1.95

86
%

$
3.09

$
2.95

$
0.14

5
%
Average gross selling price per unit - hemp products

$
8.22

$
8.04

$
0.18

2
%

$
8.01

$
7.29

$
0.72

10
%

	For the three months ended November 30,						For the six months ended November 30,
(in thousands of U.S. dollars)	2021			2020			2021			2020
Net cannabis revenue	$	58,775		$	54,766		$	1,29,224		$	1,05,968
Net beverage alcohol revenue		13,707			710			29,168			710
Distribution revenue		68,869			73,983			1,36,055			1,40,271
Wellness revenue		13,802			—			28,729			—
Cannabis gross margin		23	%		46	%		34	%		48	%
Cannabis adjusted gross margin		43	%		46	%		43	%		48	%
Beverage alcohol gross margin		57	%		60	%		57	%		60	%
Distribution gross margin		11	%		13	%		11	%		14	%
Wellness gross margin		28	%	NA				27	%	NA
Adjusted EBITDA		13,760			10,139			26,457			18,209
Cash and cash equivalents		3,31,783			1,48,205			3,31,783			1,48,205
Working capital		3,93,350			3,21,904			3,93,350			3,21,904
Free cash flow		(24,093	)		(6,863	)		(1,25,940	)		(76,918	)
Adjusted free cash flow		(15,973	)		11,343			(69,430	)		(56,254	)

~~Kilogram equivalents sold – cannabis.~~NA=This reporting segment did not exist in the prior year period. The related acquisition occurred thereafter.

Management updated our reporting segments during the six months ended November 30, 2021. While the Company reported “business under development” as a fifth reporting segment in its previous Annual Report, management determined that this no longer met the definition of a reporting segment. Our reporting segments ~~We sell two product categories: (1) dried~~revenue is primarily comprised of revenues from our cannabis, ~~which includes whole flower, ground flower~~distribution, beverage alcohol operations, and ~~pre-roll products, and (2) cannabis extracts, which includes full-spectrum and purified oil drops and capsules, and product formats infused with cannabis extract such~~wellness, as ~~edibles and vape products.~~ follows:

Revenue from Canadian medical cannabis products: Revenue from Canadian medical cannabis products increased 27% to $7.9 million and ~~number of dried cannabis grams required~~29% to produce extracted cannabis in the form of cannabis oils infused into the final product. This conversion ratio is based on the amount of active cannabinoids in the products rather than the volume of the final product.

Total kilogram equivalents sold increased for the nine months ended September 30, 2020 from the comparable period in 2019 mainly driven by sales in international markets. The decrease for the three months ended September 30, 2020 versus the comparable period in 2019 was almost entirely due to the reduction of bulk sales. We expect continued increases in kilogram equivalent grams sold as we generate sales growth in our key cannabis businesses; adult-use and international medical. Going forward we will pursue opportunistic bulk sales as we manage our product mix and optimize margins.

~~Kilograms harvested – cannabis~~. Kilograms harvested represents the weight of dried whole plants post-harvest, drying and curing. This operating metric is used to measure the production efficiency of our facilities and production team.

~~Total kilograms harvested decreased~~$16.3 million for the three and ~~nine~~six months ended ~~September~~November 30, ~~2020~~2021, compared to revenue of $6.3 million and $12.6 million for the prior year same periods. This increase in revenue from medical cannabis products is primarily driven by the contributions of legacy Tilray’s medical cannabis business resulting from the ~~comparable periods in 2019 partially~~business combination of April 30, 2021. The increase is also due to new innovative product launches, including our new brand Symbios launched earlier in the ~~closure of our High Park Gardens cannabis greenhouse production operation~~year, to address unmet medical needs and ~~partially due~~ to provide patients with more choices in managing their health conditions with medical products. There has been some offset from downward pressure caused by the ~~timing of harvests in Portugal during 2020 compared~~COVID-19 pandemic from patients unable or unwilling to ~~2019.~~ ~~Over time, it is our expectation that harvested quantities for comparable facilities will increase~~see a doctor as ~~we align production with growing sales~~well as increased competition from the adult-rec and ~~as we continue to realize efficiencies in our growing processes resulting from our capital investments.~~the price compression therein.

~~After~~Revenue from Canadian adult-use cannabis products: During the ~~permanent shut down of~~three and six months ended November 30, 2021, our ~~facility at High Park Gardens, a licensed~~gross revenue from Canadian adult-use cannabis ~~facility in Leamington, Ontario,~~product ~~our current production~~decreased 15% to $49.5 million and ~~manufacturing footprint in Canada is approximately 0.7~~increased 3% to $119.1 million square feet and our footprint in Portugal is approximately 2.6 million square feet, for a total of 3.3 million square feet worldwide. Our current growing space in Portugal is made up of 20 hectares of outdoor growing space in Alentejo, 1 hectare of greenhouse and 4 hectares of outdoor growing space in Cantanhede, and 65,000 square feet of manufacturing, processing, research, and office space in Cantanhede. We are currently under construction to complete an additional 3.4 hectares of greenhouse in Cantanhede during the remainder of 2020. Due to COVID-19, however, we have experienced minor construction delays and there is some uncertainty about the final completion date of the additional growing space. If we are unable to complete construction in a timely manner due to COVID-19, we may not achieve all our

expected harvests and production which may negatively impact our international sales. We are actively working with our contractors to maintain appropriate COVID-19 protections at our construction site in an effort to complete construction in a timely manner.

~~Thousand units sold – hemp products.~~ As a result of the acquisition of FHF Holdings Ltd. (“Manitoba Harvest”) in February 2019, we sell hemp products such as shelled hemp seed, ground hemp, broad spectrum hemp extract containing CBD and hemp seed oil that are tracked by individual units.

~~Hemp products sold~~ for the three and ~~nine~~six months ended November 30, 2021 compared to revenue of $58.2 million and $115.1 million for the prior year same periods.The three month ~~periods ending September 30, 2020~~ decreases in gross revenue is primarily due to a series of factors, as follows:

We continue to focus on expanding our product offerings to accommodate the changes in our adult-use customers, During the first quarter, we completed our first shipments to Nunavut. In the second quarter we expanded the terms of our distribution partnership with Rose LifeScience, which will now represent the entire Tilray portfolio; and expanded our partnership with Great North Distributors, Inc. to cover all of Canada, except for Quebec, using its established network.

The six months increase in gross revenue is attributable to the inclusion of Tilray legacy products in our brand portfolio offerings.

Wholesale cannabis revenue: Revenue from wholesale cannabis products increased ~~versus the comparable periods in 2019. The increase~~57% to $2.3 million and decreased 24% to $4.0 million for the three ~~month period was~~and six months ended November 30, 2021 compared to revenue of $1.4 million and $5.2 million for the prior year same periods. The Company continues to believe that wholesale cannabis revenue will remain subject to quarter-to-quarter variability and is based on opportunistic sales.

International cannabis revenue: Revenue from international cannabis products increased 220% to $13.7 million and 460% to $24.0 million for the three and six months ended November 30, 2021 compared to revenue of $4.3 million and $4.3 million for the prior year same periods. The increase is due to ~~increased promotional activity in large format retail~~the contributions of legacy Tilray’s larger international cannabis business as well as ~~accelerating sales~~newly obtained business to business transactions. In Europe, we believe that, despite continuing COVID-19 pressure, cannabis legalization (both medicinal and adult-use) will continue to gain traction, especially following actions of the German and Maltese governments. We also continue to believe that Tilray remains uniquely positioned to win in these markets with its infrastructure being the only company with EU-GMP cultivation facilities in two countries within Europe and our demonstrated commitment to the consistency, quality and safety of our products.

Germany. During the three and six months ended November 30, 2021, we continued to experience some deceleration in the growth of our business caused by the COVID-19 pandemic, which resulted in some patients unable or unwilling to see a doctor. Despite these impacts,

Portugal. We are the only approved medical cannabis product in the market, which is distributed through ~~ecommerce due~~our distribution partners to ~~COVID-19 shopping trends. The increase~~medical stakeholders throughout Portugal.

Luxembourg. We were selected by the Luxembourg Ministry of Health as the exclusive supplier for the ~~nine month period was partially due~~country’s medical cannabis program for dried flower and oils.

Switzerland. We distribute our cannabinoid-based medical extract products to ~~increased promotional activity~~Suisse patients through our partner “Lehenmatt Apotheke”.

France. We were selected as one of the four suppliers in a two-year pilot experiment to supply approximately 3,000 patients with medical cannabis.

Italy. We are one of five distributors licensed to import medical cannabis into the Italian medical cannabis market.

United Kingdom. In the quarter, we completed a shipment of a wide range of dried flower products with high, medium and ~~partially attributable~~balanced potencies into the UK medical cannabis market.

Ireland. We are one out of only three suppliers within the Irish market whose cannabinoid-based medical products are eligible for reimbursement.

Australia. We continue to strengthen the reputation of our Tilray medical brand whereby, through a contract with the Department of Health in Victoria, 90 children are now participating in a government funded seizure program utilizing our cannabinoid-based medical products, which will continue to the ~~fact that the 2019 period only reflected the post acquisition seven months activity while the 2020 period reflects a full nine months~~end of ~~hemp products sold. Looking forward, our units sold may change as some of our large format retail customers shift~~calendar year 2024.

Revenue from Distribution operations decreased 7% to ~~larger size private label offerings.~~

~~Average net selling price per gram – cannabis. The average net selling price per gram is an indicator that shows our pricing trends over time on a gram equivalent basis~~$68.9 million and ~~is impacted by sales mix, channel and product type. We exclude revenue associated with hemp products, accessories and freight sales~~3% to arrive at cannabis-related revenue. We calculate average net selling price per gram by dividing cannabis-related revenue by kilogram equivalents sold. As Cannabis 2.0 products become a larger percentage of our mix, and because Cannabis 2.0 products include more value-added activities and the cannabis inputs will be a lower portion of the overall cost and value of the products, we may change this operating metric from per gram to unit measures.

~~The average net selling price per gram increased~~$136.1 million for the three and six months ended ~~September~~November 30, ~~2020 from comparable period in 2019 due~~2021 compared to ~~a shift~~revenue of $74.0 million and $140.3 million for the prior year same periods.Included in distribution ~~channels~~revenue is $68.0 million and ~~product mix. International Markets increased to 26%~~$133.0 million of revenue from ~~22% compared to~~CC Pharma, and $0.9 million and $3.1 million of revenue from other distribution companies for the ~~same period in 2019. Additionally, higher-priced Cannabis 2.0 products, which didn’t exist~~three and six months ended November 30, 2021 versus $72.0 million and $136.2 million from CC Pharma and $2.0 million and $4.1 million from other distribution companies, respectively, in the ~~comparable period~~prior year same periods.

The decrease in ~~2019, continued to grow as part of our Adult-use business. The average net selling price per gram decreased for~~revenue during the ~~nine months~~three-months ended ~~September~~November 30, ~~2020 from the comparable period in 2019~~2021 is primarily due to the ~~termination~~impact of changes in the exchange rate between the Euro and USD totaling a ~~supply contract that included a one-time transaction at a significantly reduced net selling price per gram~~$5.3 million reduction to the comparable prior period. Additionally, the decrease in ~~Q2 2020.~~

We expect our average selling price per gram to continue to increase over time as our international medical cannabis sales continue to grow. However, due to COVID-19, if international sales are not realized or if construction of our new greenhouse space in Portugal is delayed we may not fully realize our expected increase in sales price because we may not have sufficient scale or product atrevenue during the ~~potency level needed to supply our growing international medical sales business.~~

~~Average cost per gram sold – cannabis. The average cost per gram sold measures~~six-months ended November 30, 2021 was also the efficiency in our cultivation, manufacturing and fulfillment operations. We deduct hemp products, inventory valuation adjustments and the cost of sales related to accessories from total cost of sales to arrive at cannabis-related cost of sales. Cannabis-related cost of sales is then divided by total kilogram equivalents sold to calculate the average cost per gram sold. As Cannabis 2.0 products become a larger percentage of our mix, and because the Cannabis 2.0 products include other input costs that can be a greater portionresult of the ~~unit cost than~~negative impact of an isolated weather event in Densborn, Germany. Specifically, heavy flooding impacted CC Pharma and forced a business closure for approximately five days leading to a decrease in net revenue in the ~~cannabis ingredients, we may change this operating metric~~period of almost $5.0 million.

Revenue from ~~per gram~~our Beverage operations increased to ~~unit measures.~~

~~The average cost per gram sold increased~~$13.7 million and $29.2 million for the three and ~~nine~~six months ended ~~September~~November 30, ~~2020 from comparable periods~~2021 compared to revenue of $0.7 million for the prior year same periods. SweetWater operates on-premises, wholesale, and specialty sales. Revenues continued to be negatively affected by the COVID-19 pandemic impacting on-premise consumers. The increase is substantially related to our acquisition of SweetWater on November 20, 2020.

Earlier in ~~2019 partly due to lower kilograms sold~~the year, our beverage operations began operating our new brewing facility in Colorado and opened a new taproom at the Denver International Airport in connection with its strategic expansion initiative. In addition, we released an extensive new line of innovative products, including seltzers, as well as a ~~result~~new beer offering developed in collaboration with our Canadian cannabis Broken Coast brand and a new vodka soda offering developed in collaboration with our Canadian cannabis Riff brand as Tilray continues to strengthen its strategic position in the U.S. by expanding its presence through acquisitions and collaboration with other Tilray cannabis brands. This strategy of ~~reduced bulk sales~~leveraging our growing portfolio of brands enables the company to launch THC-based product adjacencies upon federal legalization in the U.S.

Included in Wellness revenue is $13.8 million and partly due to product mix where Cannabis 2.0 products have higher input costs than dried flower. We expect to see improvement in our cost per gram metric as the full benefit of our cost reductions, including the closure of High Park Gardens, which was a relatively high cost facility to operate, are realized. In addition, as Cannabis 2.0 become a larger portion of our mix, these products will result in better throughput and cost absorption at our High Park Holdings processing facility.

~~Average gross selling price per unit – hemp products. The average gross selling price per unit is an indicator that shows our pricing trends over time on a unit basis~~$28.7 million from Manitoba Harvest, for our hemp products and is impacted by sales mix, channel and product type. We exclude revenue associated with cannabis, accessories and freight sales to arrive at hemp product-related revenue. We calculate average gross selling price per unit by dividing hemp product-related revenue by units sold.

~~The average gross selling price per unit for hemp products increased by 2% and 10% during~~ the three and ~~nine~~six months ended ~~September~~November 30, 2020 from the comparable periods in 2019, respectively, due to sales mix favoring larger sizes and organic product sales versus non-organic. Going forward, this trend may continue as some large format retail customers shift to larger size private label offerings.

There were no material changes to our critical accounting policies and estimates from the information provided in “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” included in our Annual Report on Form 10-K for the year ended December 31, 2019, other than those noted in “Part I, Item 1. Note 1 – Summary of Significant Accounting Policies” to our condensed consolidated financial statements (the “financial statements”) contained in this Quarterly Report on Form 10-Q. The most significant updates are as follows:

In May 2020, we announced our decision to close our High Park Gardens facility in response to the current economic climate. As a result, we have adopted an accounting policy for assets held for sale. Assets held for sale are accounted for in accordance with applicable accounting guidance provided in ASC Topic 360, Property, Plant and Equipment. We classified our assets as held for

sale if, among other criteria, the carrying amount will be recovered principally through a sale transaction rather than continued use and a sale is considered probable within one year. Assets classified as held for sale are measured at the lower of the carrying amount and fair value less costs to sell.

We have determined assets at High Park Gardens meet the criteria for held-for-sale classification and have measured these assets at the lower of their carrying amount and fair value less costs to sell. We have recorded an impairment loss recognized for the initial write-down of these assets to fair value less costs to sell in impairment of assets within the statements of net and comprehensive loss. We have presented these assets classified as held for sale separately from the other assets in the balance sheets.

~~We used a third-party real estate agent to assist us in the determination of the fair value~~2021. Manitoba Harvest was part of the assets held for sale. The agent used recent sales of similar properties to determine an implied sale price per acre of land and greenhouse space and applied this to the land and greenhouse space held for sale to estimate the fair value.

The unprecedented nature of the COVID-19 pandemic and its impact results in uncertainty about future market conditions, the impacts on our business, and consequently, the assumptions we use to develop forecasts of business performance. As a result, significant judgments and estimates have been madeacquired in the ~~qualitative and quantitative impairments and the going concern assessments at September 30, 2020.~~Arrangement. There isare no ~~guarantee that our total~~comparable revenues will grow or remain at similar levels during the next quarter of 2020. Depending on conditions, we may have to review our assumptions which may result in additional adjustments or impairments of assets. Additionally, if COVID-19 continues to negatively impact business conditions around the globe and in our key markets, we may need to further adjust our operations and headcount during the coming quarters.

In March 2020, we closed on a registered offering including Class 2 common stock that included warrants and pre-funded warrants. As a result, we have adopted an accounting policy for warrants. Warrants are accounted for in accordance with applicable accounting guidance provided in ASC Topic 815, Derivatives and Hedging – Contracts in Entity's Own Equity (“ASC 815”), as either liabilities or as equity instruments depending on the specific terms of the warrant agreement. Our warrants are classified as liabilities and are recorded at fair value. The warrants are subject to remeasurement at each settlement date and at each balance sheet date and any change in fair value is recognized as a component of change in fair value of warrant liability in the ~~statements of net loss~~prior year being presented.

Gross profit, gross margin and ~~comprehensive loss. Transaction costs allocated to warrants that are presented~~adjusted gross margin for our reporting segments

Our gross profit and gross margin for the three and six months ended November 30, 2021 and 2020, is as ~~a liability are expensed immediately within other expenses (income) in the statements of net loss and comprehensive loss.~~follows:

We estimate the fair value of the warrant liability using a Monte Carlo pricing model. We are required to make assumptions and estimates in determining an appropriate risk-free interest rate, volatility, term, dividend yield, discount due to exercise restrictions, and the fair value of common stock. Any significant adjustments to the unobservable inputs would have a direct impact on the fair value of the warrant liability.

~~Financial data is expressed in thousands of United States dollars, unless otherwise noted.~~

Three months ended September 30,

Nine months ended September 30,

2020

2019

2020

2019

Revenue

$
51,406

$
51,101

$
153,922

$
120,043

Cost of sales

Product costs

34,224

35,047

108,616

85,806

Inventory valuation adjustments

13,443

201

36,116

726

Gross profit

3,739

15,853

9,190

33,511

General and administrative expenses

12,665

20,122

49,030

49,618

Sales and marketing expenses

10,000

16,974

40,709

39,161

Research and development expenses

921

2,315

2,831

4,891

Stock-based compensation expenses

8,080

8,644

23,404

22,303

Depreciation and amortization expenses

3,425

3,200

10,353

7,457

Impairment of assets

—

—

58,210

—

Acquisition-related expenses (income), net

—

(13,454
)

—

(6,566
)
Loss from equity method investments

1,420

1,837

4,495

1,837

Operating loss

(32,772
)

(23,785
)

(179,842
)

(85,190
)
Foreign exchange (gain) loss, net

(9,319
)

2,585

5,424

1,153

Change in fair value of warrant liability

(31,913
)

—

51,275

—

Interest expenses, net

10,437

8,680

30,147

26,005

Finance income from ABG

—

(210
)

—

(557
)
Other expense (income), net

(38
)

(1,116
)

4,944

(6,185
)
Loss before income taxes

(1,939
)

(33,724
)

(271,632
)

(105,606
)
Deferred income tax expenses (recoveries)

134

2,432

(4,013
)

(3,987
)
Current income tax expenses (benefit)

243

195

505

402

Net loss

$
(2,316
)

$
(36,351
)

$
(268,124
)

$
(102,021
)
Other Financial Data

Adjusted EBITDA ⁽¹⁾

$
(1,547
)

$
(21,871
)

$
(32,531
)

$
(54,277
)

(in thousands of U.S. dollars)	For the three months ended November 30,						Change			% Change			For the six months ended November 30,						Change			% Change
Cannabis	2021			2020			2021 vs. 2020						2021			2020			2021 vs. 2020
Revenue	$	73,429		$	70,155		$	3,274			5	%	$	163,362		$	137,275	��	$	26,087			19	%
Excise taxes		(14,654	)		(15,389	)		735			(5	%)		(34,138	)		(31,307	)		(2,831	)		9	%
Net revenue		58,775			54,766			4,009			7	%		129,224			105,968			23,256			22	%
Cost of goods sold		45,259			29,632			15,627			53	%		85,450			55,407			30,043			54	%
Gross profit		13,516			25,134			(11,618	)		(46	%)		43,774			50,561			(6,787	)		(13	%)
Gross margin		23	%		46	%		(23	%)		(50	%)		34	%		48	%		(14	%)		(29	%)

Inventory valuation adjustments		12,000			—			12,000		(0%)				12,000			—			—		(0%)
Adjusted gross profit ⁽¹⁾		25,516			25,134			382			10	%		55,774			50,561			5,213			22	%
Adjusted gross margin ⁽¹⁾		43	%		46	%		10	%		(3	%)		43	%		48	%		22	%		47	%
Distribution
Revenue	$	68,869		$	73,983		$	(5,114	)		(7	%)	$	136,055		$	140,271		$	(4,216	)		(3	%)
Excise taxes		—			—			—		NM				—			—			—		NM
Net revenue		68,869			73,983			(5,114	)		(7	%)		136,055			140,271			(4,216	)		(3	%)
Cost of goods sold		61,237			64,263			(3,026	)		(5	%)		120,527			121,033			(506	)		(0	%)
Gross profit		7,632			9,720			(2,088	)		(21	%)		15,528			19,238			(3,710	)		(19	%)
Gross margin		11	%		13	%		(2	%)		(2	%)		11	%		14	%		(2	%)		(17	%)
Beverage alcohol
Revenue	$	14,544		$	754		$	13,790		NM			$	31,027		$	754		$	30,273		NM
Excise taxes		(837	)		(44	)		(793	)	NM				(1,859	)		(44	)		(1,815	)	NM
Net revenue		13,707			710			12,997		NM				29,168			710			28,458		NM
Cost of goods sold		5,921			281			5,640		NM				12,583			281			12,302		NM
Gross profit		7,786			429			7,357		NM				16,585			429			16,156		NM
Gross margin		57	%		60	%		(4	%)	NM				57	%		60	%		(4	%)	NM
Wellness
Revenue	$	13,802		$	—		$	13,802		NM			$	28,729		$	—		$	28,729		NM
Excise taxes		—			—			—		NM				—			—			—		NM
Net revenue		13,802			—			13,802		NM				28,729			—			28,729		NM
Cost of goods sold		9,970			—			9,970		NM				20,895			—			20,895		NM
Gross profit		3,832			—			3,832		NM				7,834			—			7,834		NM
Gross margin		28	%		—	%		28	%	NM				27	%		—	%		27	%	NM
Total
Revenue	$	170,644		$	144,892		$	25,752			18	%	$	359,173		$	278,300		$	80,873			29	%
Excise taxes		(15,491	)		(15,433	)		(58	)		0	%		(35,997	)		(31,351	)		(4,646	)		15	%
Net revenue		155,153			129,459			25,694			20	%		323,176			246,949			76,227			31	%
Cost of goods sold		122,387			94,176			28,211			30	%		239,455			176,721			62,734			35	%
Gross profit		32,766			35,283			(2,517	)		(7	%)		83,721			70,228			13,493			19	%
Gross margin		21	%		27	%		(6	%)		(1	%)		26	%		28	%		(3	%)		62	%

Inventory valuation adjustments		12,000			—			12,000		(0%)				12,000			—			—		(0%)
Adjusted gross profit ⁽¹⁾		44,766			35,283			9,483			27	%		95,721			70,228			25,493			36	%
Adjusted gross margin ⁽¹⁾		29	%		27	%		37	%		2	%		30	%		28	%		33	%		118	%

We report our operating results in two segments: (i) Cannabis (licensed) and (ii) Hemp (unlicensed). The business segments reflect how our operations are managed, how resources are allocated, how operating performance is evaluated by senior management and the structure of our internal financial reporting. We also evaluate revenue by product channel and source.

~~Revenue.~~ Revenue increased 1% to $51.4 million (C$68.1 million) and 28% to $153.9 million (C$208.1 million) for the three and nine months ended September 30, 2020, compared to revenue of $51.1 million and $120.0 million (C$67.8 million and C$159.3 million) for the same periods in 2019, respectively. For the three and nine months ended September 30, 2020, the increases from the comparable period in 2019 were driven by increases sales in our adult-use, international medical, and hemp channels, which were accompanied by a significant planned reduction in bulk sales.

~~Cannabis.~~ Cannabis segment revenue decreased 11% to $31.4 million (C$41.6 million) and 17% to $92.4 million (C$124.9 million) for the three and nine months ended September 30, 2020, compared to revenue of $35.5 million and $78.9 million (C$46.4 million and C$103.3 million) for the same periods in 2019, respectively. The decrease for the three months ended compared to the same period in 2019 was due to the significant planned reduction of bulk sales. Excluding bulk, revenue increased by 24% for the three months ended September 30, 2020 versus comparable period in 2019 primarily driven by increased adult-use and international medical sales. We expect continued growth in both the adult-use and international medical sales channels in 2020 while we expect to see a continued decline in bulk sales as we focus on higher margin opportunities. We also expect cannabis to reflect a higher percentage of our total revenue in coming quarters.

~~Hemp.~~ Hemp segment revenue increased 28% to $20.0 million (C$26.5 million) and 50% to $61.5 million (C$83.2 million) for the three and nine months ended September 30, 2020, compared to revenue of $15.7 million and $41.2 million (C$20.5 million and C$53.9 million) for the same periods in 2019, respectively. ~~The increase for the three month period was due to increased promotional activity in large format retail as well as accelerating sales through ecommerce due to COVID-19 shopping trends.~~ The increase for the nine month period was partially due to increased promotional activity and partially attributable to the fact that the 2019 period only reflected the post acquisition seven months of hemp revenue while the 2020 period reflects a full nine months of revenue. Until there is more clarity from the ~~Food and Drug Administration~~ (“FDA”) on CBD in the United States, we expect the hemp segment to deliver modest to little top line growth. Our team continues to explore expanded distribution for our products and other ways to generate sales growth despite the negative impact COVID-19 may have on our retail partners.

We also analyze our sales mix by dried cannabis, extracts, hemp and accessories. Cannabis as a whole represented 61% and 60% of total revenue for the three and nine months ended September 30, 2020, versus 69% and 66% for the comparable periods in 2019, respectively. Dried cannabis represented 67% and 66% of cannabis revenue for the three and nine months ended September 30, 2020, compared to 83% and 79% for the comparable periods in 2019, respectively. Cannabis extracts represented 33% and 33% of cannabis revenue for both the three and nine months ended September 30, 2020, compared to 16% and 21% for the comparable periods in 2019, respectively. Hemp products represented 39% and 40% of total revenue for the three and nine months ended September 30, 2020, compared to 31% and 34% for the comparable periods in 2019, respectively. The growth in Hemp products as a percent of total sales was largely due to the inclusion of Hemp product sales for only seven months in the 2019 period.

~~Cost of sales.~~ Cannabis gross margin:~~Cost~~ Gross margin decreased during the three and six months ended November 30, 2021 to 23% and 34% from 46% and 48% versus the prior year same periods, reflecting the addition of sales ~~increased~~of Tilray brands that have higher costs to produce than our legacy brands and a non-cash inventory write down of $12 million in November 2021. Significant efforts have been taken to reduce the Company’s cultivation costs at its legacy Tilray Canadian facilities, including announcing the shutdown of both the Enniskillen and Nanaimo facilities. In the interim and until the inventory cultivated at these facilities work their way through inventory, we expect to report lower gross margins until all inventory is cultivated at legacy Aphria facilities. Our European operations continue to work to optimize the cost structure for their cannabis growing facilities, including working with the Canadian operations team, all in an effort to continually will lower our per unit costs.

Distribution gross margin: Gross margin of 11% and 11% for the three and ~~nine~~six months ended ~~September~~November 30, ~~2020 from~~2021 slightly decreased versus the ~~comparable~~same periods in ~~2019 partially due to payments to a supplier to terminate a contract and, partially due to~~the prior year driven by increased ~~sales volumes and the associated variable~~ costs as ~~well as increased expenses at our production facilities that~~the Company’s primary source of products were ~~fully staffed~~unable to ship during border closures and ~~fully operational in 2020 compared to 2019.~~during periods of peak demand.

~~Gross margin.~~ Beverage alcohol gross margin:Gross margin of ~~-15%~~57% and ~~-15%~~57% for the three and ~~nine~~six months ended ~~September~~November 30, ~~2020 decreased from~~2021 are in line with our expectations. We did not operate in this segment until the ~~comparable periods in 2019 partially due one-time transactions associated with~~final week of the ~~terminations~~second quarter of ~~supply contracts, partially due to non-recurring inventory write-downs related to~~ the ~~closure~~prior year.

Wellness gross margin: Gross margin of ~~High Park Gardens~~28% and ~~other facilities, and write-downs for obsolescence, spoilage and excess inventory. Excluding the impact of these non-recurring adjustments, gross margin was~~ 27% ~~and 19%~~ for the three and ~~nine~~six months ended ~~September~~November 30, ~~2020, respectively. For~~2021 are in line with our expectations and consistent with the ~~remainder of 2020, we expect to see improved gross margins due to lower costs at our facilities resulting from cost cutting measures, additional operating efficiencies from more throughput~~preceding fiscal quarter. We acquired the wellness business in the Arrangement and ~~better fixed cost absorption, and~~did not operate in this segment during the availability of low cost third-party supply for any supplemental product required. Going forward, and as we better align inventory levels and sales, we do not expect to incur material non recurring inventory write downssame periods during prior year.

~~Cost~~Operating expenses are comprised of ~~sales.~~ ~~Cost of sales~~general and administrative, share-based compensation, selling, amortization, marketing and promotion, research and development, and transaction costs. These costs increased by $26.2 million and $102.3 million for the three and ~~nine~~six months ended ~~September~~November 30, ~~2020 from the comparable periods in 2019~~2021 as compared to prior year same periods. This was primarily~~due to~~ ~~sales volume increases and partially~~ due to ~~lower absorption rates at~~reporting full quarters of operating expenses for SweetWater and Tilray, including non-cash amortization charges associated with definite life intangible assets acquired and general and administrative expenses. The remaining increase is from transaction costs related to non-recurring expenses associated with our ~~facilities.~~current acquisitions and evaluation of future potential acquisition, and one-time litigation costs associated with the acquired net assets.

During the three and six months ended November 30, 2021, increased by 18% and 53% as compared to prior year same periods.

Executive compensation decreased in the three months and increased the six months ended ~~September~~November 30, ~~2020 represents 0% gross margin change from comparable~~2021. The slight decrease in the three months compared to the prior period is primarily related to one-time changes in ~~2019. Gross margin of 37%~~the overall compensation structure. The increase for the ~~nine months ended September 30, 2020 represents 5% gross margin decline from~~six month period compared to the ~~comparable periods in 2019~~prior period is primarily due to ~~year-to-date impact~~an increase in the number of ~~a one-time inventory adjustment made~~directors and executive level personnel on our board of directors and executive management team, respectively, and an increase in ~~Q2 2020~~base salaries commensurate with the increased complexity of our Company.

Office and ~~partially~~general increased during the three and six months ended November 30, 2021 primarily due to ~~a sales mix shift to larger~~reporting SweetWater and ~~lower margin package sizes.~~Tilray for the periods and the additional one-time costs associated with the upcoming closure of our Nanaimo facility.

~~Operating expenses~~Salaries and wages decreased in the three months and increased the six months ended November 30, 2021. The slight decrease from the prior period is primarily related to one-time changes in the overall compensation structure. The increase is primarily due to additions associated with new acquisitions from prior year. The Company’s headcount increased to approximately 1,800 employees as a result of the Arrangement compared to 1,000 employees as of November 30, 2020.

~~(in thousands~~The Company recognized stock-based compensation expense of ~~United States dollars)~~

Three months ended September 30,

Nine months ended September 30,

2020

2019

Change

% Change

2020

2019

Change

% Change

General and administrative expenses

$
12,665

$
20,122

$
(7,457
)

(37
)%

$
49,030

$
49,618

$
(588
)

(1
)%
Sales and marketing expenses

10,000

16,974

(6,974
)

(41
)%

40,709

39,161

1,548

4
%
Research and development expenses

921

2,315

(1,394
)

(60
)%

2,831

4,891

(2,060
)

(42
)%
Stock-based compensation expenses

8,080

8,644

(564
)

(7
)%

23,404

22,303

1,101

5
%
Depreciation and amortization expenses

3,425

3,200

225

7
%

10,353

7,457

2,896

39
%
Impairment of assets

—

—

—

—

58,210

—

58,210

100
%
Acquisition-related expenses (income), net

—

(13,454
)

13,454

(100
)%

—

(6,566
)

6,566

(100
)%
Loss from equity method investments

1,420

1,837

(417
)

100
%

4,495

1,837

2,658

100
%
Total operating expenses

$
36,511

$
39,638

$
(3,127
)

(8
)%

$
189,032

$
118,701

$
70,331

59
%
(as a percentage of revenue)

General and administrative expenses

25
%

39
%

32
%

41
%

Sales and marketing expenses

19
%

33
%

26
%

33
%

Research and development expenses

2
%

5
%

2
%

4
%

Stock-based compensation expenses

16
%

17
%

15
%

19
%

Depreciation and amortization expenses

7
%

6
%

7
%

6
%

Impairment of assets

0
%

0
%

38
%

0
%

Acquisition-related expenses (income), net

0
%

-26
%

0
%

-5
%

��

Loss from equity method investments

3
%

4
%

3
%

2
%

Total operating expenses

71
%

78
%

123
%

99
%

~~General~~$8.3 million and ~~administrative.~~ ~~General and administrative expenses decreased~~$17.7 million for the three and ~~nine~~six months ended ~~September~~November 30, ~~2020 from~~2021 compared to $5.5 million and $8.3 million for the ~~comparable~~same periods in ~~2019 generally~~the prior year. The increase is primarily due to ~~implemented cost savings initiatives. During~~increased number of employees and the ~~nine~~accelerated vesting of certain of our stock-based compensation awards tied to the Arrangement. Stock options are valued using the Black-Scholes valuation model and represents a non-cash expense, restricted share units (“RSUs”) are valued based on the graded vesting and the grant date fair value.

Insurance expense for the three and six months ended ~~September~~November 30, ~~2020, we reduced general~~2021 increased due primarily to our directors and ~~administrative headcount by 227 positions and incurred $3.1 million of non-recurring costs within general and administrative expenses primarily associated with severance payments, resulting in~~officers’ insurance policy. This increase reflects an increase in ~~general and administrative expenses for such period.~~premium rates, as the Company continued with legacy Tilray’s rating history.

~~Sales and marketing.~~ ~~Sales and marketing expenses decreased for~~Selling costs

For the three months ended ~~September~~ November 30, ~~2020 from~~2021, the ~~comparable period in 2019 primarily due~~Company incurred selling costs of $9.2 million or 5.9% of revenue as compared to ~~cost savings measures~~$6.1 million and ~~partially due to the delay~~4.2% of sales and marketing programs as result of COVID19. During the nine months ended September 30, 2020, sales and marketing expenses increased from the comparable period in 2019 partly due to having a full nine months of Manitoba Harvest expenses versus only seven monthsrevenue in the prior year ~~(acquired February 28, 2019)~~same period. For the six months ended November 30, 2021, the Company incurred selling costs of $16.6 million or 5.1% of revenue as compared to $11.9 million and ~~partly due~~4.3% of revenue in the prior year same period. These costs relate to ~~investments behind~~third-party distributor commissions, shipping costs, Health Canada cannabis fees, and patient acquisition and maintenance costs. Patient acquisition and ongoing patient maintenance costs include funding to individual clinics to assist with additional costs incurred by clinics resulting from the ~~growth~~education of ~~Cannabis 2.0~~.patients using the Company’s products. The increase in selling costs as a percent of revenue in both the three and six-month periods resulted from incurred costs associated with multiple distributors in the same location, which represent a duplication of costs that will be reduced upon achievement of synergies. The increase is mainly driven by the combination of legacy Tilray.

The Company incurred non-production related amortization charges of $29.0 million and ~~development.~~ ~~Research and development expenses decreased~~$59.8 million for the three and ~~nine~~six months ended ~~September~~November 30, ~~2020~~2021 compared to $4.2 million and $8.3 million in the prior year same periods. The increase is associated with the amortization on the acquired definite life intangible assets from SweetWater and Tilray.

For the ~~comparable periods~~three and six months ended November 30, 2021, the Company incurred marketing and promotion costs of $7.1 million and $12.6 million as compared to $4.3 million and $9.2 million in ~~2019 primarily due~~the prior year same periods. The increase is mainly driven by the combination of legacy Tilray.

Research and development costs were $0.5 million and $1.3 million during the three and six months ended November 30, 2021 compared to ~~right-sizing~~$0.2 million and $0.3 million in the ~~departmental structure.~~prior year same periods. These relate to external costs associated with the development of new products. Although the Company spends a significant amount on research and development, the majority of these costs remain in costs of sales, as the Company does not reclassify research and development costs related to the cost of products consumed in research and development activities.

The three month decrease is associated with the closing of the SweetWater acquisition in the prior period. This ~~initiative not only delivered savings but also resulted~~six month increase is associated with the solicitation of shareholder votes supporting an increase in ~~establishing a more agile R&D team capable~~the number of ~~developing future innovations.~~authorized common stock shares, transaction closing costs related to the Arrangement, the MM Transaction and the evaluation of other potential acquisitions and one-time litigation costs.

For the three and six ~~Stock-based compensation expenses increased~~months ended November 30, 2021, the Company recognized a change in fair value of its APHA 24 convertible debentures of $56.4 million and $95.7 million, compared to a decrease in value of $70.7 million and $70.3 million for the ~~nine months ended September 30, 2020 from~~prior year same periods. The change is driven primarily by the ~~comparable period~~changes in ~~2019 primarily due to~~ the ~~issuance~~Company’s share price and the change in the trading price of ~~stock options and restricted stock units under~~ the ~~2018 Equity Incentive Plan throughout 2019 and 2020.~~

~~Depreciation and amortization.~~ ~~Depreciation and amortization expenses increased~~convertible debentures. Additionally, for the three and ~~nine~~ six months ended ~~September~~November 30, ~~2020~~2021 Company recognized a change in fair value of its warrants of resulting in a gain of $20.2 million and $37.7 million acquired as part of the Arrangement, also as a result of the decrease in our share price. Furthermore, for three and six months ended November 30, 2021 the Company recognized a loss of $9.5 million and $15.2 million, resulting from the ~~comparable~~changes in foreign exchange rates during the period, compared to losses of $3.4 million and $19.7 million for the prior year same periods, largely associated with the strengthening of the US dollar against the Canadian dollar. The remaining other losses relate to changes in 2019 predominantly due to increased investments in cultivation and production facilities in Portugal and some investment in our Canadian facilities. We expect depreciation and amortization to continue to increase as our capital projects are completed and assets are put into service.

~~Impairment of assets.~~ ~~For the nine months ended September 30, 2020, we incurred non-cash impairment charges of $58.2 million.~~

~~In the first quarter of 2020, due to the lack of clarity from the FDA regarding CBD products~~fair value in the ~~United States, COVID-19 related negative impacts on retail shopping,~~Company’s convertible notes receivable and ~~a commensurate decrease~~long-term investments.

We have included in ~~demand projections for CBD products, we~~ ~~incurred non-cash impairment charges of:~~this report measures of financial performance that are not defined by GAAP. We believe that these measures provide useful information to investors and include these measures in other communications to investors. These non-GAAP measures include:

~~In the second quarter of 2020, primarily related to our decision to close the High Park Gardens facility, we incurred additional non-cash impairment charges of $25.1 million~~ ~~which included impairment charges of:~~

~~Foreign exchange (gain) loss, net.~~ The impact of foreign exchange for the three and nine months ended September 30, 2020 was a gain of $9.3 million and a loss of $5.4 million, compared to a loss of $2.6 million and $1.2 million, for the comparable periods in 2019, respectively. As we hold a significant portion of our cash balances in Canadian dollars, the fluctuation in foreign exchange rates between Canadian dollars and United States dollars drove the foreign exchange loss for nine months ended September 30, 2020.

~~Change in fair value of warrant liability~~. In March 2020 we closed an equity offering which resulted in a warrant liability recorded at fair value. The warrant liability is marked to market, with the primary underlying input into the warrant valuation being our own stock price. Due to the movements in the market price of our stock since the offering closed, the fair value of the warrant liability decreased by $31.9 million during the three months ended September 30, 2020, and increased by $51.3 million during the nine months ended September 30, 2020.

~~Interest expense, net.~~ Interest expense, net for the three and nine months ended September 30, 2020 was $10.4 million and $30.1 million, compared to $8.7 million and $26.0 million, for the comparable periods in 2019, respectively. The increase was primarily attributable to the Senior Facility which was entered into on February 28, 2020. We expect an increase in interest expense in 2020 to reflect a full year of expense related to the Senior Facility.

~~Finance income from ABG.~~ ~~Finance income from ABG decreased for the three and nine months ended September 30, 2020 as the ABG finance receivable was written-off during the three months ended March 31, 2020.~~

~~Other expense (income), net.~~ Other expense (income), net increased for the three and nine months ended September 30, 2020 from the comparable periods in 2019, as equity investments measured at fair value had a decline in value in 2020 compared to an increase in value in the comparable periods in 2019. In addition, we incurred $4.0 million of issuance costs associated with the March 2020 equity offering.

~~Net loss decreased~~For each of these non-GAAP financial measures, we are providing below a reconciliation of the differences between the non-GAAP measure and the most directly comparable GAAP measure, an explanation of why our management and Board of Directors believe the non-GAAP measure provides useful information to investors and any additional purposes for which our management and Board of Directors use the ~~three months ended~~non-GAAP measures. These non-GAAP measures should be viewed in addition to, and ~~increased~~not in ~~the nine months ended September 30, 2020 from~~lieu of, the comparable ~~periods~~GAAP measures.

All of these non-GAAP financial measures should be considered in ~~2019 primarily due to the impact~~addition, and not in lieu of, the ~~change in fair value of warrant liability, combined with the impairment of assets and the (gain) loss on foreign exchange.~~

Adjusted earnings before interest, tax and depreciation (“Adjusted EBITDA”) improved for the three and nine months ended September 30, 2020 from the comparable periods in 2019 generally due to reductions in operating expenses, improved margins (excluding one time adjustments) due to cost reductions, and sales and geographic mix shifts.

~~To supplement our~~ financial ~~statements, which are prepared~~measures calculated and presented in accordance with accounting principles generally accepted in the United States ~~generally accepted accounting principles~~of America, (“GAAP”)~~, we use certain measures, as described below, to understand and evaluate our operating performance.~~. These measures, which may be different than similarly titled measures used by other companies, are presented to help investors’ overall understanding of our financial performance and should not be considered a substitute for, or superior to, the financial information prepared and presented in accordance with GAAP.

Adjusted net loss represents a non-GAAP financial measure that does not have any standardized meaning prescribed under GAAP and may not be comparable to similar measures presented by other companies. Adjusted net income is calculated as net (loss) income plus (minus) the unrealized loss (gain) on convertible debentures, a non-cash item, share-based compensation, foreign exchange (loss) gain, all non-cash items, and transaction costs, costs which will not necessarily continue in future periods depending on the frequency of additional M&A considered by the Company. It represents a measure management uses in evaluating operating results to reduce the impact of the volatility caused by fair value accounting of instruments associated with our capital structure, that have no impact on operations. The increase in adjusted net loss is primarily driven by higher net loss stemming from higher amortization costs associated with the definite lived assets acquired during the year, the additional general and administrative costs associated with Tilray for the full quarter and increased non-cash unrealized loss on changes to the fair value of our convertible debentures.

Adjusted EBITDA is a non-GAAP financial measure that does not have any standardized meaning prescribed by GAAP and may not be comparable to similar measures presented by other companies. The Company calculates adjusted EBITDA as net (loss) income before income taxes, net interest expense, depreciation and amortization, equity in net loss of equity-method investees, inventory write downs, stock-based compensation, integration activities, transaction costs, unrealized currency gains and losses and other adjustments.

(The Company’s management believes that this presentation provides useful information to management, analysts and investors regarding certain additional financial and business trends relating to its results of operations and financial condition. In addition, management uses this measure for reviewing the financial results of the Company and as a component of performance-based executive compensation.

We do not consider Adjusted EBITDA in ~~thousands~~isolation or as an alternative to financial measures determined in accordance with GAAP. The principal limitation of ~~United States dollars)~~Adjusted EBITDA is that it excludes certain expenses and income that are required by GAAP to be recorded in our consolidated financial statements. In addition, Adjusted EBITDA is subject to inherent limitations as this metric reflects the exercise of judgment by management about which expenses and income are excluded or included in determining Adjusted EBITDA. In order to compensate for these limitations, management presents Adjusted EBITDA in connection with GAAP results.

For the period ended November 30, 2021, adjusted EBITDA increased primarily from favorable effects of new lines of business, offset by the inclusion of legacy Tilray’s cannabis business, while we work to achieve our synergies plan, as follows:

Adjusted EBITDA should not be considered in isolation from, or as a substitute for, net loss. There are a number of limitations related to the use of Adjusted EBITDA as compared to net loss, the closest comparable GAAP measure. Adjusted EBITDA ~~excludes:~~adjusts for the following:

Gross profit (excluding inventory valuation adjustments) is a non-GAAP measure calculated in the cannabis segment. It is calculated as revenue less cost of sales, adjusted to add back inventory valuation adjustments.

Gross margin percentage (excluding inventory valuation adjustments) is a non-GAAP measure calculated in the cannabis segment. It is calculated as the gross profit (excluding inventory valuation adjustments), as described above, divided by revenue.

~~Gross profit (excluding inventory valuation adjustments and purchase accounting value step-up)~~

Gross profit (excluding inventory valuation adjustments and purchase accounting value step-up) is a non-GAAP measure calculated in the hemp segment. It is calculated as revenue less cost of sales, adjusted to add back inventory valuation adjustments and purchase accounting value step-up of $0 for the three and nine months ended September 30, 2020 (2019 - $0 and $2,041).

~~Gross margin percentage (excluding inventory valuation adjustments and purchase accounting value step-up)~~

Gross margin percentage (excluding inventory valuation adjustments and purchase accounting value step-up) is a non-GAAP measure calculated in the hemp segment calculated as the gross profit (excluding inventory valuation adjustments and purchase accounting value step-up), as defined above, divided by revenue.

As of September 30, 2020, we had cash and cash equivalents of $155.2 million which were held for working capital and general corporate purposes. This represents an overall increase of $58.4 million since December 31, 2019. Our primary need for liquidity is to fund working capital requirements, capital expenditures, debt service obligations and for general corporate purposes. Our ability to fund operations and make planned capital expenditures and debt service obligations depends on future operating performance and cash flows, which are subject to prevailing economic conditions and financial, business and other factors. Our financial statements, in Part I, Item 1 of this Form 10-Q, have been prepared on a going concern basis, which assumes we will continue to be in operation for the foreseeable future and, accordingly, will be able to realize our assets and discharge our liabilities in the normal course of operations as they come due. Further information can be found in Part I, Item 1 of this Form 10-Q, in the Notes to Condensed Consolidated Financial Statements in Note 1, “Summary of Significant Accounting Policies.”

~~During the nine months ended September 30, 2020, we successfully raised funds with the following financing activities:~~

~~During the three~~Liquidity and ~~nine months ended September 30, 2020, we have experienced minor disruptions to~~Capital Resources

We actively manage our ~~business due to COVID-19. In particular, we believe the impacts of COVID-19 on customer~~cash and patient behavior in our key markets, the impact on the opening of new cannabis retail outlets in the Canadian market, and the impact on retail markets in general, have introduced unexpected challenges and have resulted in suppressed sales across the majority of our businesses. We have largely been able to maintain satisfactory production levels at our facilities and have not experienced any outbreaks of COVID-19 among our employees. While we have been able to mitigate many of the recent impacts of COVID-19, there remain uncertainties about how the pandemic may influence consumer and patient behaviors, cannabis and retail markets in general, our selling and manufacturing operations, and capital markets, in the future. If COVID-19 negatively impacts one or more of these matters we may have to raise additional capital on potentially unattractive terms and or significantly reduce our costsinvestments in order to ~~fully~~internally fund ~~our business. Currently, we do not anticipate having to take these actions but, due to our inability to assess the full future impact of COVID-19~~operating needs, make scheduled interest and principal payments on our ~~customers, financial markets,~~borrowings, and ~~our own business, we are continually evaluating many factors~~make acquisitions. We believe that ~~will help us make decisions in a timely manner.~~

~~On June 5, 2020, we entered into the First Amendment~~existing cash, cash equivalents, short-term investments and cash generated by operations, together with access to ~~the Senior Facility. The First Amendment provides that the Senior Facility will only require interest payments for the remainder~~external sources of ~~its term and all outstanding principal payments~~funds, will be ~~due at maturity, February 28, 2022. We have been,~~sufficient to meet our domestic and currently are, in full compliance with all terms of the Senior Facility and will not incur any fees or penalties in connection with the First Amendment. Additionally, and at such time as the lender’s business may allow, the lender may make the additional proceeds of $9.9 million (C$13.3 million) available during the term of the Credit Agreement, at its sole discretion. Concurrently, with the First Amendment, the lender also approved our ability to sell the High Park Gardens facility, if and when we desire. As part of any sale of the High Park Gardens facility, the Lender has agreed that we may retain 60% of any sales proceeds (net of all expenses, fees and taxes), and that the lender shall receive 40% of all sales proceeds (net of all expenses, fees and taxes). All sales proceeds to the lender will be applied as a repayment of principal on the Senior Facility, without any prepayment penalties or fees.

The warrants issued as part of the registered offering contain anti-dilution price protection features which, so long as the warrants remain outstanding, allow us to only issue up to $20.0 million in aggregate gross proceeds under our at-the-market offering program at prices less than the $5.95 per share exercise price of the warrants, and in no event more than $6.0 million per quarter, at prices below the $5.95 per share exercise price of the warrants, without triggering the price protection features.

The warrants are to be settled in registered shares, and the registration statement is required to be active, unless such shares may be subject to an applicable exemption from registration requirements. The holders, at their sole discretion, may elect to a cashless exercise, and be issued un-registered shares in accordance with Section 3(a)(9) of the 1933 Act. In the event we do not maintain an effective registration statement, we may be required to pay a daily cash penalty equal to 1% of the number of shares of Class 2 common stock due to be issued multiplied by any trading price of the Class 2 common stock between the exercise date and the share

~~delivery date, as selected by the holder. Alternatively, we may deliver registered Class 2 common stock purchased by~~foreign capital needs in the ~~open market. We may also be required to pay cash if we do not have sufficient authorized shares to deliver to the holders upon exercise, which could have a material impact to our business.~~

Due to uncertainties we may face in raising additional equity financing in the future, which may be further impacted by the economic downturn and unprecedented conditions due to COVID-19, there remains uncertainty what impact this may have on managements assumptions used to develop these forecasts. Accordingly, we have concluded it is probable we can implement plans that would effectively mitigate the conditions and events that raise substantial doubt about the entity’s ability to continue as a going concern for the next twelve months.foreseeable future.

The following table sets forth the major components of our ~~Condensed Consolidated Statements~~statements of ~~Cash Flows~~cash flows for the periods presented:

The ~~change~~changes in net cash used byin operating activities during the six months ended November 30, 2021 compared to the prior year same period is primarily related to ~~changes~~payments associated with the Arrangement, income taxes at Aphria Diamond and accounts payable and accrued liabilities decreases in ~~working capital fluctuations~~the period. This net cash used in operating activities was positively impacted by reductions in inventory and ~~changes in non-cash expenses, all~~collections of ~~which are highly variable.~~accounts receivable.

The ~~nine months ended September 30, 2020 did not have significant~~change in net cash used in investing activities in the first two fiscal quarters of 2022 as compared to the ~~same period~~first two fiscal quarters of 2021 is primarily due to cash paid for the SweetWater acquisition in 2019 during which we acquired Manitoba Harvest and Natura Naturals, made our investment in the ABG Profit Participation Arrangement, and made purchases of significant property and equipment related to our expansion projects in Canada and Portugal.fiscal year 2021.

Cash used in financing activities in the first two fiscal quarters of 2022 as compared to the first two fiscal quarters of 2021 is primarily due to an early payment on SweetWater’s term loan facility and the share capital financing completed in fiscal year 2021 that did not recur in fiscal year 2022.

Free cash flow and adjusted free cash flow are non-GAAP measures. Free cash flow is relevant to management and investors, because it represents the cash flow available to the Company to repay creditors or potentially make distributions to investors. The ~~change in~~measure is comprised of two GAAP amounts deducted from each other which are net cash ~~provided by financing~~flow used in operating activities ~~during the nine months ended September 30, 2020 relates to~~less investments, net of proceeds from ~~equity offerings, including our at-the-market program,~~disposals, in capital and ~~debt financing.~~intangible assets. Adjusted free cash flow removes the cash impact of acquisitions from free cash flow. Our free cash flow and adjusted free cash flow were, as follows:

As of September 30, 2020, Tilray holds 8,532,243 shares of stock in Kiaro Brands Inc. (Kiaro) at a balance of $3.6 million within Other Investments. Effective October 13, 2020, Kiaro went public as Kiaro Holdings Corp. (Ticker: KO) on the TSX Venture Exchange at a price of CAD $0.17 per share. The completion Refer to Part I, Financial Information, Note 24 Subsequent Events of this ~~transaction will impact the manner~~interim report.

At November 30, 2021, we ~~assess the fair value reporting of our investment, which will continue to be presented within Other Investments.~~

During the three months ended September 30, 2020, we successfully terminated or renegotiated several significant supply contracts. On August 5, 2020, we reached an agreement with an unrelated third party and terminated supply agreements for purchase commitments of $17.4 million. As part of the agreement, we will not seek reimbursement of an advance deposit we had previously provided to the third-party supplier of which $4.9 million remained outstanding as of June 30, 2020. We included the $4.9 million in inventory valuation adjustments in cost of sales that related to the write off of the advance deposit in our statements of net loss and comprehensive loss. In addition, we paid $3.7 million in cash and $1.5 million in shares of our Class 2 common stock. The other contracts that were renegotiated, resulted in more favorable terms to us and have relieved us of any future purchase commitments. The total value of future commitments that have been avoided amounts to $46.5 million. We do not believe the termination or restructuring of these contracts will have any negative impacts on our ability to competitively source products required to conduct our business.

We did not ~~have during the periods presented, and we do not currently~~ have any off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K that have had, or are likely to have, a material current or future effect on our consolidated financial statements.

In addition to the ~~rules~~litigation described in the Part II, Item 1 - Legal Proceedings, the Company is and ~~regulations~~may be a defendant in lawsuits from time to time in the normal course of business. While the results of litigation and claims cannot be predicted with certainty, the Company believes the reasonably possible losses of such matters, individually and in the aggregate, are not material. Additionally, the Company believes the probable final outcome of such matters will not have a material adverse effect on the Company’s consolidated results of operations, financial position, cash flows or liquidity.

Our financial statements are prepared in accordance with accounting principles generally accepted in the United States. The accounting principles we use require us to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the ~~SEC.~~financial statements and amounts of income and expenses during the reporting periods presented. We believe in the quality and reasonableness of our critical accounting policies; however, materially different amounts may be reported under different conditions or using assumptions different from those that we have applied. The accounting policies that have been identified as critical to our business operations and to understanding the results of our operations pertain to revenue recognition, valuation of inventory, valuation of long-lived assets, goodwill and intangible assets, stock-based compensation and valuation allowances for deferred tax assets. The application of each of these critical accounting policies and estimates is discussed in Part II, Item 7, Management’s Discussion and Analysis of Financial Condition and Results of Operations, of our Annual Report on Form 10-K for the fiscal year ended May 31, 2021.

A description of recently issued accounting pronouncements that may potentially impact our financial position and results of operations is disclosed in “Part I, Item 1. Note 12 – ~~Summary~~Basis of ~~Significant Accounting Policies”~~presentation and summary of significant accounting policies” to our financial statements appearing elsewhere in this Quarterly Report on Form 10-Q.

~~Interest rate~~There have been no significant changes in market risk is the risk that the value or yield of available-for-sale debt securities may decline if interest rates decline or that the value of financial liabilities will increase if interest rates increase. Fluctuations in interest rates may impact the level of income and expense recorded on these financial instruments. A 1% changefrom those addressed in the ~~interest rate~~Company’s Annual Report on Form 10-K for the fiscal year ended May 31, 2021 during the three months ended November 30, 2021. See the information set forth in ~~effect on September 30, 2020 would not have a material effect on i) the fair value of our available-for-sale debt securities as the majority~~Part II, Item 7A, Quantitative and Qualitative Disclosures About Market Risk, of the portfolio consists of convertible debt instruments with fixed interest rates ranging from 10% - 12%, or ii) the convertible note financial liabilities as they bear interest at a fixed rate of 5% and are not publicly traded. The Senior Facility bears interestCompany’s Annual Report on the outstanding principal balance at an annual rate equal to the Canadian prime rate plus 8.05%. A hypothetical 1% increase in the Canadian prime rate would result in an increase of $0.1 million and $0.3 million recorded in interest expenseForm 10-K for the ~~three and nine months~~fiscal year ended ~~September 30, 2020.~~May 31, 2021.

As of September 30, 2020, we held long-term equity investments at fair value and equity investments under the measurement alternative. These investment in equities were acquired as part of our strategic transactions. Accordingly, the changes in fair values of investment in equities measured at fair value or under the measurement alternative are recognized through other expense (income), net in the statements of net loss and comprehensive loss. Because of the uncertainty surrounding the COVID-19 outbreak, there is increased risk of declines in fair values of our equity investments if conditions have not been significantly improved and global stock markets have not recovered from recent declines. Based on the fair value of investment in equities held as of September 30, 2020, a hypothetical decrease of 10% in the prices for these companies would reduce the fair values of the investments and result in unrealized loss recorded in other expense (income), net by $0.2 million.

Our condensed consolidated financial statements are expressed in United States dollars, but we have net assets and liabilities denominated in a variety of currencies, the most significant of which are the Canadian dollar and the Euro. As a result, we are exposed to foreign currency translation gains and losses. Revenue and expenses of all foreign operations are translated into United States dollars at the foreign currency exchange rates that approximate the rates in effect at the dates when such items are recognized. A 10% change in the exchange rates for the Canadian dollar would affect the carrying value of net assets by approximately $23.6 million as of September 30, 2020, with a corresponding impact to accumulated other comprehensive loss. We are also exposed to risk related to changes in the value of the Euro’s due to our one construction commitment in Portugal. We have not historically engaged in hedging transactions and do not currently contemplate engaging in hedging transactions to mitigate foreign exchange risks. As we continue to recognize gains and losses in foreign currency transactions, depending upon changes in future currency rates, such gains or losses could have a significant, and potentially adverse, effect on our results of operations.

Management, with the participation of our Chief Executive Officer and Chief Financial Officer (the Company’s principal executive officer and principal financial officer, respectively), evaluated the effectiveness of the Company’s

We maintain disclosure controls and procedures ~~as of September 30, 2020. The~~(as that term ~~“disclosure controls and procedures,” as~~is defined in Rules 13a-15(e) and 15d-15(e) under the Exchange ~~Act, (or “DCPs”), means controls and other procedures of a company~~Act) that are designed to ensure that information required to be disclosed ~~by a company~~ in ~~the~~our reports ~~that it files or submits~~ under the Exchange Act is recorded, processed, and summarized and reported within the time periods specified in the SEC’s rules and ~~forms. DCPs include, without limitation, controls~~forms, and ~~procedures designed to ensure~~ that such information ~~required to be disclosed by a company in the reports that it files or submits under the Exchange Act~~ is accumulated and communicated to ~~the company’s~~our management, including ~~its principal executive~~our Chief Executive Officer and ~~principal financial officers,~~Chief Financial Officer, as appropriate, to allow timely decisions regarding required ~~disclosure. Management recognizes that any~~disclosures. Any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving ~~their objectives and management necessarily applies its judgment in evaluating~~ the ~~cost-benefit relationship of possible controls and procedures.~~

~~Based on the~~desired control objectives. An evaluation of the ~~Company’s DCPs~~effectiveness of the design and operation of our disclosure controls and procedures as of ~~September 30, 2020,~~ the ~~Company’s~~end of the period covered by this Quarterly Report was made under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer.

Based upon this evaluation, our Chief Executive Officer and Chief Financial Officer have concluded that, as ~~a result~~ of November 30, 2021, our disclosure controls and procedures (a) are effective to ensure that information required to be disclosed by us in reports filed or submitted under the ~~material weaknesses~~Exchange Act is timely recorded, processed, summarized and reported and (b) include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in reports filed or submitted under the ~~Company’s internal control described in~~Exchange Act is accumulated and communicated to our ~~Annual Report on Form 10-K for the year ended December 31, 2019, as of such date, the Company’s DCPs were not effective.~~

~~As previously described in Item 9A of~~management, including our ~~Annual Report on Form 10-K for the year ended December 31, 2019, the Company began implementing a remediation plan to address the material weaknesses mentioned above. Management strengthened the depth~~Chief Executive Officer and ~~experience of its finance organization with the addition of a new~~ Chief Financial Officer, ~~(CFO) during~~as appropriate to allow timely decisions regarding required disclosure.

Consistent with guidance issued by the ~~first quarter~~SEC, the scope of ~~2020~~management’s assessment of the effectiveness of our disclosure controls and procedures did not include the addition of a Global Corporate Controller in the second quarter of 2020. Management will continue to increase the depth and experience within our operations, accounting and finance organizations, and design and implement improved processes and internal controls ~~with~~over financial reporting of legacy Tilray, which we acquired on April 30, 2021. Legacy Tilray represented 8.9% of our consolidated assets and 25.8% of our consolidated revenues as of and for the intent of increasing the use of system-based processes to limit manual calculations. The material weaknesses will not be considered remediated until the applicable controls operate for a sufficient period of time and management has concluded, through testing, that these controls are operating effectively.quarter ended November 30, 2021.

There have been no changes in ~~the Company’s internal~~our “internal control over financial ~~reporting~~reporting” (as defined in ~~Rule~~Rules 13a-15(f) and ~~15(d)-5(f)~~15d-15(f) under the Exchange Act) that occurred during the ~~three months ended September 30, 2020~~period covered by this Quarterly Report that have materially affected, or are reasonably likely to materially affect, ~~the Company’s~~our internal control over financial reporting. As mentioned above, the Company acquired legacy Tilray on April 30, 2021. The Company is in the process of reviewing the internal control structure of legacy Tilray and, if necessary, will make appropriate changes as it integrates legacy Tilray into the Company’s overall internal control over financial reporting process.

~~We are currently involved in, and may in~~"Item 3. Legal Proceedings" of our Annual Report on Form 10-K for the ~~future become involved in,~~fiscal year ended May 31, 2021 includes a discussion of our legal proceedings. There have been no material changes from the legal proceedings ~~claims~~described in our Form 10-K, except with respect to the matters disclosed below.

Class Action Suits and ~~investigations in the ordinary course of our business. Although the results of these legal proceedings, claims~~Shareholder Derivative Suits – U.S. and investigations cannot be predicted with certainty, we do not believe that, other than with the possible exception of those matters described below, the final outcome of any matters that we are currently involved in are reasonably likely to have a material adverse effect on our business, financial condition or results of operations. Regardless of final outcomes, however, any such proceedings, claims, and investigations may nonetheless impose a significant burden on management and employees and be costly to defend, with unfavorable preliminary or interim rulings.Canada

~~An adverse judgment or award against the Company in any matter could result in an event of default under the terms of the Senior Facility or our convertible notes.~~

~~420 Investments Ltd. Litigation~~Authentic Brands Group Related Class Action (New York, United States)

On ~~February 21,~~May 4, 2020, ~~420 Investments Ltd., as Plaintiff (“420”),~~Ganesh Kasilingam filed a lawsuit in the U.S. District Court for the Southern District of New York, against Tilray, Inc., Brendan Kennedy and ~~High Park Shops Inc.~~Mark Castaneda, on behalf of himself and a putative class, seeking to recover damages for alleged violations of Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Kasilingam litigation”). The complaint alleged that Tilray and the individual defendants overstated the anticipated advantages of the Company’s revenue sharing agreement with Authentic Brands Group (“~~High Park”~~ABG”), ~~as Defendants, in Calgary, Alberta~~announced on January 15, 2019, and that the plaintiff suffered losses when Tilray’s stock price dropped after Tilray recognized an impairment with respect to the ABG deal on March 2, 2020.

On September 27, 2021, the U.S. District Court entered an Opinion & Order granting the Defendants’ motion to dismiss the complaint in the ~~Court of Queen’s Bench of Alberta. In August 2019,~~Kasilingam litigation.On December 3, 2021, the lead plaintiff filed a second amended complaint alleging similar claims against Tilray and ~~High Park entered into an Arrangement Agreement with 420 and others (the “Arrangement Agreement”). Pursuant~~Brendan Kennedy. The Defendants intend to ~~the Arrangement Agreement, High Park was~~file a motion to acquire the securities of 420. In February 2020, Tilray and High Park gave notice of termination of the Arrangement Agreement. 420 alleges that the termination was unlawful and without merit and further alleges that the Defendants had no legal basis to terminate. 420 alleges that the Defendants did not meet their contractual and good faith obligations under the Arrangement Agreement. 420 seeks an order of specific performance (compelling the closing of the Arrangement Agreement). Alternatively, in the absence of specific performance, 420 seeks damages in the stated amount of C$110 million, plus C$20 million in aggravated damages. The Tilray and High Park Statement of Defense and counterclaim were both filed on March 20, 2020. 420’s Statement of Defense to our counterclaim was filed on April 20, 2020. No trial date has been set. dismiss this amended complaint as well.

On February 27, 2020, Tilray stockholders Deborah Braun and Nader Noorian filed a class action and derivative complaint in the Delaware Court of Chancery styled Braun v. Kennedy, C.A. No. 2020-0137-KSJM. On March 2, 2020, Tilray stockholders Catherine Bouvier, James Hawkins, and Stephanie Hawkins filed a class action and derivative complaint in the Delaware Court of Chancery styled Bouvier v. Kennedy, C.A. No. 2020-0154-KSJM. The two complaints are nearly identical, were filed by the same group of counsel, and name Brendan Kennedy, Christian Groh, Michael Blue, Maryscott Greenwood, Michael Auerbach, and Privateer Evolution, LLC (as successor to Privateer Holdings, Inc.) as defendants and Tilray as a nominal defendant.

On March 4, 2020, the Delaware Court of Chancery entered an order consolidating the two cases and designating the complaint in the Braun/Noorian action as the operative complaint. The operative complaint asserts claims for breach of fiduciary duty against Brendan Kennedy, Christian Groh, Michael Blue, and Privateer Evolution, LLC (the “Privateer Defendants”) for alleged breaches of fiduciary dutyin their alleged capacities as Tilray’s controlling stockholders and against Kennedy, Maryscott Greenwood, and Michael Auerbach for alleged breaches of fiduciary duties in their capacities as directors and/or officers of Tilray in connection with the ~~Downstream Merger.~~prior merger of Privateer Holdings, Inc. with and into a wholly owned subsidiary (the “Downstream Merger”). The ~~operative~~ complaint alleges that the Privateer Defendants breached their fiduciary duties by causing Tilray to enter into the Downstream Merger and Tilray’s Board to approve that Downstream Merger, and that Defendants Kennedy, Greenwood, and Auerbach breached their fiduciary duties as directors by approving the Downstream Merger. Plaintiffs allege that the Downstream Merger gave the Privateer Defendants hundreds of millions of dollars of tax savings without providing a corresponding benefit to Tilray and its minority stockholders and that the Downstream Merger unfairly transferred and extended Kennedy, Blue, and Groh’s control over Tilray. On July 17, 2020, the ~~stockholder~~ plaintiffs filed an amended complaint asserting substantially similar claims. On August 14, 2020, Tilray and ~~all defendants~~the Privateer Defendants moved to dismiss the amended complaint. ~~On October 14, 2020, in light of~~At the ~~Plaintiffs’ statement~~February 5, 2021 hearing on Defendants’ Motions to Dismiss, the Plaintiffs agreed that ~~certain actions may have mooted some of~~ their ~~claims related to the alleged unfair extension~~perpetuation of control ~~over Tilray,~~claims are moot and stated that they intend to move for a fee award in connection with those claims. On June 1, 2021, the Court ~~entered an order adjourning~~denied Defendants’ Motions to Dismiss the ~~planned November 4, 2020 hearing~~Amended Complaint.

In August 2021, the Company’s Board of Directors established a Special Litigation Committee (the “SLC”) of independent directors to re-assert director control and ~~removing~~investigate the ~~pending deadlines for briefing on the motions to dismiss. The parties have stipulated to an amended schedule for the motions to dismiss. The defendants believe the~~derivative claims in this ~~case are without merit,~~litigation matter. The SLC has appointed the law firm Wilson Sonsini to assist the SLC with an ongoing investigation of the underlying claim and ~~intend to defend this case vigorously, but there are no assurances as to its outcome.~~

~~On May 4, 2020, a lawsuit was filed by plaintiff Ganesh Kasilingam~~determine whether continued prosecution of such claims is in the United States District Court for the Southern District of New York, against Tilray, Inc., Brendan Kennedy and Mark Castaneda, on behalf of himself and a putative class, seeking to recover damages for alleged violations of Sections 10(b) and 20(a)best interests of the ~~Securities Exchange Act of 1934 (the “Kasilingam litigation”).~~Company. The complaint alleges that Tilray and the individual defendants overstated the anticipated advantages of the Company’s revenue sharing agreement with Authentic Brands Group (“ABG”), announced on January 15, 2019, and that the plaintiffs suffered losses when Tilray’s stock price dropped after Tilray recognized an impairment with respect to the ABG deal on March 2, 2020. On August 6, 2020 the court entered an order appointing Saul Kassin as Lead Plaintiff and The Rosen Law Firm, P.A. as Lead Counsel. Lead Plaintiff filed an amended complaint on October 5, 2020. The Amended Complaint asserts the same Sections 10(b) and 20(a) claims against the same defendants on largely the same theory, and includes new allegations that the Company’s reported inventory, cost of sales, and gross margins in its financial reports during the class period were false and misleading because Tilray improperly

recorded unsellable “trim” as inventory and understated the cost of sales for its products. The Company and the individual defendants believe the claims are without merit, and intend to defend vigorously against them, but there can be no assurances as to the outcome.

On April 10, 2020, a shareholder derivative lawsuit was filed in the United States District Court for the Eastern District of New York (EDNY) by Chad Gellner, Matthew Rufo, and Melvyn Klein, allegedly on behalf of Tilray, Inc., that piggy‐backs on the Kasilingam litigation referenced above. It named the Board of Directors and Mark Castaneda as defendants. The theory of the lawsuit was that the board failed to prevent the alleged securities law violations asserted in the Kasilingam litigation. On May 29, 2020, a second shareholder derivative lawsuit was filed in the United States District Court for the Southern District of New York (SDNY) by Bo Hu asserting essentially the same claims, allegedly on behalf of Tilray, as the prior shareholder derivative action. On June 5, 2020 a third shareholder derivative lawsuit was filed in the United States District Court for the District of Delaware by Lee Morgan, again alleging essentially the same claims, on behalf of Tilray, as the prior shareholder derivative actions. On November 3, 2020, the court in the Morgan action entered a stipulated stay pending developments in the securities class action pending in the SDNY. And on June 16, 2020, the plaintiffs in the Gellner derivative action voluntarily dismissed that lawsuit in the EDNY and re‐filed it in the SDNY. The plaintiffs in the two derivative actions in the SDNY have agreed with nominal defendant Tilray and the individual defendants to consolidate the actions, and have submitted the stipulation to the court for approval.. The Company and the individual defendants believe the claims are without merit, and intend to defend vigorously against them.

On February 16, 2020, Wyckoff Farms (“Wyckoff”), a cannabinoid supplier to Tilray, emailed a demand for assurance of performance of the March 20, 2019 Cannabinoid Supply Agreement (“Supply Agreement”). Wyckoff stated that it believes that TilraySLC has anticipatorily breached its obligations under the Supply Agreement, which contemplated a five (5) year term, with an express minimum crop obligation during the first crop year from 2019-2020. Wyckoff demanded assurance that Tilray take delivery of and purchase at least 13,000 KG of product for the 2019/2020 crop year at a price of $4,600 KG of product (total purchase price $59,800,000). Wyckoff also raised additional concerns about purported additional minimum quantity purchase obligations for the remaining crop years. Tilray responded that it is within its rights under the Supply Agreement, that the contract’s only minimum purchase obligation is for the 2019 crop year, and also invoked the contractual force majeure provision in light of the impacts of FDA regulatory uncertainty and FDA action related to hemp-derived CBD, as well as the COVID-19 pandemic. On March 5, 2020, Wyckoff submitted the dispute to binding arbitration before the American Arbitration Association (AAA) in Benton County Washington, to which Tilray responded with an Answer on March 26, 2020, disputing Wyckoff’s claims.

On June 19, 2020 High Park Holdings Ltd. (“High Park”), a wholly-owned subsidiary of Tilray, Inc., commenced a confidential arbitration against Zenabis Ltd. (“Zenabis”). The arbitration relates to certain payments and obligations under a Prepaid Supply Agreement between Zenabis and High Park. High Park seeks approximately CAD $24 million, as well additional unquantified damages and related contractual relief. Zenabis has indicated that it will be defending the claim. A hearing has been set for July 2021.

On June 16, 2020, Lisa Langevin commenced a purported class action in the Alberta Court of Queen’s Bench, on her behalf and on behalf of a proposed class of all medicinal and recreational users in Canada of the defendants’ cannabis products who consumed the products before their expiry date. She alleges that the defendants, including Tilray, marketed medicinal and recreational cannabis products in circumstances where the defendants misrepresented the amount of Tetrahydrocannabinol (THC) or Cannabidiol (CBD) in their respective products. As a result of the defendants’ alleged mislabeling of the cannabis products it is claimed that the plaintiff and proposed class members did not receive and consume the product that they believed that they had purchased and that this caused them loss, risk of injury and actual injury. Ms. Langevin claims that on February 13, 2020 she purchased Canaca – TenUp manufactured and distributed by Tilray. She had it tested and allegedly found that it only contained 43% of the claimed amount of THC. The Statement of Claim seeks $500,000,000 in damages and restitution and $5,000,000 in punitive damages plus interest and costs collectively from the defendants. On July 20, 2020 Plaintiff filed an Amended Statement of Claim, as well as an Amended Amended Statement of Claim. We plan to vigorously defend against this action.

We assess our liabilities and contingencies in connection with outstanding legal proceedings utilizing the latest information available. Where it is probable that we will incur a loss and the amount of the loss can be reasonably estimated, we record a liability in its consolidated financial statements. These legal reserves may be increased or decreased to reflect any relevant developments on a quarterly basis. Where a loss is not probable or the amount of loss is not estimable, we do not accrue legal reserves. While the outcome of legal proceedings is inherently uncertain, based on information currently available and available insurance coverage, our management believes that it has established appropriate legal reserves. Any incremental liabilities arising from pending legal proceedings are not expectedsuccessfully moved to have ~~a material adverse effect on our consolidated financial position, consolidated results of operations, or consolidated cash flows. However, it is possible that~~ the ~~ultimate resolution of these matters, if unfavorable, may be material to our consolidated financial position, consolidated results of operations, or consolidated cash flows.~~Plaintiff’s discovery stayed during their investigation.

~~Careful consideration should be given to the following risk factors, in addition to the other information set forth in this Quarterly~~“Item 1A. Risk Factors” of our Annual Report on Form ~~10-Q and in~~10-K for the fiscal year ended May 31, 2021 includes a discussion of our known material risk factors, other ~~documents~~than risks that ~~we file with~~could apply to any issuer or offering. A summary of our risk factors is included below. There have been no material changes from the ~~SEC or publicly in Canada, in evaluating our company and our business. Investing~~risk factors described in our securities involves a high degree of risk. If any of the following risks actually occur, our business, financial condition, results of operations and future growth prospects could be materially and adversely affected. Additional risks and uncertainties not currently known to us or that we currently consider to not be material may also materially and adversely affect our company and our business.

The COVID-19 pandemic continues to result in extended government-ordered closures of significant portions of the global economy, including in the United States, Canada, Portugal, and Germany, places in which we conduct significant business, and could adversely affect our ability to conduct normal business operations, and harm our business and future results of operations and financial condition.

On March 11, 2020, the World Health Organization declared the outbreak of the coronavirus, or COVID-19, a pandemic. The United States, Canada, the European Union and governments around the world have declared national emergencies in response to COVID-19, which is significantly impacting worldwide economic activity. While it is unclear how the COVID-19 pandemic will ultimately effect the cannabis industry and the global economy, we have and continue to update many of our operational procedures and some of our competitors have been forced to take extreme measures, including closing cultivation facilities and significant workforce reductions. Pending the spread of this novel virus, we could likewise be forced to take extreme measures. See “The recent global COVID-19 pandemic has coincided with periods of significant volatility in financial, commodities and other markets, resulting in global recessionary conditions, which could adversely affect our business, future results of operations and financial condition.”

In our primary market of Canada, the Canadian national government and its provinces and municipalities have announced aggressive actions to reduce the spread of the disease, including limiting non-essential gatherings of people, ceasing all non-essential travel, ordering certain businesses and government agencies to cease non-essential operations at physical locations and issuing “social or physical distancing” orders, which direct individuals to remain at their places of residence. The province of Ontario, where we grow and manufacture adult-use cannabis and other cannabis products, has deemed our supply chain operations to be an essential service. The province of British Columbia, where we grow and manufacture cannabis products for medicinal purposes, has explicitly deemed the manufacture and sale of adult-use and medicinal cannabis by Licensed Producers (as defined under the Cannabis Act) to be an essential service. On August 4, 2020, the British Columbia government extended its Provincial State of Emergency to August 18, 2020, and it may extend or rescind such order as necessary. The province of British Columbia remains in Phase 3 of its 4-phased restart plan; however, should COVID-19 conditions deteriorate in the province, British Columbia health officials may pause or revert to a reduced phase.

On April 2, 2020, with respect to COVID-19, Public Safety Canada released guidance that differentiated between medical and adult-use cannabis. The guidance specifically identified that the manufacturing, logistics, warehouse operations and distribution of cannabis for medical purposes are considered essential services. This was non-binding federal guidance, and Canadian provinces and territories maintain the legislative authority to implement and execute response actions within their jurisdictions. We cannot predict what actions individual provinces may take that differ from federal Canadian guidance with respect to medicinal cannabis. ~~While we have not experienced significant disruption in our medicinal channel to date, this federal designation is nonbinding and advisory in~~

~~nature, and, if amended or fully rescinded, could further disrupt our medicinal cannabis production and sales and restrict our ability to participate in clinical trials. See “~~There has been limited study on the effects of medical cannabis and future clinical research studies may lead to conclusions that dispute or conflict with our understanding and belief regarding the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis.”

On March 23, 2020, the Ontario provincial government issued a mandatory closure of all non-essential workplaces. This closure was scheduled to be in effect for 14 days with the possibility of extending this order as COVID-19 evolves. Additionally, on April 3, 2020, the Ontario government expanded the province's list of non-essential businesses to include cannabis retail stores, temporarily leaving online ordering and mail delivery of cannabis by the Ontario Cannabis Store as the only legal means of recreational access. Subsequently, effective July 29, 2020, Ontario prohibited privately-run cannabis stores from providing delivery and curbside pickup services to customers, which could have a negative impact on our sales. On April 27, 2020, the government issued a “Framework for Re-Opening the Province,” which calls for the phased re-opening of businesses and a continued emphasis on work-from-home arrangements. The Province remains in a paused state, with some regions more populated regions in Stage 3 and lesser populated regions in Stage 2 of the Framework for Re-Opening. While Licensed Producers in Ontario are currently considered an essential supply chain operation under provincial laws, there can be no assurance that such designation will remain in effect. If our growing and manufacturing operations at Enniskillen and London, Ontario are deemed non-essential, and are required to close for a significant period of time, our revenues and our results of operations would be significantly reduced. Government mandated shutdowns could impede our supply chains, our general ability to transport and receive raw materials and inputs, and our ability to deliver finished products to our customers. Additionally, our senior executives, employees, contractors, suppliers, and other partners may be prevented from conducting business activities altogether, or may experience additional disruptions, due to personal sickness, remote working conditions, or additional facility shutdowns.

Manitoba Harvest USA, LLC has followed a phased reopening plan. From July 25, 2020 to November 4, 2020, Manitoba Harvest USA, LLC was in Phase 4. However, as a result of the deterioration of public health results, Phase 4 measures were paused and Phase 1 was re-introduced on November 4, 2020. Manitoba Harvest USA, LLC has production facilities in Winnipeg and Ste. Agathe, which produce hemp-related food products and accordingly have been deemed essential. ~~While our facilities at~~ both Winnipeg and Ste. Agathe remain open and producing according to schedule, and the U.S./Canadian border closure has exempted food transport as an essential cross-border service, we cannot predict effect of future governmental actions related to COVID-19 on this critical supply chain. If our manufacturing operations at Winnipeg and Ste. Agathe are deemed non-essential, and are required to close for a significant period of time, or the U.S.-Canadian border were closed to food transport, our general ability to transport and receive raw materials, inputs and final products would be significantly impacted. The U.S.-Canadian border closure remains in effect with still no official reopening date at this time. Although we remain COVID free at both sites, and are following all COVID protocols, an outbreak could significantly delay or reduce our ability to manufacture, package and/or distribute our products.

In addition, we have started to experience some delays or disruptions in supply chain due to COVID, most notably with rigid and flexible plastic-based packaging components. We have seen our lead times increase with no notice from 6 weeks to 20+ weeks on some items. As a result, our customers could experience some shortages in market of select SKUs. While we have managed to work with our packaging suppliers to avoid significant shortages to our customers to date, and are continuing to work closely with all of our suppliers, prolonged shortages or delays in packaging materials could impact our ability to meet demand, and significantly harm our business.

On March 20, 2020, following the declaration of the state of emergency by the President of the Republic on March 18, 2020, the Portuguese government adopted several actions to reduce the spread of COVID-19, including ordering certain businesses and government agencies to cease non-essential operations at physical locations and ordering “social distancing,” which directs individuals to remain at their places of residence. ~~On April 2, 2020, these orders were extended to April 17, 2020, and on April 17, 2020, these measures were extended to May 2, 2020, with the possibility of further renewals or extensions.~~ As of May 3, 2020, the Portuguese government declared the so-called situation of calamity, involving lighter restrictions to business activities and a soft law duty of individuals to remain at their places of residence. ~~On July 31, 2020,~~ the Portuguese government declared the so-called alert situation, to be effective between August 1 and August 14, 2020. This alert situation, which was extended to August 31, 2020, softened some restrictions to business activities but kept social distancing rules (including mandatory remote work in certain cases). A so-called contingency situation, declared on September 11, 2020 and effective at least between September 15 and September 30, 2020, maintains the restrictions to some business activities and keeps social distancing rules, including mandatory remote work in certain cases and prohibiting gatherings of more than a small number of people. While our facility in Portugal has not been subject to a ~~mandatory closure by Portuguese authorities~~, there can be no assurance that such operational status will remain in effect or that the government will not restore harder measures to reduce the spread of COVID-19. If the government mandated closure of our Portugal facility, or otherwise ordered harder restrictions to business activities or employees’ movement, we would lose ability to ~~export~~

~~medicinal cannabis across the European Union, applicable member states, or elsewhere in the region, which could have a material effect on our business, financial condition and results of operations.~~

We are currently building an additional greenhouse of 3.4 hectares in Cantanhede during the remainder of 2020 and currently expect full completion by the end of the first quarter of 2021. Due to COVID-19, we have and may continue to experience construction delays and cannot guarantee the final completion date of the growing space. If we are unable to complete construction in a timely manner due to COVID-19, we may not achieve all our expected harvests and production, which may negatively impact our international sales. While we are actively working with our contractors to maintain appropriate COVID-19 protections at our construction site in an effort to complete construction in a timely manner, there can be no guarantees that we will not continue to experience delays as a result of this pandemic.

During March and April 2020, the Federal German government and its 16 state governments have passed different laws, regulations, resolutions and guidelines in response to the COVID-19 pandemic, including contact restrictions and closure of retail stores. Although the most severe lock down measures have been lifted subsequently, they might be restored if infection rates go up again which is somewhat expected towards fall. Our German offices have opened under strict safety and sanitary restrictions and most employees have voluntarily continued remote work. Our medical sales force has started to visit pharmacies and physicians’ offices, but physicians remain unreceptive to this approach. While we have experienced minimal disruption in supply of medicinal products to patients via pharmacies and physicians, there can be no assurance that future governmental measures or patient preferences and demand will curtail such activity. We have observed a strong decrease in new patients visiting doctors’ offices or switching therapies as patients avoid physical office visits and rely on known therapies or self-medicate, which could lead to reduced patient demand and revenues. Additionally, if medicinal cannabis is deemed non-essential by the German government, or we were unable to import our medicinal products into Germany from Canada and Portugal, it could have a material impact on our business, financial condition and results of operations.

COVID-19 has coincided with periods of significant volatility in global financial, commodities and other markets, resulting in continued global recessionary conditions, which could adversely affect our business, future results of operations and financial condition.

As a result of the COVID-19 pandemic, many states and cities across Canada, the U.S. and European Union declared health emergencies, lockdowns, travel restrictions, and quarantines, prohibiting gatherings of more than a small number of people and ordering or urging most businesses and workplaces to close or operate on a very restricted basis. In addition, there has been significant financial market volatility and government action intended to mitigate the economic impact of COVID-19. See “~~The price of our Class 2 common stock in public markets has experienced and may experience severe fluctuations.”~~

The economic effects of these and related actions and events across the world have included: large numbers of partial or full business closures; large numbers of people being furloughed or laid off; large increases in unemployment; large numbers of workers being partially or wholly ordered to work from home; large numbers of businesses at risk of insolvency as revenues drop off precipitously, especially in businesses related to travel, hospitality, leisure, and physical personal services; large numbers of investors realizing substantial losses in their portfolios and retirement funds; inability of companies to access to capital markets or complete mergers; and large numbers of consumers being unwilling to undertake significant discretionary spending.

Given the ongoing and dynamic nature and significance of the events described above, we are not able to enumerate all potential risks to our business; however, we believe that in addition to the impacts described above, other current and potential impacts of these recent events include, but are not limited to:

It is difficult to predict any additional impact of the COVID-19 pandemic on our businesses. Our efforts to mitigate the adverse impacts of COVID-19 may not be effective, and in any case are likely to only be a partial mitigant. The full extent of impacts resulting from the COVID-19 pandemic and other events beyond our control will depend on future developments, which are highly uncertain and unpredictable, including new information which may emerge concerning the severity of the pandemic and further action, including governmental, cannabis regulatory and other federal, state and local actions, taken to prevent, treat, or mitigate the spread of COVID-19, among others. In addition, the COVID-19 pandemic could result in business disruption to us, and if unable to recover from such a business disruption on a timely basis, the businesses, financial condition, and results of operations of Tilray would be adversely affected. We may also incur additional costs to remedy damages caused by such disruptions, which could adversely affect our financial condition and results of operations.

The adult-use cannabis industry, and the regulations governing this industry, may develop in a way that is significantly different from our current expectations, resulting in our decreased ability, or inability, to compete in this market and industry.

The Cannabis Act and the accompanying regulations, or the CR, became effective in October 2017 and allows individuals over the age of 18 to legally purchase, process and cultivate limited amounts of cannabis for adult use in Canada. There is no assurance that the adult-use cannabis industry, and the regulations governing this industry, will continue to develop as anticipated. There are and will be significant restrictions on the marketing, branding, product formats, product composition, packaging, and distribution channels allowed under the CR, which may reduce the value of certain of our products and brands or negatively impact our ability to compete with other companies in the adult-use cannabis market in Canada. For instance, the CR includes a requirement for health warnings on product packaging, the limited ability to use logos and branding (only one brand name and one brand element per package), restrictions on packaging itself, and restrictions on types and avenues of marketing; further, Cannabis 2.0 regulations (which came into force in October 2019, allowing new cannabis form factors) govern the production and sale of new classes or forms of cannabis products (including vapes and edibles), and impose considerable restrictions on product composition, labeling, and packaging in addition to being subject to similar marketing restrictions as existing form factors. Additional marketing and product composition restrictions have been imposed by some provinces and territories and are subject to changing interpretation without notice. Provincial or other legislation containing additional restrictions, such as a complete ban on marketing, may impact our ability to do so. Such additional restrictions may impair our ability to develop our adult-use brands, and a complete ban on marketing or additional product restrictions imposed under future regulations, may make it uneconomic or unfeasible for us to introduce our entire portfolio of brands and products into the Canadian market, which means that we will be unable to reap the full benefit of the exclusive rights we have secured to such brands and products or launch new products. Further, each province and territory of Canada has the ability to separately regulate the distribution of cannabis within such province or territory, and the rules (including associated regulations) adopted by these provinces or territories vary significantly. Furthermore, some provinces and territories impose significant restrictions on our ability to merchandise products; for example, some provinces impose restrictions on investment in retailers or distributors and their employees as well as in our ability to negotiate for preferential retail space or in-store marketing. Such variance may make participation in the adult-use cannabis market uneconomic or of limited economic benefit for us in those provinces or territories and could result in significant additional compliance or other costs and limitations on our ability to compete successfully in each such market.

~~Any failure on our part to comply with supplier standards established by provincial or territorial distributors could prevent us from accessing certain markets in Canada.~~

Government-run provincial and territorial distributors in Canada require suppliers to meet certain service and business standards, and routinely assess for compliance with such standards. Any failure by us to comply with such standards could result in our being downgraded or disqualified as a supplier, and would severely impede or eliminate our ability to access certain markets within Canada. See Risk Factor “We depend on significant customers for a substantial portion of our revenue. If we fail to retain or expand our customer relationships or if this significant customer were to terminate its relationship with us or reduce its purchases, our revenue could decline significantly.”

~~The adult-use cannabis market in Canada is continuing to develop and may experience supply fluctuations resulting in revenue and price decreases.~~

As a result of the legalization of adult cannabis use in Canada, the market for adult-use cannabis is continuing to develop, resulting in fluctuations in supply and demand. Licensed Producers, and others licensed to produce cannabis under the CR, may not be able to produce enough cannabis to meet adult-use demand. This may result in lower than expected sales and revenues and may result in increased competition for sales and sources of supply. This competition may adversely affect our adult-use business and there is no guarantee that we will be able to supply or acquire the supply, on commercially reasonable terms or at all, to meet the demand for medical and adult-use cannabis.

In addition, we and other cannabis producers in Canada may produce more cannabis than is needed to satisfy the collective demand of the Canadian medical and adult-use markets, and we may be unable to export that oversupply into other legal markets. During the third quarter we incurred an inventory valuation adjustment of $13.4 million which was mainly comprised of a $5.2 million paid in cash and shares of our Class 2 common stock in connection with the termination of supply agreement on August 5, 2020. As a result, the available supply of cannabis could exceed demand, resulting in a significant decline in the market price for cannabis. If this were to occur, there is no assurance that we would be able to generate sufficient revenue from the sale of adult-use cannabis to result in profitability and sufficient liquidity. Regulatory restrictions or over supply conditions in our primary markets could result in inventory adjustments.

~~The illicit supply of cannabis and cannabis-based products may reduce our sales and impede our ability to succeed in the medical and adult-use cannabis markets.~~

In addition to competition from Licensed Producers and those able to produce cannabis legally without a license, we also face competition from unlicensed and unregulated market participants, including illegal dispensaries and illicit market suppliers selling cannabis and cannabis-based products in Canada.

Despite the legalization of medical and adult-use cannabis in Canada, illicit market operations remain abundant and are a substantial competitor to our business. In addition, illegal dispensaries and illicit market participants may be able to (i) offer products with higher concentrations of active ingredients that are either expressly prohibited or impracticable to produce under current Canadian regulations, (ii) brand products more explicitly, and (iii) describe/discuss intended effects of products. As these illicit market participants do not comply with the regulations governing the medical and adult-use cannabis industry in Canada, their operations frequently have significantly lower costs.

As a result of the competition presented by the illicit market for cannabis, any unwillingness by consumers currently utilizing these unlicensed distribution channels to begin purchasing from licensed retailers for any reason or any inability or unwillingness of law enforcement authorities to enforce laws prohibiting the unlicensed cultivation and sale of cannabis and cannabis-based products could (i) result in the perpetuation of the illicit market for cannabis, (ii) adversely affect our market share and (iii) adversely impact the public perception of cannabis use and licensed cannabis producers and dealers, all of which would have a materially adverse effect on our business, operations and financial condition. Furthermore, given the recent effects of COVID-19 on regulated Cannabis retail, it is possible that legal cannabis consumers revert to the illicit market as a matter of convenience. See “~~Risks Related to COVID-19.”~~

~~We may ultimately be unsuccessful in developing and offering new products in our Canadian markets.~~

Cannabis 2.0 regulations permit Licensed Producers to develop new cannabis form factors, including CBD and THC-infused drinks, edibles and non-flower products, such as vapes. We have and will continue to develop strategic partnerships to participate in these new product market opportunities with partners who can provide complementary product development and support capabilities. Strategic initiatives around new products involve significant investment of management time and resources in order to successfully execute and maintain, for novel products that may not generate sufficient market demand. Additionally, there can be no guarantee that such new product offerings, even if successfully developed, will have unit economics that generate an appropriate return on investment. Cannabis 2.0 could result in diversions of management attention, a strain on existing financial and other resources or a lack of product demand for our newly developed form factors, any of which could have a material adverse effect on our business, results of operations and financial condition.

The vape market is a niche market that remains subject to a great deal of uncertainty and is still evolving. Recent negative public sentiment and regulatory scrutiny of vaporizing in the United States may cause Health Canada to further limit usage and diminish Canadian consumer demand for our cannabis vape products.

Cannabis vape products in Canada are regulated under the CR. Although this legislation sets clear rules and standards for the manufacture, composition, packaging, and marketing of cannabis vape products, these rules and standards predate the spate of vaping-related health issues that have recently arisen in the United States. These issues and accompanying negative public sentiment may prompt Health Canada or individual provinces/territories to further limit or defer industry’s ability to sell cannabis vape products, and may also diminish consumer demand for such products. In December of 2019, the Provinces of Quebec and Newfoundland &

Labrador announced they would prohibit the sale of cannabis vape products through regulated channels, citing health concerns recently discovered in the United States. There can be no assurance that we will be able to meet any additional compliance requirements or regulatory restrictions, or remain competitive in face of unexpected changes in market conditions.

Vaping, electronic cigarettes and related products were recently developed and therefore the scientific community has not had a sufficient period of time to study the long-term health effects of their use. Currently, there is no way of knowing whether these products are safe for their intended use and the medical community is still studying these products’ health effects. If the scientific community were to determine conclusively that use of any or all of these products poses long-term health risks, market demand for these products and their use could materially decline. Such a determination could also lead to litigation and significant regulation.

Loss of demand for our products, product liability claims and increased regulation stemming from unfavorable scientific studies on cannabis vaping products could have a material adverse effect on our business, results of operations and financial condition.

The adult-use cannabis industry in Canada is subject to many of the same risks as the medical cannabis industry, including risks related to our need for regulatory approvals, the early status and uncertain growth of this industry and the competition we expect to face in this industry.

The adult-use cannabis industry in Canada is subject to certain risks that are unique to this industry, as well as the risks that are currently applicable to the medical cannabis industry, which are described under the heading above titled “~~Risk Factors-Risks Related to Medical Cannabis Business.”~~

If any of these shared risks occur, our business, financial condition, results of operations and prospects could be adversely affected in a number of ways, including by our not being able to successfully compete in the adult-use cannabis industry and by our being subject to fines, damage awards and other penalties as a result of regulatory infractions or other claims brought against us.

~~We may be unsuccessful in competing in the legal adult-use cannabis market in Canada.~~

Our Canadian adult-use business faces enhanced competition from other Licensed Producers, those individuals and corporations who are licensed under the CR to participate in the adult-use cannabis industry and those that have applied for licenses under the CR. Moreover, the CR allows individuals to cultivate, propagate, harvest and distribute up to four cannabis plants per household, provided that each plant meets certain requirements. If we are unable to effectively compete with other suppliers to the adult-use cannabis market, or a significant number of individuals take advantage of the ability to cultivate and use their own cannabis, our success in the adult-use business may be limited and may not fulfill the expectations of management, securities analysts or investors.

Certain of our competitors have significantly greater financial, production, marketing, research and development and technical and human resources than we do. As a result, our competitors may be more successful than us in gaining market penetration and market share. Our commercial opportunity in the adult-use market could be reduced or eliminated if our competitors produce and commercialize products for the adult-use market that, among other things, are safer, more effective, more convenient or less expensive than the products that we may produce, have greater sales, marketing and distribution support than our products, enjoy enhanced timing of market introduction and perceived effectiveness advantages over our products and receive more favorable publicity than our products. If our adult-use products do not achieve an adequate level of acceptance by the adult-use market, we may not generate sufficient revenue from these products, and our adult-use business may not become profitable.

There may be industry consolidation of one or more competitors, which could increase the competitive advantage of certain competitors and reduce overall market share opportunities. Increased consolidation and new and disparate provincial regulations could have a material effect on our business and results of operations.

We are dependent upon regulatory approvals and licenses for our ability to grow, process, package, store, sell and export medical cannabis and other products derived therefrom, and these regulatory approvals are subject to ongoing compliance requirements, reporting obligations and fixed terms requiring renewal.

Our ability to grow, process, package, store and sell cannabis products for medical purposes in Canada is dependent on our current Health Canada licenses under the CR, covering our production facility and patient call center at our Tilray North America Campus in Nanaimo, British Columbia, or Tilray Nanaimo. We also hold licenses under the CR covering our facilities in Enniskillen, London, and Leamington, Ontario. These licenses allow us to produce cannabis in bulk and finished forms at these facilities and to sell and distribute such cannabis in Canada. They also allow us to export medical cannabis in bulk and finished form to and from specified jurisdictions around the world, subject to obtaining, for each specific shipment, an export approval from Health Canada and an import approval (or no objection notice) from the applicable regulatory authority in the country to or from which the export or import is being made. These CR licenses are valid for fixed periods and will need to be renewed at the end of such periods.

We also hold licenses under the CR covering our facilities in Enniskillen, London, and Leamington, Ontario which we use to service the adult-use market and support the medical market as needed. These licenses allow us to produce, sell, and distribute cannabis and/or cannabis products in Canada. These licenses are valid for fixed periods and will need to be renewed at the end of such periods.

Our ability to operate in our facility at our Tilray European Union Campus located in Cantanhede, Portugal, or Tilray Portugal, is dependent on our current authorization for the cultivation, import and export of cannabis and our Good Manufacturing Practices, or GMP, certification by the Portuguese National Authority of Medicines and Health Products, or INFARMED, for manufacture of cannabis as an active pharmaceutical ingredient, and is dependent on our current authorization for the manufacture of finished cannabis products and GMP certification for manufacture of cannabis as a finished medicinal product. Our GMP certification issued in May 2020 allows the facility to manufacture medical cannabis extracts in-house and export GMP-produced finished medical cannabis products, including dried flower and oils. Our current authorization for cultivation, import and export of cannabis, which includes a new cultivation site located in Reguengos de Monsaraz as of June 1, 2020, is valid for a single growing season at a time and notification to INFARMED is needed to renew the license for subsequent growing seasons. All licenses are subject to ongoing compliance and reporting requirements and renewal.

Any future medical cannabis production facilities that we operate in Canada or elsewhere will also be subject to separate licensing requirements under the CR or applicable local legal requirements. Although we believe that we will meet the requirements of the CR for future renewals of our existing licenses, and grants of permits under such licenses, and to obtain corresponding licenses for any future facilities in Canada, there can be no assurance that existing licenses will be renewed or new licenses obtained on the same or similar terms as our existing licenses, nor can there be any assurance that Health Canada will continue to issue import or export permits on the same terms or on the same timeline, or that other countries will allow, or continue to allow, imports or exports.

Further, we are subject to ongoing inspections by Health Canada and INFARMED to monitor our compliance with their licensing requirements. Most recently, our facilities received fully compliant inspection ratings on the following dates: Natura Naturals Inc. (June 2019), Tilray Canada Ltd. (February 2020), High Park Holdings Ltd. (May 2020) and High Park Farms Ltd. (April 2020). Our existing licenses and any new licenses that we may obtain in the future in Canada or other jurisdictions may be revoked or restricted at any time in the event that we are found not to be in compliance. Should we fail to comply with the applicable regulatory requirements or with conditions set out under our licenses, should our licenses not be renewed when required, be renewed on different terms, or be revoked, we may not be able to continue producing or distributing medical cannabis in Canada or other jurisdictions or to export medical cannabis outside of Canada or Portugal. In addition, we may be subject to enforcement proceedings resulting from a failure to comply with applicable regulatory requirements in Canada or other jurisdictions, which could result in damage awards, a suspension of our existing approvals, a withdrawal of our existing approvals, the denial of the renewal of our existing approvals or any future approvals, recalls of products, product seizures, the imposition of future operating restrictions on our business or operations or the imposition of civil, regulatory or criminal fines or penalties against us, our officers and directors and other parties. These enforcement actions could delay or entirely prevent us from continuing the production, testing, marketing, sale or distribution of our medical products and divert management’s attention and resources away from our business operations.

The laws, regulations and guidelines generally applicable to the medical cannabis industry in Canada, Europe and other countries may change in ways that impact our ability to continue our business as currently conducted or proposed to be conducted.

The successful execution of our medical cannabis business objectives is contingent upon compliance with all applicable laws and regulatory requirements in Canada, Europe and other jurisdictions, including the requirements of the CR in Canada, and obtaining all other required regulatory approvals for the sale, import and export of our medical cannabis products. The commercial medical cannabis industry is a relatively new industry in Canada and the CR is a regime that has only been in effect in its current form since October 2018. The effect of Health Canada’s administration, application and enforcement of the regime established by the CR on us and our business in Canada, or the administration, application and enforcement of the laws of other countries by the appropriate regulators in those countries, may significantly delay or impact our ability to participate in the Canadian medical cannabis market or medical cannabis markets outside Canada, to develop medical cannabis products and produce and sell these medical cannabis products. Further, Health Canada, INFARMED or the regulatory authorities in other countries in which we operate or to which we export our medical cannabis products may change their administration, interpretation or application of the applicable regulations or their compliance or enforcement procedures at any time. Any such changes could require us to revise our ongoing compliance procedures, requiring us to incur increased compliance costs and expend additional resources. There is no assurance that we will be able to comply or continue to comply with applicable regulations.

Our ability to produce and sell our medical products in, and export our medical products to, other jurisdictions outside of Canada is dependent on compliance with additional regulatory and other requirements.

We are required to obtain and maintain certain permits, licenses or other approvals from regulatory agencies in countries and markets outside of Canada in which we operate, or to which we export, to produce or export to, and sell our medical products in, these countries, including, in the case of certain countries, the ability to demonstrate compliance with GMP standards. Our current certification of compliance with GMP standards for production at Tilray Nanaimo and any other GMP certification that we may receive in the future subject us, or will in the future subject us, to extensive ongoing compliance reviews to ensure that we continue to

maintain compliance with GMP standards. There can be no assurance that we will be able to continue to comply with these standards. While there has been a global reduction in passenger and cargo flights as a result of COVID-19, we have not been prevented from exporting medicinal cannabis at this time. However, there is no guarantee that future governmental actions in Canada, Portugal or other countries, or future market-oriented transportation capacity issues, will limit or altogether restrict the import and export of cannabis for medical purposes.

The continuation or expansion of our international operations depends on our ability to renew or secure necessary permits, licenses and other approvals. An agency’s denial of or delay in issuing or renewing a permit, license or other approval, or revocation or substantial modification of an existing permit, license or approval, could prevent us from continuing our operations in, marketing efforts in, or exporting to countries other than Canada. For example, Tilray Nanaimo’s current certification of GMP compliance must be renewed via re-inspection prior to June 30, 2021, and our failure to maintain such certification, or to comply with applicable industry quality assurance standards or receive similar regulatory certifications at any of our other facilities, may prevent us from continuing the expansion of our international operations. In addition, the export and import of medical cannabis is subject to United Nations treaties establishing country-by-country national estimates and our export and import permits are subject to these estimates which could limit the amount of medical cannabis we can export to any particular country.

The long-term effect of the legalization of adult-use cannabis in Canada on the medical cannabis industry is unknown, and may have a significant negative effect upon our medical cannabis business if our existing or future medical use customers decide to purchase products available in the adult-use market instead of purchasing medical use products from us.

According to recent Canadian government statistics, medicinal cannabis patient numbers continue to experience decline. A continued decrease in the overall size of the medical cannabis market in Canada as a result of the legal adult-use market or other factors may reduce our medical sales and revenue prospects in Canada. Factors that may influence demand for medical cannabis include the availability of product in each market, the price of medical cannabis products in relation to similar adult-use cannabis products, and the ease with which each market can be accessed in the individual provinces and territories of Canada. The impact of adult-use cannabis on the medical market is not yet fully understood as the market is still in a state of flux. In addition, new form factors have just been legalized and the degree to which these products will be made available on the medical market versus adult use is not yet known.Moreover, the CR regulation of cannabis for medical purposes is expected to be reviewed in light of the adult-use market. The effect on our business, and the medical cannabis market in general, of such a review is uncertain.

There has been limited study on the effects of medical cannabis and future clinical research studies may lead to conclusions that dispute or conflict with our understanding and belief regarding the medical benefits, viability, safety, efficacy, dosing and social acceptance of cannabis.

Research regarding the medical benefits, viability, safety, efficacy and dosing of cannabis or isolated cannabinoids (such as CBD and THC) remains in relatively early stages. There have been few clinical trials on the benefits of cannabis or isolated cannabinoids conducted by us or by others, and certain trials in which we participate have been delayed by COVID-19. While our trials have begun again recruit patients as medical institutions re-start their programs, there can be no assurance that these trials will continue on a timeframe acceptable to our business and on appropriate profitability horizons, particularly as COVID-19 infections spike.

Future research and clinical trials may draw opposing conclusions to statements contained in the articles, reports and studies we have relied on or could reach different or negative conclusions regarding the medical benefits, viability, safety, efficacy, dosing or other facts and perceptions related to medical cannabis, which could adversely affect social acceptance of cannabis and the demand for our products.

Tilray Nanaimo, Manitoba Harvest, High Park Farms, High Park Processing Facility and Tilray Portugal are integral to our business and adverse changes or developments affecting any of these facilities may have an adverse impact on us.

Currently, our activities and resources are primarily focused on the operation of Tilray Nanaimo, Manitoba Harvest, High Park Farms, Tilray Portugal and our current licenses under the CR are specific to Tilray Nanaimo, High Park Farms, High Park Gardens and our High Park Processing Facility. Adverse changes or developments affecting these facilities, including, but not limited to, disease or infestation of our crops, a fire, an explosion, a power failure, a natural disaster or a material failure of our security infrastructure, could reduce or require us to entirely suspend our production of cannabis. A significant failure of our site security measures and other facility requirements, including any failure to comply with regulatory requirements under the CR, could have an impact on our ability to continue operating under our Health Canada licenses and our prospects of renewing our Health Canada licenses, and could also result in a suspension or revocation of these Health Canada licenses. As we produce much of our medical cannabis products in Tilray Nanaimo, any event impacting our ability to continue production at Tilray Nanaimo, or requiring us to delay production, would prevent us from continuing to operate our business until operations at Tilray Nanaimo could be resumed, or until we were able to commence production at another facility.

We are currently expanding our Tilray Portugal facilities. We expect the expanded facilities will significantly increase our cultivation, growing, processing and distribution capacity; however, development impediments such as construction delays or cost over-runs in respect to the development of these facilities, howsoever caused, could delay or prevent our ability to produce cannabis at

these facilities. It is also possible that the final costs of the major equipment contemplated by our capital expenditure program relating to the development of Tilray Portugal may be significantly greater than anticipated, in which circumstance we may be required to curtail, or extend the timeframes for completing, such capital expenditure plans which would reduce our production capacity.

If we are unsuccessful in scaling operations at our facilities, we may become increasingly reliant on third-party cannabis suppliers, potentially at higher prices than our own cost to produce, which would have a negative impact on gross profit margins.

The medical cannabis industry and market are relatively new, and this industry and market may not continue to exist or develop as anticipated or we may ultimately be unable to succeed in this industry and market.

We are operating our current business in a relatively new medical cannabis industry and market, and our success depends on our ability to attract and retain patients. In addition to being subject to general business risks applicable to a business involving an agricultural product and a regulated consumer product, we need to continue to build brand awareness of our Tilray brand in the medical cannabis industry and make significant investments in our business strategy and production capacity. These investments include introducing new products into the markets in which we operate, adopting quality assurance protocols and procedures, building our international presence and undertaking regulatory compliance efforts. These activities may not promote our medical products as effectively as intended, or at all, and we expect that our competitors will undertake similar investments to compete with us for market share. Competitive conditions, consumer preferences, regulatory conditions, patient requirements, healthcare practitioner prescribing practices, and spending patterns in this industry and market are relatively unknown and may have unique characteristics that differ from other existing industries and markets and that cause our efforts to further our business to be unsuccessful or to have undesired consequences. As a result, we may not be successful in our efforts to attract and retain patients or to develop new medical cannabis products and produce and distribute these medical cannabis products to the markets in which we operate or to which we export in time to be effectively commercialized, or these activities may require significantly more resources than we currently anticipate in order to be successful.

We compete for market share with other companies, including other producers licensed by Health Canada, some of which have longer operating histories and more financial resources and manufacturing and marketing experience than we have.

We face, and we expect to continue to face, intense competition from Licensed Producers and other potential competitors, some of which have longer operating histories and more financial resources and manufacturing and marketing experience than we have. In addition, it is possible that the medical cannabis industry will undergo consolidation, creating larger companies with financial resources, manufacturing and marketing capabilities and product offerings that are greater than ours. As a result of this competition, we may be unable to maintain our operations or develop them as currently proposed, on terms we consider acceptable, or at all.

There are currently hundreds of applications for Licensed Producer status being processed by Health Canada. The number of licenses granted and the number of Licensed Producers ultimately authorized by Health Canada could have an adverse impact on our ability to compete for market share in Canada’s medical cannabis industry. We expect to face additional competition from new market entrants that are granted licenses under the CR or existing license holders that are not yet active in the industry. If a significant number of new licenses are granted by Health Canada, we may experience increased competition for market share and may experience downward price pressure on our medical cannabis products as new entrants increase production.

In addition, the CR permits patients in Canada to produce a limited amount of cannabis for their own medical purposes or to designate a person to produce a limited amount of cannabis on their behalf for such purposes. Widespread reliance upon this allowance could reduce the current or future consumer demand for our medical cannabis products.

If the number of users of cannabis for medical purposes in Canada increases, the demand for products will increase. This could result in the competition in the medical cannabis industry becoming more intense as current and future competitors begin to offer an increasing number of diversified medical cannabis products. Conversely, if there is a contraction in the medical market for cannabis in Canada, competition for market share may increase. To remain competitive, we intend to continue to invest in research and development and sales and patient support; however, we may not have sufficient resources to maintain research and development and sales and patient support efforts on a competitive basis.

In addition to the foregoing, the legal landscape for medical cannabis use is changing internationally. We have operations outside of Canada, which may be affected as other countries develop, adopt and change their medical cannabis laws. Increased international competition, including competition from suppliers in other countries who may be able to produce at lower cost, and limitations placed on us by Canadian or other regulations, might lower the demand for our medical cannabis products on a global scale.

~~General Business Risks and Risks Related to Our Financial Condition and Operations~~

~~We have a limited operating history and a history of net losses, and we may not achieve or maintain profitability in the future.~~

We began operating in 2014 and have yet to generate a profit. We generated a net loss of $2.31 million for the quarter ended September 30, 2020, and net losses of $321.2million, $67.7 million and $7.8 million for the years ended December 31, 2019, 2018 and 2017, respectively. Our accumulated deficit was $727.2 million as of September 30, 2020. We intend to continue to expend significant funds to increase our growing capacity, complete strategic mergers and acquisitions, invest in research and development, expand our marketing and sales operations and meet the compliance requirements as a public company.

Our efforts to grow our business may be more costly than we expect and we may not be able to increase our revenue enough to offset higher operating expenses. We may incur significant losses in the future for a number of reasons, including as a result of unforeseen expenses, difficulties, complications and delays, the other risks described in this Quarterly Report on Form 10-Q and other unknown events. The amount of future net losses will depend, in part, on the growth of our future expenses and our ability to generate revenue. If we continue to incur losses in the future, the net losses and negative cash flows incurred to date, together with any such future losses, will have an adverse effect on our stockholders’ equity and working capital. Because of the numerous risks and uncertainties associated with producing cannabis products, as outlined herein, we are unable to accurately predict when, or if, we will be able to achieve profitability. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods. If we are unable to achieve and sustain profitability, the market price of our Class 2 common stock may significantly decrease and our ability to raise capital, expand our business or continue our operations may be impaired.

We have become subject to increased litigation, arbitrations and demands as a result of the downstream merger, stock price decline, cannabis regulatory and industry changes, supply relationships and other matters, which could result in significant legal liability, additional costs, management distraction and damage to our reputation.

We have been named as a defendant in a class action relating to the merger of Privateer Holdings, Inc. with and into our wholly owned subsidiary (referred to as the Downstream Merger), a class action related to the drop in our stock price, and other litigation and demands relating to business decisions, regulatory and industry changes, supply relationships, and our business acquisition matters and related activities. Litigation may include claims for substantial compensatory or punitive damages or claims for indeterminate amounts of damages. We and our subsidiaries are also involved from time to time in other reviews, investigations and proceedings (both formal and informal) by governmental and self-regulatory agencies regarding our business. These matters also could result in adverse judgments, settlements, fines, penalties, injunctions or other relief.

~~We have incurred~~and may continue to incur substantial costs and expenses relating directly to these actions. Responding to such actions could divert management’s attention away from our business operations and result in substantial costs. For more information on our pending legal proceedings, see “Part II, Item 1. Legal Proceedings” in this Quarterly Report on Form 10-Q.

~~We are exposed to risks relating to the laws of various countries as a result of our international operations.~~

We currently conduct operations in multiple countries and plan to expand these operations. As a result of our operations, we are exposed to various levels of political, economic, legal and other risks and uncertainties associated with operating in or exporting to these jurisdictions. These risks and uncertainties include, but are not limited to, changes in the laws, regulations and policies governing the production, sale and use of cannabis and cannabis-based products, political instability, instability at the United Nations level, currency controls, fluctuations in currency exchange rates and rates of inflation, labor unrest, changes in taxation laws, regulations and policies, restrictions on foreign exchange and repatriation and changing political conditions and governmental regulations relating to foreign investment and the cannabis business more generally.

Changes, if any, in the laws, regulations and policies relating to the advertising, production, sale and use of cannabis and cannabis-based products or in the general economic policies in these jurisdictions, or shifts in political attitude related thereto, may adversely affect the operations or profitability of our international operations in these countries. As we explore novel business models, such as global co-branded products, cannabinoid clinics and cannabis retail, international regulations will become increasingly challenging to manage. Specifically, our operations may be affected in varying degrees by government regulations with respect to, but not limited to, restrictions on advertising, production, price controls, export controls, controls on currency remittance, increased income taxes, restrictions on foreign investment, land and water use restrictions and government policies rewarding contracts to local competitors or requiring domestic producers or vendors to purchase supplies from a particular jurisdiction. Failure to comply strictly with applicable laws, regulations and local practices could result in additional taxes, costs, civil or criminal fines or penalties or other expenses being levied on our international operations, as well as other potential adverse consequences such as the loss of necessary permits or governmental approvals.

Furthermore, although we have begun production at Tilray Portugal with a view toward facilitating exports of our cannabis products to countries in the EU (or, as permissible, elsewhere) from Portugal rather than from Canada, there is no assurance that these EU (or non-EU) countries will authorize the import of our cannabis products from Portugal, or that Portugal will authorize or continue to authorize such exports, or that such exports will provide us with advantages over our current EU export strategy. Each country in the EU (or elsewhere) may impose restrictions or limitations on imports that require the use of, or confer significant advantages upon, producers within that particular country. As a result, we may be required to establish production facilities similar to Tilray Portugal in one or more countries in the EU (or elsewhere) where we wish to distribute our cannabis products in order to take advantage of the favorable legislation offered to producers in these countries. In December of this year an on-site audit by the German GMP

inspectorate will take place at our Düsseldorf offices. Preparation of such audit will bind resources, especially in the Regulatory and Quality departments. A renewal/prolongation of our GMP license in Germany is the precondition to allow import, distribution and sale of the Tilray product portfolio in the German market, and any failure to achieve such renewal could have a material impact on our business.

~~We plan to expand our business and operations into jurisdictions outside of the current jurisdictions where we conduct business, and there are risks associated with doing so.~~

We plan in the future to expand our operations and business into jurisdictions outside of the jurisdictions where we currently carry on business. There can be no assurance that any market for our products will develop in any such foreign jurisdiction. We may face new or unexpected risks or significantly increase our exposure to one or more existing risk factors, including economic instability, new competition, changes in laws and regulations, including the possibility that we could be in violation of these laws and regulations as a result of such changes, and the effects of competition. These factors may limit our capability to successfully expand our operations in, or export our products to, those other jurisdictions.

~~We may be unable to sustain our revenue growth and development, and may be forced to adjust our operations accordingly.~~

Our revenue has grown in recent years. Our ability to sustain this growth will depend on a number of factors, many of which are beyond our control, including, but not limited to, the availability of sufficient capital on suitable terms, changes in laws and regulations respecting the production and distribution of cannabis products, competition from other Licensed Producers, the size of the black market, the size of the Canadian adult-use market, and our ability to produce sufficient volumes of our cannabis-based products to meet demand. Regulatory changes in the United States, Germany and Canada may continue to attract market entrants, therefore diluting our potential opportunity and early-mover advantage. In addition, we are subject to a variety of business risks generally associated with developing companies. Future development and expansion could place significant strain on our management personnel and likely will require us to recruit additional management personnel, and there is no assurance that we will be able to do so.

We and several of our competitors have recently taken significant cost-control measures in reaction to the intense competitive dynamic amongst Licensed Producers and the illicit market as well as other cannabis industry challenges. These measures include employee furloughs and lay-offs, brand and product portfolio prioritization and production facility closures. It is possible that we take additional cost-control measures in the future that may slow our revenue growth and development, and could result in material and other impairment charges in our statement of operations.

The Canadian adult-use marketplace may experience significant consolidation, and some of our current and future competitors will have superior resources and market share, which may significantly reduce our ability to compete due to scale, cost and pricing disadvantages.

The Canadian adult-use marketplace may experience consolidation, and some of the resulting companies that will be our competitors will have market presence, growth operations, technical and marketing capabilities and financial, personnel and other resources substantially greater than our own. In addition, some of these competitors will be able to raise capital at a lower cost than we will be able to. Consequently, some of these competitors may be able to develop and expand their growth, distribution and retail infrastructures more quickly, adapt more swiftly to new or emerging technologies and changes in customer requirements, take advantage of acquisition and other opportunities more readily and devote greater resources to the marketing and sale of their products and services than we will be able to. Additionally, the greater brand name recognition of some of our current and future competitors or our competitors decreasing prices may require us to price our products at lower levels in order to retain or obtain customers. Finally, the cost advantages of some of these competitors may give them the ability to reduce their prices for an extended period of time if they so choose.

~~Our business is subject to a variety of United States and foreign laws, many of which are unsettled and still developing and which could subject us to claims or otherwise harm our business.~~

We are subject to a variety of state and federal laws in the United States, Canada and elsewhere. In the United States, despite cannabis having been legalized at the state level for medical use in many states and for adult-use in a number of states, cannabis meeting the statutory definition of “marihuana” continues to be categorized as a Schedule I controlled substance under the federal Controlled Substances Act, or the CSA, and subject to the Controlled Substances Import and Export Act, or the CSIEA. Hemp and marijuana both originate from the Cannabis sativa plant and CBD is a constituent of both. “Marihuana” or “marijuana” is defined in the CSA as a Schedule I controlled substance whereas “Hemp�� is essentially any parts of the Cannabis sativa plant that has not been determined to be marijuana. Pursuant to the Agriculture Improvement Act of 2018, or the Farm Bill, “hemp,” or cannabis and cannabis derivatives containing no more than 0.3% of tetrahydrocannabinol, or THC, is now excluded from the statutory definition of “marijuana” and, as such, is no longer a Schedule I controlled substance under the CSA. Our activity in the United States is limited to (a) certain corporate and administrative services, including accounting, legal and creative services, (b) supply of study drug for clinical trials under DEA and FDA authorization, and (c) participation in the market for hemp and hemp-derived products containing CBD in

compliance with the Farm Bill; except as described above, we do not produce or distribute cannabis products in the United States. Therefore, we believe that we are not currently subject to the CSA or CSIEA.

We have commercialized in the United States a variety of hemp products, which might include certain cannabinoids including CBD, but would exclude THC at amounts more than 0.3%. While the Farm Bill exempted hemp and hemp derived products from the CSA, any such product commercialization will be subject to various laws, including the Farm Bill, the Federal Food, Drug and Cosmetic Act, or the FD&CA, the Dietary Supplement Health and Education Act, or DSHEA, applicable state and/or local laws, and FDA regulations. The FDA has stated in guidance and other public statements that it is prohibited to sell a food, beverage or dietary supplement to which THC or CBD has been added. While the FDA does not have a formal policy of enforcement discretion with respect to any products with added CBD, the agency has stated that its primary focus for enforcement centers on products that put the health and safety of consumers at risk, such as those claiming to prevent, diagnose, mitigate, treat, or cure diseases in the absence of requisite approvals. While the agency’s enforcement to date has therefore focused on products containing CBD and that make drug-like claims, there is the risk that the FDA could expand its enforcement activities and require us to alter our marketing for our hemp-derived CBD products or cease distributing them altogether. Nevertheless, the regulation of hemp and CBD in the United States has been a constantly evolving and changing landscape, with changes in federal and state laws and regulation occurring on a frequent basis. Violations of applicable FDA and other laws could result in warning letters, significant fines, penalties, administrative sanctions, injunctions, convictions or settlements arising from civil proceedings.

We are further subject to a variety of laws and regulations in the United States, Canada and elsewhere that prohibit money laundering, including the Proceeds of Crime and Terrorist Financing Act (Canada) and the Money Laundering Control Act (United States), as amended, and the rules and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced by governmental authorities in the United States, Canada or any other jurisdiction in which we have business operations or to which we export. Although we believe that none of our activities implicate any applicable money laundering statutes, in the event that any of our business activities, any dividends or distributions therefrom, or any profits or revenue accruing thereby are found to be in violation of money laundering statutes, such transactions may be viewed as proceeds of crime under one or more of the statutes described above or any other applicable legislation, and any persons, including such United States-based investors, found to be aiding and abetting us in such violations could be subject to liability. Any violations of these laws, or allegations of such violations, could disrupt our operations, involve significant management distraction and involve significant costs and expenses, including legal fees. We could also suffer severe penalties, including criminal and civil penalties, disgorgement and other remedial measures.

~~We are required to comply concurrently with federal, state or provincial, and local laws in each jurisdiction where we operate or to which we export our products.~~

Various federal, state or provincial and local laws govern our business in the jurisdictions in which we operate or propose to operate, or to which we export or propose to export our products, including laws and regulations relating to health and safety, conduct of operations and the production, management, transportation, storage and disposal of our products and of certain material used in our operations. Compliance with these laws and regulations requires concurrent compliance with complex federal, provincial or state and local laws. These laws change frequently and may be difficult to interpret and apply. Compliance with these laws and regulations requires the investment of significant financial and managerial resources, and a determination that we are not in compliance with these laws and regulations could harm our brand image and business. Moreover, it is impossible for us to predict the cost or effect of such laws, regulations or guidelines upon our future operations. Changes to these laws or regulations could negatively affect our competitive position within our industry and the markets in which we operate, and there is no assurance that various levels of government in the jurisdictions in which we operate will not pass legislation or regulation that adversely impacts our business.

~~United States regulations relating to hemp-derived CBD products are unclear and rapidly evolving, and may not develop on our anticipate timeframe or in a way most favorable to our business objectives.~~

Our participation in the market for hemp-derived CBD products in the United States and elsewhere may require us to employ novel approaches to existing regulatory pathways. Although the passage of the Farm Bill in December 2018 legalized the cultivation of hemp in the United States to produce products containing CBD and other non-THC cannabinoids, it remains unclear how the FDA will regulate this industry, and whether and when the FDA will propose or implement new or additional regulations. On May 31, 2019, the FDA held a public hearing to obtain scientific data and information about the safety, manufacturing, product quality, marketing, labeling, and sale of products containing cannabis or cannabis-derived compounds, including CBD. The FDA has also formed an internal working group to evaluate the potential pathways to market for CBD products. It remains unclear how CBD products will be regulated by the agency going forward.

In addition, such products may be subject to regulation at the state or local levels. While the Farm Bill created a pathway under which hemp and its derivatives are exempted from the definition of marijuana and, therefore, no longer at risk for deemed a Schedule I controlled substance under the CSA and would be protected from interference in interstate commerce, notwithstanding the ongoing implementation of those provisions, state and local authorities have issued their own restrictions on the cultivation or sale of hemp or hemp-derived CBD. This includes laws that ban the cultivation or possession of hemp or any other plant of the cannabis genus and derivatives thereof, such as CBD. State regulators may take enforcement action against food and dietary supplement

products that contain CBD, or enact new laws or regulations that prohibit or limit the sale of such products. Unforeseen regulatory obstacles or compliance costs may hinder our ability to successfully compete in the market for such products.

We may seek to enter into strategic alliances, or amend or expand the scope of currently existing relationships, with third parties that we believe will have a beneficial impact on us, and there are risks that such strategic alliances or expansions of our currently existing relationships may not enhance our business in the desired manner.

We currently have, and may adjust the scope of, and may in the future enter into, strategic alliances with third parties that we believe will complement or augment our existing business. Examples of such strategic alliances include our agreement with Sandoz, and our joint venture with AB InBev. Our ability to complete further strategic alliances is dependent upon, and may be limited by, among other things, the availability of suitable candidates and capital. In addition, strategic alliances could present unforeseen integration obstacles or costs, may not enhance our business and may involve risks that could adversely affect us, including the investment of significant amounts of management time that may be diverted from operations in order to pursue and complete such transactions or maintain such strategic alliances. We may become dependent on our strategic partners and actions by such partners could harm our business. Future strategic alliances could result in the incurrence of debt, impairment charges, costs and contingent liabilities, and there can be no assurance that future strategic alliances will achieve, or that our existing strategic alliances will continue to achieve, the expected benefits to our business or that we will be able to consummate future strategic alliances on satisfactory terms, or at all.

~~We may not be able to successfully identify and execute future acquisitions, dispositions or other equity transactions or to successfully manage the impacts of such transactions on our operations.~~

Material acquisitions, dispositions and other strategic transactions involve a number of risks, including: (i) the potential disruption of our ongoing business; (ii) the distraction of management away from the ongoing oversight of our existing business activities; (iii) incurring additional indebtedness; (iv) the anticipated benefits and cost savings of those transactions not being realized fully, or at all, or taking longer to realize than anticipated; (v) an increase in the scope and complexity of our operations and (vi) the loss or reduction of control over certain of our assets. Material acquisitions have been and may continue to be material to our business strategy. There is no guarantee that any acquisitions will be accretive, or that past or future acquisitions will not result in additional impairments or write downs.

The existence of one or more material liabilities of an acquired company that are unknown to us at the time of acquisition could result in our incurring those liabilities. A strategic transaction may result in a significant change in the nature of our business, operations and strategy, and we may encounter unforeseen obstacles or costs in implementing a strategic transaction or integrating any acquired business into our operations.

~~We are subject to risks inherent in an agricultural business, including the risk of crop failure.~~

We grow cannabis, which is an agricultural process. As such, our business is subject to the risks inherent in the agricultural business, including risks of crop failure presented by weather, insects, plant diseases and similar agricultural risks. Although we currently grow our products indoors under climate-controlled conditions, we are developing outdoor operations and there can be no assurance that natural elements, such as insects and plant diseases, will not entirely interrupt our production activities or have an adverse effect on our business.

We depend on significant customers for a substantial portion of our revenue. If we fail to retain or expand our customer relationships or if this significant customer were to terminate its relationship with us or reduce its purchases, our revenue could decline significantly.

We believe that our operating results for the foreseeable future will continue to depend on sales to a small number of customers. These customers have no purchase commitments and may cancel, change or delay purchases with little or no notice or penalty. As a result of this customer concentration, our revenue could fluctuate materially and could be materially and disproportionately impacted by purchasing decisions of these customers or any other significant customer. In the future, these customers may decide to purchase less product from us than they have in the past, may alter purchasing patterns at any time with limited notice, or may decide not to continue to purchase our products at all, any of which could cause our revenue to decline materially and materially harm our financial condition and results of operations. If we are unable to diversify our customer base, we will continue to be susceptible to risks associated with customer concentration.

We may be unable to attract or retain key personnel with sufficient experience in the cannabis industry, and we may be unable to attract, develop and retain additional employees required for our development and future success.

Our success is largely dependent on the performance of our management team and certain employees and our continuing ability to attract, develop, motivate and retain highly qualified and skilled employees. Qualified individuals are in high demand, and we may incur significant costs to attract and retain them. The loss of the services of any key personnel, or an inability to attract other suitably qualified persons when needed, could prevent us from executing on our business plan and strategy, and we may be unable to find adequate replacements on a timely basis, or at all. We do not currently maintain key-person insurance on the lives of any of our key personnel.

Further, each director and officer, as well as certain additional key personnel, of a company that holds a license is subject to the requirement to obtain and maintain a security clearance from Health Canada under the CR. Moreover, under the CR, an individual with security clearance must be physically present on site when other individuals are conducting activities with cannabis. Under the CR, a security clearance is valid for a limited time and must be renewed before the expiry of a current security clearance. There is no assurance that any of our existing personnel who presently or may in the future require a security clearance will be able to obtain or renew such clearances or that new personnel who require a security clearance will be able to obtain one. A failure by an individual in a key operational position to maintain or renew his or her security clearance could result in a reduction or complete suspension of our operations. In addition, if an individual in a key operational position leaves us, and we are unable to find a suitable replacement who is able to obtain a security clearance required by the CR in a timely manner, or at all, we may not be able to conduct our operations at planned production volume levels or at all. In addition, the CR requires us to designate a qualified individual in charge who is responsible for supervising activities relating to the production of study drug for clinical trials, which individual must meet certain educational and security clearance requirements. If our current designated qualified person in charge fails to maintain his security clearance, or if our current designated qualified person in charge leaves us and we are unable to find a suitable replacement who meets these requirements, we may no longer be able to continue our clinical trial activities.

~~Increased labor costs, potential organization of our workforce, employee strikes and other labor-related disruption may adversely affect our operations.~~

Apart from certain employees in Portugal, none of our employees are represented by a labor union or subject to a collective bargaining agreement. In Portugal, some of our employees are subject to a government-mandated collective bargaining agreement, which grants affected employees certain additional benefits beyond those required by the local labor code. We cannot assure you that our labor costs going forward will remain competitive because in the future our workforce may organize and labor agreements may be put in place that have significantly higher labor rates and company obligations; at the same time, our competitors may maintain significantly lower labor costs, thereby reducing or eliminating our comparative advantages vis-à-vis one or more of our competitors or the larger industry; additionally, our labor costs may increase in connection with our growth.

Significant interruptions in our access to certain supply chains, including recently as a result of COVID-19, for key inputs such as raw materials, electricity, water and other utilities may impair our cannabis growing operations.

Our business is dependent on a number of key inputs and their related costs (certain of which are sourced in other countries and on different continents), including raw materials, supplies and equipment related to our operations, as well as electricity, water and other utilities. We operate global manufacturing facilities, and have dispersed suppliers and customers. Governments may regulate or restrict the flow of our labor or our products, and the Company's operations, suppliers, customers and distribution channels could be severely impacted. COVID 19 could also have an adverse impact on consumer demand for our products and prices for our raw materials. While we have not experienced any material supply chain disruptions at this time as a result of COVID-19, any significant future governmental-mandated or market-related interruption, price increase or negative change in the availability or economics of the supply chain for key inputs and, in particular, rising or volatile energy costs could curtail or preclude our ability to continue production. In addition, our operations would be significantly affected by a prolonged power outage.

Our ability to compete and grow cannabis is dependent on us having access, at a reasonable cost and in a timely manner, to skilled labor, equipment, parts and components. No assurances can be given that we will be successful in maintaining our required supply of labor, equipment, parts and components. See “The COVID-19 pandemic has developed rapidly, resulting in government ordered closures of significant portions of the global economy, including in the United States, Canada, Portugal, and Germany, places in which we conduct significant business, and could adversely affect our ability to conduct normal business operations, and harm our business and future results of operations and financial condition.”

We may require third party supply of quality cannabis flower to meet consumer demand or regulatory requirements, which may adversely affect our cost of goods sold and subject us to unreliable supply chains or product quality.

Our business is highly dependent on the production and sale of acceptable and certifiable cannabis flower. Our operations may not produce sufficient volumes of cannabis flower or particular cultivars (commonly referred to as “strains”) to meet consumer demand. It is also possible that our cannabis flower production fails to meet our strict internal quality standards or external regulation specifications. This may require us to contract to purchase cannabis flower from third parties. There is no guarantee we will be able to source cannabis flower at attractive prices or that any third party-sourced product will meet our quality standards and all regulatory requirements. If we are unable to source sufficient cannabis flower for any of these reasons, our sales goals may not be achieved or

~~our costs may increase, or both may occur. An increasing reliance on third party cannabis flower supply could materially impact our business reputation, financial condition and results of operations.~~

~~Fluctuations in cannabinoid prices relative to contracted prices with third party suppliers could negatively impact our earnings.~~

A portion of our results of operations and financial condition, as well as the selling prices for our products, are dependent upon cannabinoid supply contracts. As part of our normal course operations, we periodically enter into large and medium-to-long-term supply contracts with third-party growers. Production and pricing of cannabinoids are determined by constantly changing market forces of supply and demand over which we have limited or no control. The market for cannabis biomass is particularly volatile compared to other commoditized markets due to the relatively nascent maturity of the industry in which we operate. Furthermore, the lack of centralized data and large variations in product quality make it difficult to establish a “spot price” for cannabinoids, and develop an effective price hedging strategy. Accordingly, supply contracts with any term may prove to be costly in the future to the extent cannabinoid prices decrease dramatically or at a faster rate than anticipated. Furthermore, supply contracts typically include minimum purchase requirements which could force us to buy significant quantities of product at non-competitive prices in a rapidly changing market. Due to changing industry dynamics, we are currently re-negotiating the terms of several supply contracts, and, at this time, the outcome of those negotiations is uncertain. Our failure to successfully re-negotiate certain of these supply contracts on terms acceptable to us could result in us being contractually obligated to purchase significant amounts of products, some of which may be priced above then-current market prices, or litigation against us, or interruption of the supply of inputs for the manufacturing of our products, all of which could have a material adverse effect on our business, results of operations, financial condition, liquidity and prospects. In addition, any litigation or arbitration resulting in an adverse judgment or award against us could result in a default under our credit facility and convertible notes. See “We have become subject to increased litigation, arbitrations and demands as a result of the downstream merger, stock price decline, and cannabis regulatory and industry changes, supply relationships and other matters, which could result in significant legal liability, additional costs, management distraction and damage to our reputation.”

~~We may not be able to transport our cannabis products to consumers in a safe and efficient manner.~~

Due to our direct-to-consumer shipping model for medical cannabis in Canada, we depend on fast and efficient third-party transportation services to distribute our medical cannabis products. We also use such services to transfer bulk shipments to provinces and territories for further distribution to private and public retailers focused on non-medical consumers. Any prolonged disruption of third-party transportation services, such as any Canada Post disruptions, could have a material adverse effect on our sales volumes or satisfaction with our services. Rising costs associated with third-party transportation services used by us to ship our products may also adversely impact our profitability, and more generally our business, financial condition and results of operations.

The security of our products during transportation to and from our facilities is of the utmost concern. A breach of security during transport or delivery could result in the loss of high-value product and forfeiture of import and export approvals, since such approvals are shipment specific. Any failure to take steps necessary to ensure the safekeeping of our cannabis could also have an impact on our ability to continue supplying provinces and territories, to continue operating under our existing licenses, to renew or receive amendments to our existing licenses or to receive required new licenses.

~~Our cannabis products may be subject to recalls for a variety of reasons, which could require us to expend significant management and capital resources.~~

Manufacturers and distributors of products are sometimes subject to the recall or return of their products for a variety of reasons, including product defects, such as contamination, adulteration, unintended harmful side effects or interactions with other substances, packaging safety and inadequate or inaccurate labeling disclosure. Although we have detailed procedures in place for testing finished cannabis products, there can be no assurance that any quality, potency or contamination problems will be detected in time to avoid unforeseen product recalls, regulatory action or lawsuits, whether frivolous or otherwise. If any of the cannabis products produced by us are recalled due to an alleged product defect or for any other reason, we could be required to incur the unexpected expense of the recall and any legal proceedings that might arise in connection with the recall. As a result of any such recall, we may lose a significant amount of sales and may not be able to replace those sales at an acceptable gross profit or at all. In addition, a product recall may require significant management attention or damage our reputation and goodwill or that of our products or brands.

Additionally, product recalls may lead to increased scrutiny of our operations by Health Canada or other regulatory agencies, requiring further management attention, increased compliance costs and potential legal fees, fines, penalties and other expenses. Any product recall affecting the cannabis industry more broadly, whether or not involving us, could also lead consumers to lose confidence in the safety and security of the products sold by Licensed Producers generally, including products sold by us.

We may be subject to product liability claims or regulatory action if our products are alleged to have caused significant loss or injury. This risk is exacerbated by the fact that cannabis use may increase the risk of serious adverse side effects.

As a manufacturer and distributor of products which are ingested by humans, we face the risk of exposure to product liability claims, regulatory action and litigation if our products are alleged to have caused loss or injury. We may be subject to these types of claims due to allegations that our products caused or contributed to injury or illness, failed to include adequate instructions for use or failed to include adequate warnings concerning possible side effects or interactions with other substances. This risk is exacerbated by the fact that cannabis use may increase the risk of developing schizophrenia and other psychoses, symptoms for individuals with bipolar disorder, and other side effects. Furthermore, we are now offering an expanded assortment of form factors as a result of Cannabis 2.0, some of which may have adverse side effects. See “In connection with the amended Canadian adult-use regulations which became effective October 17, 2019 and permitted new classes of cannabis on December 16, 2019, we will now offer cannabis-only vape products in Canada. The vape market is a niche market that remains subject to a great deal of uncertainty and is still evolving. Recent negative public sentiment and regulatory scrutiny of vaporizing in the United States may cause Health Canada to further limit usage and diminish Canadian consumer demand for our cannabis vape products.”

~~Previously unknown adverse reactions resulting from human consumption of cannabis products alone or in combination with other medications or substances could also occur.~~

In addition, the manufacture and sale of cannabis products, like the manufacture and sale of any ingested product, involves a risk of injury to consumers due to tampering by unauthorized third parties or product contamination. We have in the past recalled, and may again in the future have to recall, certain of our cannabis products as a result of potential contamination and quality assurance concerns. A product liability claim or regulatory action against us could result in increased costs and could adversely affect our reputation and goodwill with our patients and consumers generally. There can be no assurance that we will be able to maintain product liability insurance on acceptable terms or with adequate coverage against potential liabilities. Such insurance is expensive and may not be available in the future on acceptable terms, or at all. The inability to obtain sufficient insurance coverage on reasonable terms or to otherwise protect against potential product liability claims could result in us becoming subject to significant liabilities that are uninsured and also could adversely affect our commercial arrangements with third parties.

~~We rely on third-party distributors to distribute our products, and those distributors may not perform their obligations.~~

We rely on third-party distributors, including pharmaceutical distributors, courier services, and government agencies, and may in the future rely on other third parties, to distribute our products. If these distributors do not successfully carry out their contractual duties, if there is a delay or interruption in the distribution of our products, or if these third parties damage our products, it could negatively impact our revenue from product sales. Any damage to our products, such as product spoilage, could expose us to potential product liability, damage our reputation and the reputation of our brands or otherwise harm our business.

~~We, or the cannabis industry more generally, may receive unfavorable publicity or become subject to negative consumer or investor perception.~~

We believe that the cannabis industry is highly dependent upon positive consumer and investor perception regarding the benefits, safety, efficacy and quality of the cannabis distributed to consumers. The perception of the cannabis industry and cannabis products, currently and in the future, may be significantly influenced by scientific research or findings, regulatory investigations, litigation, political statements, media attention and other publicity (whether or not accurate or with merit) both in Canada and in other countries relating to the consumption of cannabis products, including unexpected safety or efficacy concerns arising with respect to cannabis products or the activities of industry participants. There can be no assurance that future scientific research, findings, regulatory proceedings, litigation, media attention or other research findings or publicity will be favorable to the cannabis market or any particular cannabis product or will be consistent with earlier publicity. Adverse future scientific research reports, findings and regulatory proceedings that are, or litigation, media attention or other publicity that is, perceived as less favorable than, or that questions, earlier research reports, findings or publicity (whether or not accurate or with merit) could result in a significant reduction in the demand for our cannabis products. Further, adverse publicity reports or other media attention regarding the safety, efficacy and quality of cannabis, or our products specifically, or associating the consumption of cannabis with illness or other negative effects or events, could adversely affect us. This adverse publicity could arise even if the adverse effects associated with cannabis products resulted from consumers’ failure to use such products legally, appropriately or as directed.

~~Certain events or developments in the cannabis industry more generally may impact our reputation.~~

Damage to our reputation can result from the actual or perceived occurrence of any number of events, including any negative publicity, whether true or not. As a producer and distributor of cannabis, which is a controlled substance in Canada that has previously been commonly associated with various other narcotics, violence and criminal activities, there is a risk that our business might attract negative publicity. There is also a risk that the actions of other Licensed Producers or of other companies and service providers in the cannabis industry may negatively affect the reputation of the industry as a whole and thereby negatively impact our reputation. The increased usage of social media and other web-based tools used to generate, publish and discuss user-generated content and to connect with other users has made it increasingly easier for individuals and groups to communicate and share negative opinions and views in regards to our activities and the cannabis industry in general, whether true or not.

We do not ultimately have direct control over how we or the cannabis industry is perceived by others. Reputational issues may result in decreased investor confidence, increased challenges in developing and maintaining community relations and present an impediment to our overall ability to advance our business strategy and realize on our growth prospects.

~~If we are not able to comply with all safety, health and environmental regulations applicable to our operations and industry, we may be held liable for any breaches of those regulations.~~

Safety, health and environmental laws and regulations affect nearly all aspects of our operations, including product development, working conditions, waste disposal, emission controls, the maintenance of air and water quality standards and land reclamation, and, with respect to environmental laws and regulations, impose limitations on the generation, transportation, storage and disposal of solid and hazardous waste. Continuing to meet GMP standards, which we follow voluntarily, requires satisfying additional standards for the conduct of our operations and subjects us to ongoing compliance inspections in respect of these standards. Compliance with safety, health and environmental laws and regulations can require significant expenditures, and failure to comply with such safety, health and environmental laws and regulations may result in the imposition of fines and penalties, the temporary or permanent suspension of operations, the imposition of clean-up costs resulting from contaminated properties, the imposition of damages and the loss of or refusal of governmental authorities to issue permits or licenses to us or to certify our compliance with GMP standards. Exposure to these liabilities may arise in connection with our existing operations, our historical operations and operations that we may undertake in the future. We could also be held liable for worker exposure to hazardous substances and for accidents causing injury or death. There can be no assurance that we will at all times be in compliance with all safety, health and environmental laws and regulations notwithstanding our attempts to comply with such laws and regulations.

Changes in applicable safety, health and environmental standards may impose stricter standards and enforcement, increased fines and penalties for non-compliance, more stringent environmental assessments of proposed projects and a heightened degree of responsibility for companies and their officers, directors and employees. We are not able to determine the specific impact that future changes in safety, health and environmental laws and regulations may have on our industry, operations and/or activities and our resulting financial position; however, we anticipate that capital expenditures and operating expenses will increase in the future as a result of the implementation of new and increasingly stringent safety, health and environmental laws and regulations. Further changes in safety, health and environmental laws and regulations, new information on existing safety, health and environmental conditions or other events, including legal proceedings based upon such conditions or an inability to obtain necessary permits in relation thereto, may require increased compliance expenditures by us.

We may not be able to obtain adequate insurance coverage in respect of the risks our business faces, the premiums for such insurance may not continue to be commercially justifiable or there may be coverage limitations and other exclusions which may result in such insurance not being sufficient to cover potential liabilities that we face.

We currently have insurance coverage, including product liability insurance, protecting many, but not all, of our assets and operations. Our insurance coverage is subject to coverage limits and exclusions and may not be available for the risks and hazards to which we are exposed. In addition, no assurance can be given that such insurance will be adequate to cover our liabilities, including potential product liability claims, or will be generally available in the future or, if available, that premiums will be commercially justifiable. If we were to incur substantial liability and such damages were not covered by insurance or were in excess of policy limits, we may be exposed to material uninsured liabilities that could impede our liquidity, profitability or solvency.

~~We may become subject to liability arising from any fraudulent or illegal activity by our employees, contractors, consultants and others.~~

We are exposed to the risk that our employees, independent contractors, consultants, service providers and licensors may engage in fraudulent or other illegal activity. Misconduct by these parties could include intentional undertakings of unauthorized activities, or reckless or negligent undertakings of authorized activities, in each case on our behalf or in our service that violate: (i) government regulations, specifically Health Canada regulations; (ii) manufacturing standards; (iii) Canadian federal and provincial healthcare laws and regulations; (iv) laws that require the true, complete and accurate reporting of financial information or data; (v) United States federal laws banning the possession, sale or importation of cannabis into the United States and prohibiting the financing of activities outside the United States that are unlawful under Canadian or other foreign laws or (vi) the terms of our agreements with insurers. In particular, we could be exposed to class action and other litigation, increased Health Canada inspections and related sanctions, the loss of current GMP compliance certifications or the inability to obtain future GMP compliance certifications, lost sales and revenue or reputational damage as a result of prohibited activities that are undertaken in the growing or production process of our products without our knowledge or permission and contrary to our internal policies, procedures and operating requirements.

We cannot always identify and prevent misconduct by our employees and other third parties, including service providers and licensors, and the precautions taken by us to detect and prevent this activity may not be effective in controlling unknown, unanticipated or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from such misconduct. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business, including the imposition of civil, criminal or administrative

~~penalties, damages, monetary fines and contractual damages, reputational harm, diminished profits and future earnings or curtailment of our operations.~~

~~We may experience breaches of security at our facilities or loss as a result of the theft of our products.~~

Because of the nature of our products and the limited legal channels for distribution, as well as the concentration of inventory in our facilities, we are subject to the risk of theft of our products and other security breaches. A security breach at any one of our facilities could result in a significant loss of available products, expose us to additional liability under applicable regulations and to potentially costly litigation or increase expenses relating to the resolution and future prevention of similar thefts, any of which could have an adverse effect on our business, financial condition and results of operations.

We may be subject to risks related to our information technology systems, including the risk that we may be the subject of a cyber-attack and the risk that we may be in non-compliance with applicable privacy laws.

We have entered into agreements with third parties for hardware, software, telecommunications and other information technology, or IT, services in connection with our operations. Our operations depend, in part, on how well we and our vendors protect networks, equipment, IT systems and software against damage from a number of threats, including, but not limited to, cable cuts, damage to physical plants, natural disasters, intentional damage and destruction, fire, power loss, hacking, computer viruses, vandalism, theft, malware, ransomware and phishing attacks. We are increasingly reliant on Cloud-based systems for economies of scale and our mobile workforce, which could result in increased attack vectors or other significant disruptions to our work processes. Any of these and other events could result in IT system failures, delays or increases in capital expenses. Our operations also depend on the timely maintenance, upgrade and replacement of networks, equipment and IT systems and software, as well as preemptive expenses to mitigate the risks of failures. The failure of IT systems or a component of IT systems could, depending on the nature of any such failure, adversely impact our reputation and results of operations.

There are a number of laws protecting the confidentiality of certain patient health information and other personal information, including patient records, and restricting the use and disclosure of that protected information. In particular, the privacy rules under the Personal Information Protection and Electronics Documents Act (Canada), or the PIPEDA, the European Unions’ General Data Protection Regulation, or the GDPR, and similar laws in other jurisdictions, protect medical records and other personal health information by limiting their use and disclosure to the minimum level reasonably necessary to accomplish the intended purpose. We collect and store personal information about our consumers and are responsible for protecting that information from privacy breaches. A privacy breach may occur through a procedural or process failure, an IT malfunction or deliberate unauthorized intrusions. Theft of data for competitive purposes, particularly patient lists and preferences, is an ongoing risk whether perpetrated through employee collusion or negligence or through deliberate cyber-attack. Moreover, if we are found to be in violation of the privacy or security rules under PIPEDA or other laws protecting the confidentiality of patient health information, including as a result of data theft and privacy breaches, we could be subject to sanctions and civil or criminal penalties, which could increase our liabilities and harm our reputation.

As cyber threats continue to evolve, we may be required to expend significant additional resources to continue to modify or enhance our protective measures or to investigate and remediate any information security vulnerabilities. While we have implemented security resources to protect our data security and information technology systems, such measures may not prevent such events. Significant disruption to our information technology system or breaches of data security could have a material adverse effect on our business financial condition and results of operations.

~~We may be unable to expand our operations quickly enough to meet demand or manage our operations beyond their current scale.~~

There can be no assurance that we will be able to manage our expanding operations, including any acquisitions, effectively, that we will be able to sustain or accelerate our growth or that such growth, if achieved, will result in profitable operations, that we will be able to attract and retain sufficient management personnel necessary for continued growth or that we will be able to successfully make strategic investments or acquisitions. This challenge has been compounded with the launch of multiple new form factors as a result of Cannabis 2.0. See “~~Cannabis 2.0 allows for new and untested Cannabis products and form factors, and we may ultimately be unsuccessful in developing and offering these new products in our Canadian markets.”~~

Demand for cannabis-based products is dependent on a number of social, political and economic factors that are beyond our control. There is no assurance that an increase in existing demand will occur, that we will benefit from any such demand increase or that our business will remain profitable even in the event of such an increase in demand. If we are unable to achieve or sustain profitability, the value of our Class 2 common stock and the notes may significantly decrease.

The cannabis industry continues to face significant funding challenges, and we may not be able to secure adequate or reliable sources of funding required to operate our business or increase our production to meet consumer demand for our products.

The continued development of our business will require significant additional financing, and there is no assurance that we will be able to obtain the financing necessary to achieve our business objectives. Our ability to obtain additional financing will depend

on investor demand, our performance and reputation, market conditions, and other factors. Our inability to raise such capital could result in the delay or indefinite postponement of our current business objectives or our inability to continue to operate our business. On February 28, 2020, we entered into a senior secured credit facility with Bridging Finance Inc., for an aggregate principal amount of $59.6 million, as further amended on June 5, 2020, the “Senior Credit Facility.” On March 17, 2020, we issued Class 2 common stock, pre-funded warrants and warrants, resulting in net proceeds of approximately $85.3 million. There can be no assurance that additional capital or other types of equity or debt financing will be available if needed or that, if available, the terms of such financing will be favorable to us. See “~~Our senior secured credit facility contains covenant restrictions that may limit our ability to operate our business.”~~

In addition, from time to time, we may enter into transactions to acquire assets or the capital stock or other equity interests of other entities. Our continued growth may be financed, wholly or partially, with debt, which may increase our debt levels above industry standards. Any debt financing secured in the future could involve restrictive covenants relating to capital raising activities and other financial and operational matters, which may make it more difficult for us to obtain additional capital and to pursue business opportunities, including potential acquisitions. Debt financings may also contain provisions that, if breached, may entitle lenders or their agents to accelerate the repayment of loans or realize a first priority security over our significant operating assets, and there is no assurance that we would be able to repay such loans in such an event or prevent the enforcement of security granted pursuant to any such debt financing.

~~Our senior secured credit facility contains covenant restrictions that may limit our ability to operate our business.~~

On February 28, 2020, we entered into the Senior Credit Facility. The Senior Credit Facility contains, and any of our other future debt agreements may contain, covenant restrictions that limit our ability to operate our business, including restrictions on our ability to, among other things, invest in our existing facilities, incur additional debt or issue guarantees, create additional liens, repurchase stock or make other restricted payments, and make certain voluntary prepayments of specified debt. As a result of these covenants, our ability to respond to changes in business and economic conditions and engage in beneficial transactions, including to obtain additional financing as needed, may be restricted. Furthermore, our failure to comply with our debt covenants could result in a default under our debt agreements, which could permit the holders to accelerate our obligation to repay the debt. If any of our debt is accelerated, we may not have sufficient funds available to repay it.

~~Servicing our debt will require a significant amount of cash, and we may not have sufficient cash flow from our business to pay our substantial debt.~~

As of September 30, 2020, we had $484.1 million in aggregate principal indebtedness (refer to Notes 12 & 13) to the consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q).

Our substantial consolidated indebtedness may increase our vulnerability to any generally adverse economic and industry conditions. We and our subsidiaries may, subject to the limitations in the terms of our existing and future indebtedness, incur additional debt, secure existing or future debt or recapitalize our debt. Our ability to make scheduled payments of the principal of, to pay interest on or to refinance our current and future indebtedness, depends on our future performance, which is subject to economic, financial, competitive and other factors beyond our control. Our business has not generated positive cash flow from operations. If this continues in the future, we may not have sufficient cash flows to service our debt and make necessary capital expenditures. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or highly dilutive. Our ability to refinance our current and future indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which could result in a default on our debt obligations.

~~We incur increased costs as a result of operating as a public company and our management is required to devote substantial time to compliance initiatives.~~

As a public company, we have incurred and will incur significant legal, accounting and other expenses that we did not incur prior to our IPO. In addition, the Sarbanes-Oxley Act of 2002, or the Sarbanes-Oxley Act, and rules implemented by the SEC and the Nasdaq Global Select Market, impose various requirements on public companies, including requirements to file annual, quarterly and event-driven reports with respect to our business and financial condition and operations and establish and maintain effective disclosure and financial controls and corporate governance practices. Effective January 1, 2020, we became a “large accelerated filer” under SEC reporting rules and, and are required to file our annual report and quarterly reports more quickly than we previously had been required to file them, which may require us to dedicate additional resources to the timely filing of such reports. In addition, pursuant to Section 404 of the Sarbanes-Oxley Act, or Section 404, we are required to furnish a report by our management on our Internal Controls over Financial Reporting (“ICFR”), which must be accompanied by an attestation report on ICFR issued by our independent registered public accounting firm. To achieve compliance with Section 404 within the prescribed period, we have documented and evaluated our ICFR, which has been both costly and challenging. We expect our costs to increase substantially in order to comply with these

additional and more burdensome requirements. Our existing management team has and will continue to devote a substantial amount of time to these compliance initiatives, and we may need to hire additional personnel to assist us with complying with these requirements. Moreover, these rules and regulations have increased and will continue to increase our legal and financial compliance costs and will make some activities more time consuming and costly.

~~Management may not be able to successfully implement adequate internal controls over financial reporting.~~

Management is responsible for establishing and maintaining adequate internal control over financial reporting. As defined in Rules 13a-15(f) and 15d(f) under the Exchange Act, internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of our financial reporting and the preparation of financial statements for external purposes in accordance with United States Generally Accepted Accounting Principles (“U.S. GAAP”). Our management and other personnel have limited experience operating a public company, which may result in a failure of our ICFR and Disclosure Controls and Procedures (“DCP”) necessary to ensure timely and accurate reporting of operational and financial results. Due to inherent limitations, our internal control over financial reporting may not prevent or detect all misstatements, including the possibility of human error, the circumvention or overriding of controls, or fraud.

A material weakness is a deficiency, or combination of control deficiencies, in internal control over financial reporting, such that there is a reasonable possibility that a material misstatement of the annual or interim financial statements will not be prevented or detected on a timely basis.

~~As of December 31, 2019 we identified material weaknesses in two components of internal control as defined by COSO 2013 (Control Environment and Control Activities).~~

We did not maintain an effective control environment based on the criteria established in the COSO framework. We have identified deficiencies in the principles associated with the control environment of the COSO framework. Specifically, these control deficiencies constitute material weaknesses, either individually or in the aggregate, relating to: (i) appropriate organizational structure, reporting lines, and authority and responsibilities in pursuit of objectives, (ii) our commitment to attract, develop, and retain competent individuals, and (iii) holding individuals accountable for their internal control related responsibilities.

~~As of December 31, 2019, we did not maintain an effective control environment to allow for the accurate and timely filing of our financial statements primarily attributable to the following factor:~~

We did not fully design and implement effective control activities based on the criteria established in the COSO framework. We have identified deficiencies in the principles associated with the control activities component of the COSO framework. Specifically, these control deficiencies constitute material weaknesses, either individually or in the aggregate, relating to: (i) selecting and developing control activities that contribute to the mitigation of risks to the achievement of objectives to acceptable levels, and (ii) deploying control activities through policies that establish what is expected and procedures that put policies into action.

~~We did not have effective controls in response to the risks of material misstatement. This material weakness is primarily attributable to the following factors:~~

Due to the existence of the above material weaknesses, management, including the CEO and CFO, has concluded that our internal control over financial reporting was not effective as of December 31, 2019. We are actively working on a remediation plan to cure our previously reported material weaknesses; however, there is a risk we may not able to implement all control changes required to fully cure such material weaknesses. If not cured, these material weaknesses create a reasonable possibility that a material misstatement to the consolidated financial statements will not be prevented or detected on a timely basis.

~~Conflicts of interest may arise between us and our directors and officers as a result of other business activities undertaken by such individuals.~~

We may be subject to various potential conflicts of interest because some of our directors and executive officers may be engaged in a range of business activities. In addition, our directors and executive officers are permitted under their applicable agreements with us to devote time to their outside business interests, so long as such activities do not materially or adversely interfere with their duties to us and subject to any contractual restrictions restricting such activities. These business interests could require the

investment of significant time and attention by our executive officers and directors. In some cases, our executive officers and directors, including our Chief Executive Officer and President, Brendan Kennedy and board member, Michael Auerbach, may have fiduciary obligations associated with business interests that interfere with their ability to devote time to our business and affairs, which could adversely affect our operations. Please refer to the section titled “~~Transactions with Related Persons” in our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April 30, 2020, for further information.~~

~~Third parties with whom we do business may perceive themselves as being exposed to reputational risk as a result of their relationship with us.~~

The parties with whom we do business, or would like to do business, may perceive that they are exposed to reputational risk as a result of our business activities relating to cannabis, which could hinder our ability to establish or maintain business relationships. These perceptions relating to the cannabis industry may interfere with our relationship with service providers, particularly in the financial services industry.

~~Tax and accounting requirements may change in ways that are unforeseen to us and we may face difficulty or be unable to implement or comply with any such changes.~~

We are subject to numerous tax and accounting requirements, and changes in existing accounting or taxation rules or practices, or varying interpretations of current rules or practices, could have a significant adverse effect on our financial results, the manner in which we conduct our business or the marketability of any of our products. We currently have international operations and plan to expand such operations in the future. These operations, and any expansion thereto, will require us to comply with the tax laws and regulations of multiple jurisdictions, which may vary substantially. Complying with the tax laws of these jurisdictions can be time consuming and expensive and could potentially subject us to penalties and fees in the future if we were to fail to comply.

~~Because a significant portion of our sales are generated in Canada, fluctuations in foreign currency exchange rates could harm our results of operations.~~

The reporting currency for our financial statements is the United States dollar. We derive a significant portion of our revenue and incur a significant portion of our operating costs in Canada, and changes in exchange rates between the Canadian dollar and the United States dollar may have a significant, and potentially adverse, effect on our results of operations. Our primary risk of loss regarding foreign currency exchange rate risk is caused by fluctuations in the exchange rates between the United States dollar and the Canadian dollar, although as we expand internationally, we will be subject to additional foreign currency exchange risks. Because we recognize revenue in Canada in Canadian dollars, if the Canadian dollar weakens against the United States dollar it would have a negative impact on our Canadian operating results upon the translation of those results into U.S. dollars for the purposes of consolidation. In addition, a weakening of the Canadian dollar against the United States dollar would make it more difficult for us to meet our obligations under the convertible notes. We have not historically engaged in hedging transactions and do not currently contemplate engaging in hedging transactions to mitigate foreign exchange risks. As we continue to recognize gains and losses in foreign currency transactions, depending upon changes in future currency rates, such gains or losses could have a significant, and potentially adverse, effect on our results of operations.

~~We may have exposure to greater than anticipated tax liabilities, which could seriously harm our business.~~

Our income tax obligations are based on our corporate operating structure and third-party and intercompany arrangements, including the manner in which we develop, value and use our intellectual property and the valuations of our intercompany transactions. The tax laws applicable to our international business activities, including the laws of the United States, Canada and other jurisdictions, are subject to change and uncertain interpretation. The taxing authorities of the jurisdictions in which we operate may challenge our methodologies for valuing developed technology, intercompany arrangements or transfer pricing, which could increase our worldwide effective tax rate and the amount of taxes that we pay and seriously harm our business. Taxing authorities may also determine that the manner in which we operate our business is not consistent with how we report our income, which could increase our effective tax rate and the amount of taxes that we pay and could seriously harm our business. In addition, our future income taxes could fluctuate because of earnings being lower than anticipated in jurisdictions that have lower statutory tax rates and higher than anticipated in jurisdictions that have higher statutory tax rates, by changes in the valuation of our deferred tax assets and liabilities or by changes in tax laws, regulations or accounting principles.

We are subject to regular review and audit by United States federal and state and foreign tax authorities. Any adverse outcome from a review or audit could seriously harm our business. In addition, determining our worldwide provision for income taxes and other tax liabilities requires significant judgment by management, and there are many transactions where the ultimate tax determination is uncertain. Although we believe that the amounts recorded in our financial statements are reasonable, the ultimate tax outcome relating to such amounts may differ for such period or periods and may seriously harm our business. Furthermore, due to shifting economic and political conditions, tax policies, laws, or rates in various jurisdictions may be subject to significant changes in ways that impair our financial results. Our results of operations and cash flows could be adversely effected by additional taxes

imposed on us prospectively or retroactively or additional taxes or penalties resulting from the failure to comply with any collection obligations or failure to provide information for tax reporting purposes to various government agencies.

~~The long-term effect of United States tax reform or the recently enacted CARES Act could adversely affect our business and financial condition.~~

On December 22, 2017, the legislation commonly referred to as the Tax Cuts and Jobs Act (the “U.S. Tax Act”) was enacted, which contains significant changes to United States tax law. The U.S. Act requires complex computations to be performed that were not previously required by U.S. tax law, significant judgments to be made in interpretation of the provisions of the U.S. Tax Act, significant estimates in calculations, and the preparation and analysis of information not previously relevant or regularly produced. The U.S. Treasury Department, the IRS, and other standard-setting bodies will continue to interpret or issue guidance on how provisions of the U.S. Tax Act will be applied or otherwise administered. As future guidance is issued, we may make adjustments to amounts that we have previously recorded that may materially impact our financial statements in the period in which the adjustments are made. Additionally, further guidance may be forthcoming from the Financial Accounting Standards Board and SEC, as well as regulations, interpretations and rulings from state tax agencies, which could result in additional impacts, possibly with retroactive effect. Any such changes or potential additional impacts could adversely affect our business and financial condition. We will continue to examine and assess the impact this tax reform legislation may have on our business. On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (CARES Act) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. In addition, the CARES Act allows NOLs incurred in 2018, 2019, and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. Further it provides for increased deductibility of interest expense in 2019 and 2020. We are currently evaluating the impact of the CARES Act, but we do not currently expect that the NOL carryback provision or increased interest deductibility of the CARES Act to result in a material cash benefit to us.

We may be subject to risks related to the protection and enforcement of our intellectual property rights, or intellectual property we license from others, and may become subject to allegations that we or our licensors are in violation of intellectual property rights of third parties.

The ownership, licensing and protection of trademarks, patents and intellectual property rights are significant aspects of our future success. Unauthorized parties may attempt to replicate or otherwise obtain and use our products and technology. Policing the unauthorized use of our current or future trademarks, patents or other intellectual property rights now or in the future could be difficult, expensive, time consuming and unpredictable, as may be enforcing these rights against the unauthorized use by others. Identifying the unauthorized use of intellectual property rights is difficult as we may be unable to effectively monitor and evaluate the products being distributed by our competitors, including parties such as unlicensed dispensaries and black-market participants, and the processes used to produce such products. In addition, in any infringement proceeding, some or all of our trademarks, patents or other intellectual property rights or other proprietary know-how, and that which we license from others, or arrangements or agreements seeking to protect the same for our benefit, may be found invalid, unenforceable, anti-competitive or not infringed or may be interpreted narrowly and such proceeding could put existing intellectual property applications at risk of not being issued.

In addition, other parties may claim that our products, or those that we license from others, infringe on their proprietary or patent protected rights. Such claims, whether or not meritorious, may result in the expenditure of significant financial and managerial resources and legal fees, result in injunctions or temporary restraining orders or require the payment of damages. As well, we may need to obtain licenses from third parties who allege that we have infringed on their lawful rights. Such licenses may not be available on terms acceptable to us, or at all. In addition, we may not be able to obtain or utilize on terms that are favorable to us, or at all, licenses or other rights with respect to intellectual property that we do not own.

We also rely on certain trade secrets, technical know-how and proprietary information that are not protected by patents to maintain our competitive position. Our trade secrets, technical know-how and proprietary information, which are not protected by patents, may become known to or be independently developed by competitors, which could adversely affect us.

We license some intellectual property rights, and the failure of the owner of such intellectual property to properly maintain or enforce the intellectual property underlying such licenses could have a material adverse effect on our business, financial condition and performance.

We are party to a number of licenses, including with entities formerly affiliated with the former Privateer Holdings, Inc. (“Privateer Holdings”) that give us rights to use third-party intellectual property that is necessary or useful to our business. Our success will depend, in part, on the ability of the licensor to maintain and enforce its licensed intellectual property, in particular, those intellectual property rights to which we have secured exclusive rights. Without protection for the intellectual property we have licensed, other companies might be able to offer substantially similar products for sale or utilize substantially similar processes, which could have a material adverse effect on us.

Any of our licensors may allege that we have breached our license agreement, whether with or without merit, and accordingly seek to terminate our license. If successful, this could result in our loss of the right to use the licensed intellectual property, which could adversely affect our ability to commercialize our products or services, as well as have a material adverse effect on us.

We may not realize the full benefit of the clinical trials or studies that we participate in because the terms of some of our agreements to participate do not give us full rights to the resulting intellectual property, the ability to acquire full rights to that intellectual property on commercially reasonable terms or the ability to prevent other parties from using that intellectual property.

Although we have participated in several clinical trials, we are not the sponsor of many of these trials and, as such, do not have full control over the design, conduct and terms of the trials. In some cases, for instance, we are only the provider of a cannabis study drug for a trial that is designed and initiated by an independent investigator within an academic institution. In such cases, we are often not able to acquire rights to all the intellectual property generated by the trials. Although the terms of all clinical trial agreements entered into by us provide us with, at a minimum, ownership of intellectual property relating directly to the study drug being trialed (~~e.g.~~ intellectual property relating to use of the study drug), and ownership of intellectual property that does not relate directly to the study drug is often retained by the institution. As such, we are vulnerable to any dispute among the investigator, the institution and us with respect to classification and therefore ownership of any particular piece of intellectual property generated during the trial. Such a dispute may affect our ability to make full use of intellectual property generated by a clinical trial.

Where intellectual property generated by a trial is owned by the institution, we are often granted a right of first negotiation to obtain an exclusive license to such intellectual property. If we exercise such a right, there is a risk that the parties will fail to come to an agreement on the license, in which case such intellectual property may be licensed to other parties or commercialized by the institution.

We may not realize the full benefit of our licenses if the licensed material has less market appeal than expected, or if restrictions on packaging and marketing hinder our ability to realize value from our licenses, and our licenses may not be profitable to us.

An integral part of our Canadian adult-use cannabis business strategy involves obtaining territorially exclusive licenses to produce products using various brands and images. As a licensee of brand-based properties, we have no assurance that a particular brand or property will translate into a successful adult-use cannabis product. Additionally, a successful brand may not continue to be successful or maintain a high level of sales. As well, the popularity of licensed properties may not result in popular products or the success of the properties with the public. Promotion, packaging and labelling of adult-use cannabis is strictly regulated. These restrictions may further hinder our ability to benefit from our licenses. Acquiring or renewing licenses may require the payment of minimum guaranteed royalties that we consider to be too high to be profitable, which may result in losing licenses we currently hold when they become renewable under their terms or missing business opportunities for new licenses. If we are unable to acquire or maintain successful licenses on advantageous terms, or to derive sufficient revenue from sales of licensed products, our adult-use business may not be successful.

~~The price of our Class 2 common stock in public markets has experienced and may experience severe fluctuations.~~

The market price for our Class 2 common stock, and the market price of stock of other companies operating in the cannabis industry, has been extremely volatile. For example, during the nine months ended September 30, 2020, the trading price of our Class 2 common stock ranged between a low sales price of $2.43 and a high sales price of $22.95 and included single day fluctuations as high as 64.13%. Additionally, during 2019, the trading price of our Class 2 common stock fluctuated between a low sales price of $15.57 and a high sales price of $106.00 per share. The market price of our Class 2 common stock may continue to be volatile and subject to wide fluctuations in response to numerous factors, many of which are beyond our control, including the following: (i) actual or anticipated fluctuations in our quarterly results of operations; (ii) recommendations by securities research analysts; (iii) changes in the economic performance or market valuations of other issuers that investors deem comparable to us; (iv) the addition or departure of our executive officers or other key personnel; (v) the release or expiration of lock-up or other transfer restrictions on our common stock, such as release of 11 million Class 2 shares on April 3, 2020 and 19.5 million shares of Class 1 and Class 2 common stock on June 5, 2020, each associated with the Downstream Merger; (vi) sales or perceived sales, or the expectation of future sales, of our common stock; (vii) significant acquisitions or business combinations, strategic partnerships, joint ventures or capital commitments by or involving us or our competitors; and (viii) news reports relating to trends, concerns, technological or competitive developments, regulatory changes and other related issues in the cannabis industry or our target markets. See “COVID-19 has coincided with periods of significant volatility in financial, commodities and other markets, resulting in global recessionary conditions, which could adversely affect our business, future results of operations and financial condition.”

~~Future sales or distributions of our securities could cause the market price for our Class 2 common stock to fall significantly.~~

Sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the market perception that the holders of a large number of shares of our Class 2 common stock intend to sell our Class 2 common stock, could significantly reduce the market price of our Class 2 common stock.

Pursuant to the Downstream Merger, former Privateer Holdings stockholders who received shares of our common stock in the Downstream Merger entered into a lock-up agreement. Each Privateer Holdings equity holder who received shares of our stock in the Downstream Merger is subject to a lock-up allowing for the sale of such shares only under certain circumstances over a two-year period. During the first year following the closing of the Downstream Merger, unless otherwise approved by us, shares will be released only pursuant to certain offerings or sales arranged by and at our discretion. We may also determine to release shares from the lock-up in the absence of an offering or arranged sale if we determine it to be in the Company’s best interest, and we may treat the release of such shares as permitted sales.

On April 3, 2020, we released 11 million shares of our Class 2 common stock, and on June 5, 2020, we released 19.5 million shares of our Class 1 and Class 2 common stock from the restrictions under the Downstream Merger lock-up agreement. We cannot predict the effect, if any, that sales of those released shares or any future public sales of our securities or the availability of these securities for sale will have on the market price of our Class 2 common stock. In aggregate, 30.5 million shares of Class 1 and Class 2 common stock have been released from the lock-up restrictions of the Downstream Merger, representing approximately 40.2% of the originally locked-up shares (including for purposes of such percentage calculation shares that remain subject to escrow and/or subject to outstanding assumed stock options). The Downstream Merger agreement requires at least 50% of the locked-up shares to be released by the one-year anniversary of the closing of the Downstream Merger (December 12, 2020), which is approximately 7 million shares (with permitted sales and previously released shares being credited towards and included in such 50%). The remaining 50% of the shares subject to the lock-up restrictions are required to be released on an equal quarterly basis over the following 12 months, unless we choose to release them on a more accelerated schedule. The release of the remaining portion of shares subject to the lock-up on the described schedule, or on a more accelerated basis, could put significant downward pricing pressure on our stock. If the market price of our Class 2 common stock were to drop as a result, this might impede our ability to raise additional capital and might cause our remaining stockholders to lose all or part of their investment.

The terms of our outstanding warrants may limit our ability to raise additional equity capital or pursue acquisitions, which may result in us having insufficient funds to operate our business and significant dilution to existing stockholders.

On March 13, 2020, we entered into an underwriting agreement with Canaccord Genuity LLC relating to the issuance and sale of 7,250,000 shares of our Class 2 common stock, pre-funded warrants to purchase 11,750,000 shares of our Class 2 common stock and accompanying warrants to purchase 19,000,000 shares of our Class 2 common stock at a price to the public of $4.76 per share for Class 2 common stock and accompanying warrant and $4.7599 per pre-funded warrant and accompanying warrant. The accompanying warrants, or the warrants, are not exercisable until six months after the date of issuance. The issuance of shares of our Class 2 common stock and exercise of the pre-funded warrants thereafter resulted in an issuance of 19,000,000 additional shares of Class 2 common stock.

The warrants contain a price protection, or anti-dilution feature, pursuant to which, the exercise price of such warrants will be reduced to the consideration paid for, or the exercise price or conversion price of, as the case may be, any newly issued securities issued at a discount to the original warrant exercise price of $5.95 per share. The anti-dilution feature was approved by our stockholders, and, therefore, the exercise price of the warrants may end up being lower than $5.95 per share, which could result in significant incremental dilution to existing stockholders.

Additionally, so long as the warrants remain outstanding, we may only issue up to $20 million in aggregate gross proceeds under our at-the-market offering program at prices less than the exercise price of the warrants, and in no event more than $6 million per quarter at prices below the exercise price of the warrants, without triggering the warrant’s anti-dilution feature described in the paragraph immediately above. If our stock price were to remain below the warrant exercise price of $5.95 per share for an extended time, we may be forced to lower the warrant exercise price at unfavorable terms in order to fund our ongoing operations. See “The cannabis industry continues to face significant funding challenges, and we may not be able to secure adequate or reliable sources of funding required to operate our business or increase our production to meet consumer demand for our products.”

~~If securities or industry analysts do not publish research, or publish inaccurate or unfavorable research, about our business, our stock price and trading volume could decline.~~

The trading market for our Class 2 common stock depends, in part, on the research and reports that securities or industry analysts publish about us or our business. We do not have any control over these analysts. If one or more of the securities or industry analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. In addition, if our operating results fail to meet the forecast of analysts, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.

We may not have the ability to raise the funds necessary to settle conversions of the convertible notes in cash or to repurchase the convertible notes upon a fundamental change, and our future debt may contain limitations on our ability to pay cash upon conversion or repurchase of the convertible notes.

Holders of the convertible notes have the right to require us to repurchase their convertible notes upon the occurrence of a fundamental change at a fundamental change repurchase price equal to 100% of the principal amount of the convertible notes to be repurchased, plus accrued and unpaid interest, if any. In addition, upon conversion of the convertible notes, unless we elect to deliver solely shares of our Class 2 common stock to settle such conversion (other than paying cash in lieu of delivering any fractional share), we will be required to make cash payments in respect of the convertible notes being converted. However, we may not have enough available cash or be able to obtain financing at the time we are required to make repurchases of convertible notes surrendered. In addition, our ability to repurchase the convertible notes or to pay cash upon conversions of the convertible notes may be limited by law, by regulatory authority or by agreements governing our future indebtedness. Our failure to repurchase convertible notes at a time when the repurchase is required by the indenture or to pay any cash payable on future conversions of the convertible notes as required by the indenture would constitute a default under the indenture. A default under the indenture or the fundamental change itself could also lead to a default under agreements governing our existing or future indebtedness. If the repayment of the related indebtedness

were to be accelerated after any applicable notice or grace periods, we may not have sufficient funds to repay the indebtedness and repurchase the convertible notes or make cash payments upon conversions thereof.

~~The conditional conversion feature of the convertible notes, if triggered, may adversely affect our financial condition and operating results.~~

In the event the conditional conversion feature of the convertible notes is triggered, holders of convertible notes will be entitled to convert the convertible notes at any time during specified periods at their option. If one or more holders elect to convert their convertible notes, unless we elect to satisfy our conversion obligation by delivering solely shares of our Class 2 common stock (other than paying cash in lieu of delivering any fractional share), we would be required to settle a portion or all of our conversion obligation through the payment of cash, which could adversely affect our liquidity. In addition, even if holders of convertible notes do not elect to convert their convertible notes, we could be required under applicable accounting rules to reclassify all or a portion of the outstanding principal of the convertible notes as a current rather than long-term liability, which would result in a material reduction of our net working capital.

~~Our stockholders may be subject to dilution resulting from future offerings of common stock by us.~~

We may raise additional funds in the future by issuing common stock or equity-linked securities. Holders of our securities have no preemptive rights in connection with such further issuances. Our board of directors has the discretion to determine if an issuance of our capital stock is warranted, the price at which such issuance is to be effected and the other terms of any future issuance of capital stock. In addition, additional common stock will be issued by us in connection with the exercise of options or grant of other equity awards granted by us. Such additional equity issuances could, depending on the price at which such securities are issued, substantially dilute the interests of the holders of our existing securities.

~~Conversion of the convertible notes may dilute the ownership interest of our stockholders or may otherwise depress the price of our Class 2 common stock.~~

The conversion of some or all of the convertible notes may dilute the ownership interests of our stockholders. Upon conversion of the convertible notes, we have the option to pay or deliver, as the case may be, cash, shares of our Class 2 common stock, or a combination of cash and shares of our Class 2 common stock. If we elect to settle our conversion obligation in shares of our Class 2 common stock or a combination of cash and shares of our Class 2 common stock, any sales in the public market of our Class 2 common stock issuable upon such conversion could adversely affect prevailing market prices of our Class 2 common stock. In addition, the existence of the convertible notes may encourage short selling by market participants because the conversion of the convertible notes could be used to satisfy short positions, or anticipated conversion of the convertible notes into shares of our Class 2 common stock could depress the price of our Class 2 common stock.

~~It is not anticipated that any dividends will be paid to holders of our Class 2 common stock for the foreseeable future, if ever.~~

No dividends on our Class 2 common stock have been paid to date. We anticipate that, for the foreseeable future, we will retain future earnings and other cash resources for the operation and development of our business. The payment of any future dividends will be at the discretion of our board of directors after taking into account many factors, including our earnings, operating results, financial condition and current and anticipated cash needs. Further, our future ability to pay cash dividends on our Class 2 common stock is limited by the terms of the ~~Senior Credit Facility~~ ~~and cannot be paid without the consent of Bridging Finance Inc., as well as any future debt or preferred securities.~~

~~Provisions in our corporate charter documents could make an acquisition of us more difficult and may prevent attempts by our stockholders to replace or remove our current management.~~

Provisions in our corporate charter and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of us that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our Class 2 common stock, thereby depressing the market price of our Class 2 common stock. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Because our board of directors is responsible for appointing the members of our management team, these provisions could in turn affect any attempt by our stockholders to replace current members of our management team. Among others, these provisions include the following:

~~Certain jurisdictions may take positions adverse to investments in, or investors themselves, in cannabis companies.~~

Certain jurisdictions may prohibit or restrict its citizens or residents from investing in or transacting with companies involved in the cannabis industry, even if such companies only conduct business in jurisdictions where cannabis is legal. For example, if an investor in the United Kingdom profits from an investment in a cannabis producer or supplier, such investment may technically violate the United Kingdom Proceeds of Crime Act 2002. Similar prohibitions or restrictions may apply in other jurisdictions where cannabis has not been legalized. In addition, such prohibitions and restriction may limit your ability to receive dividends if such dividends were to be declared in the future. However, no dividends on our Class 2 common stock have been paid to date and we do not anticipate that, for the foreseeable future, we will pay cash dividends on our Class 2 common stock.

~~As a result of an investment in our securities, you could be prevented from entering the United States or become subject to a lifetime ban on entry into the~~ ~~United States.~~

United States Customs and Border Protection (“CBP”) has confirmed that border agents may seek to permanently ban any foreign visitor who admits to working or investing in the cannabis industry, or admits to having used cannabis, even though adult-use cannabis is now legal in Canada. CBP confirmed that investing even in publicly-traded cannabis companies is considered facilitation of illicit drug trade under CBP policy. This policy is limited to citizens of foreign countries and not citizens of the United States. Therefore, as a result of an investment in our securities, if you are not a citizen of the United States, you could be prevented from entering the United States or could become subject to a lifetime ban on entry into the United States.

~~Certain provisions in the indenture governing the convertible notes may delay or prevent an otherwise beneficial takeover attempt of us.~~

Certain provisions in the indenture governing the convertible notes may make it more difficult or expensive for a third party to acquire us. For example, the indenture governing the convertible notes requires us to repurchase the convertible notes for cash upon the occurrence of a fundamental change and, in certain circumstances, to increase the relevant conversion rate for a holder that converts its convertible notes in connection with a make-whole fundamental change. A takeover of us may trigger the requirement that we repurchase the convertible notes and/or increase the conversion rate, which could make it more costly for a potential acquirer to engage in such takeover. Such additional costs may have the effect of delaying or preventing a takeover of us that would otherwise be beneficial to investors.

Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware and the federal district courts of the United States of America will be the exclusive forums for substantially all disputes between us and our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

~~Our amended and restated certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for:~~

Our amended and restated certificate of incorporation further provides that the federal district courts of the United States of America will be the exclusive forum for resolving any complaint asserting a cause of action arising under the Securities Act. This exclusive forum provision would not apply to suits brought to enforce any liability or duty created by the Exchange Act or any other claim for which the federal courts have exclusive jurisdiction. To the extent that any such claims may be based upon federal law claims, Section 27 of the Exchange Act creates exclusive federal jurisdiction over all suits brought to enforce any duty or liability created by the Exchange Act or the rules and regulations thereunder. Furthermore, Section 22 of the Securities Act creates concurrent jurisdiction for federal and state courts over all suits brought to enforce any duty or liability created by the Securities Act or the rules and regulations thereunder. Investors cannot waive compliance with the federal securities laws and the rules and regulations thereunder.

Our restated certificate of incorporation also provides that any person or entity purchasing or otherwise acquiring any interest in shares of our capital stock will be deemed to have notice of and to have consented to this choice of forum provision. It is possible that a court of law could rule that the choice of forum provision contained in our restated certificate of incorporation is inapplicable or unenforceable if it is challenged in a proceeding or otherwise.

These exclusive-forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage lawsuits against us and our directors, officers and other employees. If a court were to find the exclusive-forum provision in our amended and restated certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business.

On October 13, 2021, Tilray entered into an assignment and assumption agreement with Double Diamond Holdings Ltd. (“DDH”), an Ontario corporation, pursuant to which, among other things, Tilray acquired from DDH a promissory note in the amount of CAD$34,300,000 (the “Note”) payable by 1974568 Ontario Limited (“Aphria Diamond”). DDH is a joint venturer with Aphria Inc. (Tilray’s wholly-owned subsidiary) in Aphria Diamond. As ~~previously disclosed under Subsequent Events in our Quarterly Report on Form 10-Q~~consideration for the ~~period ended June 30, 2020, filed with the SEC on August 10, 2020, in August 2020, the Company~~Note, Tilray issued ~~202,224~~ 2,677,596 shares of its Class 2 common stock ~~in connection~~to DDH.

Effective November 10, 2021, Tilray entered into a termination and settlement agreement with ABG Intermediate Holdings 2, LLC (“ABG”) and certain of its affiliates. Pursuant to this settlement agreement, the ~~termination~~Company issued 215,901 shares of ~~a supply contract with an unrelated third party.~~ ~~The issuance of the~~its Class 2 common stock ~~described above~~to ABG in exchange for the release of certain claims.

On December 1, 2021, the Company acquired all of the membership interests of Cheese Grits, LLC, a Georgia based company (the “SW Acquisition”) that owned the real estate utilized and previously leased by SweetWater Brewing Company. . As consideration for the SW Acquisition, the Company paid a purchase price at closing equal to $30,665,000, which was ~~exempt~~satisfied through the assumption of outstanding debt as well as the issuance of 843,687 shares of Tilray’s Class 2 common stock. On December 17, 2021, the Company issued an additional 82,224 Class 2 common shares as consideration for the SW Acquisition.

On December 7, 2021, the Company acquired all of the membership interests of Double Diamond Distillery LLC (d/b/a Breckenridge Distillery), a Colorado limited liability company (the “Breckenridge Acquisition”). As consideration for the Breckenridge Acquisition, the Company paid a purchase price in an aggregate amount equal to $102,900,000, which purchase price was satisfied through the issuance of 11,245,511 shares of Tilray’s Class 2 common shares to the selling unitholders.

On December 17, 2021, the Company acquired intellectual property and inventory relating to the Alpine and Green Flash craft brew brands from ~~registration under~~WC IPA LLC (the “Alpine Acquisition”). As consideration for the Alpine Acquisition, the Company paid a purchase price in an aggregate amount equal to $5,133,000 which purchase price was satisfied through the payment of cash and the issuance of 366,308 shares of Tilray’s Class 2 common shares.

Each of the foregoing issuances of Tilray’s Class 2 common stock was made in reliance on the exemption provided by Section 4(a)(2) of the Securities Act of 1933, as amended, ~~as a transaction by an issuer~~for the offer and sale of securities not involving a public ~~offering.~~ offering. No underwriter participated in the offer and sale of the shares issued pursuant to the foregoing issuances, and no commission or other remuneration was paid or given directly or indirectly in connection therewith.

* Schedules and certain other information have been omitted pursuant to Item 601(b)(2) of Regulations S-K. The registrant will furnish copies of any such schedules to the Securities and Exchange Commission upon request.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.


		Page
PART I.	FINANCIAL INFORMATION		1
Item 1.	~~Condensed Consolidated~~ Financial Statements (Unaudited)		1
	~~Condensed~~ Consolidated ~~Balance Sheets~~Statements of Financial Position (Unaudited)		1
	~~Condensed~~ Consolidated Statements of ~~Net Loss~~Income (Loss) and Comprehensive Loss (Unaudited)		2
	~~Condensed~~ Consolidated Statements of ~~Stockholders’~~Stockholders' Equity (Unaudited)		3
	~~Condensed~~ Consolidated Statements of Cash Flows (Unaudited)		4
	Notes to ~~Condensed~~ Consolidated Financial Statements (Unaudited)		5
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations		2723
Item 3.	Quantitative and Qualitative Disclosures About Market Risk		4238
Item 4.	Controls and Procedures		4338
PART II.	OTHER INFORMATION		4440
Item 1.	Legal Proceedings		4440
Item 1A.	Risk Factors		4640
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds		7342
Item 3.	Defaults Upon Senior Securities		7342
Item 4.	Mine Safety Disclosures		7342
Item 5.	Other Information		7342
Item 6.	Exhibits		7443
Signatures		76
			44


	September 30, 2020			December 31, 2019
Assets
Current assets
Cash and cash equivalents	$	155,205		$	96,791
Accounts receivable, net of allowance for credit losses of $826 and provision for sales returns of $1,212 (December 31, 2019 - $615 and $1,400, respectively)		24,805			36,202
Inventory		89,917			87,861
Prepayments and other current assets		28,154			38,173
Assets held for sale		6,797			—
Total current assets		304,878			259,027
Property and equipment, net		187,630			184,217
Operating lease, right-of-use assets		18,460			17,514
Intangible assets, net		180,853			228,828
Goodwill		159,595			163,251
Equity method investments		8,911			11,448
Other investments		22,710			24,184
Other assets		4,324			7,861
Total assets	$	887,361		$	896,330
Liabilities
Current liabilities
Accounts payable		26,137			39,125
Accrued expenses and other current liabilities		32,526			50,829
Accrued lease obligations		3,230			2,473
Warrant liability		71,636			—
Total current liabilities		133,529			92,427
Accrued lease obligations		30,075			29,407
Deferred tax liability		48,090			53,363
Convertible notes, net of issuance costs		438,154			430,210
Senior Facility, net of transaction costs		45,944			—
Other liabilities		4,852			5,652
Total liabilities	$	700,644		$	611,059
Commitments and contingencies (refer to Note 18)
Stockholders’ equity
Class 1 common stock ($0.0001 par value, 233,333,333 and 250,000,000 shares authorized, respectively; 0 and 16,666,667 shares issued and outstanding, respectively)		—			2
Class 2 common stock ($0.0001 par value; 500,000,000 shares authorized; 133,289,944 and 86,114,560 shares issued and outstanding, respectively)		13			9
Additional paid-in capital		911,171			705,671
Accumulated other comprehensive income		2,689			9,719
Accumulated deficit		(727,156	)		(430,130	)
Total stockholders’ equity		186,717			285,271
Total liabilities and stockholders’ equity	$	887,361		$	896,330

	November 30, 2021			May 31, 2021
Assets
Current assets
Cash and cash equivalents	$	331,783		$	488,466
Accounts receivable, net		84,575			87,309
Inventory		233,020			256,429
Prepaids and other current assets		57,340			48,920
Convertible notes receivable		1,560			2,485
Total current assets		708,278			883,609
Capital assets		604,249			650,698
Right-of-use assets		13,933			18,267
Intangible assets		1,450,015			1,605,918
Goodwill		2,814,163			2,832,794
Interest in equity investees		4,440			8,106
Long-term investments		168,244			17,685
Other assets		164			8,285
Total assets	$	5,763,486		$	6,025,362
Liabilities
Current liabilities
Bank indebtedness	$	8,736		$	8,717
Accounts payable and accrued liabilities		168,300			212,813
Contingent consideration		62,339			60,657
Warrant liability		40,455			78,168
Current portion of lease liabilities		3,588			4,264
Current portion of long-term debt		31,510			36,622
Total current liabilities		314,928			401,241
Long - term liabilities
Lease liabilities		49,265			53,946
Long-term debt		151,819			167,486
Convertible debentures		554,854			667,624
Deferred tax liability		219,311			265,845
Other liabilities		320			3,907
Total liabilities		1,290,497			1,560,049
Commitments and contingencies (refer to Note 17)
Shareholders' equity
Common stock ($0.0001 par value; 990,000,000 shares authorized; 463,802,393 and 265,423,304 shares issued and outstanding, respectively)		46			46
Additional paid-in capital		4,954,547			4,792,406
Accumulated other comprehensive income		9,595			152,668
Accumulated Deficit		(527,900	)		(486,050	)
Total Tilray shareholders' equity		4,436,288			4,459,070
Non-controlling interests		36,701			6,243
Total shareholders' equity		4,472,989			4,465,313
Total liabilities and shareholders' equity	$	5,763,486		$	6,025,362

	November 30, 2021		May 31, 2021
Plants	$	19,935	$	23,083
Dried cannabis		115,970		118,269
Cannabis trim		3,725		2,931
Cannabis derivatives		28,215		24,158
Cannabis vapes		3,193		3,791
Packaging and other inventory items		22,768		31,462
Wellness inventory		12,412		15,171
Beverage alcohol inventory		4,792		5,402
Distribution inventory		22,010		32,162
Total	$	233,020	$	256,429

	November 30, 2021			May 31, 2021
Land	$	26,779		$	28,549
Production facility		411,611			346,510
Equipment		236,239			215,408
Leasehold improvement		7,444			17,059
ROU-assets under finance lease		34,798			34,726
Construction in progress		14,949			85,322
	$	731,820		$	727,574
Less: accumulated amortization		(127,571	)		(76,876	)
Total	$	604,249		$	650,698

Large accelerated filer	☒	☒	Accelerated filer	☐

Non-accelerated filer	☐	☐	Smaller reporting company	☐

Emerging growth company		☐


	Three months ended September 30,						Nine months ended September 30,
	2020			2019			2020			2019
Revenue	$	51,406		$	51,101		$	153,922		$	120,043
Cost of sales
Product costs		34,224			35,047			108,616			85,806
Inventory valuation adjustments		13,443			201			36,116			726
Gross profit		3,739			15,853			9,190			33,511
General and administrative expenses		12,665			20,122			49,030			49,618
Sales and marketing expenses		10,000			16,974			40,709			39,161
Research and development expenses		921			2,315			2,831			4,891
Stock-based compensation expenses		8,080			8,644			23,404			22,303
Depreciation and amortization expenses		3,425			3,200			10,353			7,457
Impairment of assets		—			—			58,210			—
Acquisition-related expenses (income), net		—			(13,454	)		—			(6,566	)
Loss from equity method investments		1,420			1,837			4,495			1,837
Operating loss		(32,772	)		(23,785	)		(179,842	)		(85,190	)
Foreign exchange (gain) loss, net		(9,319	)		2,585			5,424			1,153
Change in fair value of warrant liability		(31,913	)		—			51,275			—
Interest expenses, net		10,437			8,680			30,147			26,005
Finance income from ABG		—			(210	)		—			(557	)
Other expense (income), net		(38	)		(1,116	)		4,944			(6,185	)
Loss before income taxes		(1,939	)		(33,724	)		(271,632	)		(105,606	)
Deferred income tax expenses (recoveries)		134			2,432			(4,013	)		(3,987	)
Current income tax expenses (benefit)		243			195			505			402
Net loss	$	(2,316	)	$	(36,351	)	$	(268,124	)	$	(102,021	)
Net loss per share - basic and diluted		(0.02	)		(0.37	)		(2.23	)		(1.05	)
Weighted average shares used in computation of net loss per share - basic and diluted		129,100,909			98,130,507			120,128,856			96,742,626
Net loss	$	(2,316	)	$	(36,351	)	$	(268,124	)	$	(102,021	)
Foreign currency translation gain (loss), net		2,265			(4,863	)		(7,184	)		(2,414	)
Unrealized gain on available-for-sale debt securities		193			11			154			80
Other comprehensive income (loss)		2,458			(4,852	)		(7,030	)		(2,334	)
Comprehensive income (loss)	$	142		$	(41,203	)	$	(275,154	)	$	(104,355	)

	Common stock					Additional			Accumulated other						Total
	Number of shares			Amount		paid-in capital			comprehensive (loss) income			Accumulated deficit			stockholders' equity (deficit)
Balance as of December 31, 2018		93,170,867		$	10	$	302,057		$	3,763		$	(108,177	)	$	197,653
Cumulative effect adjustment from transition to ASU 2016-01		—			—		—			803			(803	)		—
Cumulative effect adjustment from transition to ASC 842		—			—		—			—			19			19
Shares issued for Natura acquisition		180,332			—		15,100			—			—			15,100
Shares issued for Manitoba Harvest acquisition		1,209,946			—		96,844			—			—			96,844
Shares issued for ABG Profit Participation Agreement		1,680,214			—		125,097			—			—			125,097
ABG finance receivable, net of finance income of $2,700		—			—		(30,292	)		—			—			(30,292	)
Shares issued under stock-based compensation plans		545,000			—		931			—			—			931
Shares issued for employee compensation		11,868			—		649			—			—			649
Stock-based compensation expenses		—			—		5,736			—			—			5,736
Other comprehensive loss		—			—		—			(456	)		—			(456	)
Net loss		—			—		—			—			(29,369	)		(29,369	)
Balance as of March 31, 2019		96,798,227		$	10	$	516,122		$	4,110		$	(138,330	)	$	381,912
Shares issued under stock-based compensation plans		530,943			—		3,483			—			—			3,483
Shares issued for investment acquisition		28,361			—		70			—			—			70
Stock-based compensation expenses		—			—		7,923			—			—			7,923
Other comprehensive income		—			—		—			2,974			—			2,974
Net loss		—			—		—			—			(36,301	)		(36,301	)
Balance at June 30, 2019		97,357,531		$	10	$	527,598		$	7,084		$	(174,631	)	$	360,061
Shares issued for common stock at-the-market, net of issuance costs		1,344,166			—		37,445			—			—			37,445
Shares issued for Manitoba Harvest acquisition		899,306			—		31,866			—			—			31,866
Shares issued for investments and S&S acquisition		433,338			—		14,438			—			—			14,438
Finance income for receivable for ABG Profit Participation Arrangement		—			—		1,393			—			—			1,393
Shares issued under stock-based compensation plans		237,402			—		2,967			—			—			2,967
Stock-based compensation expense		—			—		8,644			—			—			8,644
Other comprehensive loss		—			—		—			(4,852	)		—			(4,852	)
Net loss		—			—		—			—			(36,351	)		(36,351	)
Balance as of September 30, 2019		100,271,743		$	10	$	624,351		$	2,232		$	(210,982	)	$	415,611
Balance at December 31, 2019		102,781,225		$	11	$	705,671		$	9,719		$	(430,130	)	$	285,271
Proceeds from ABG Profit Participation Arrangement		—			—		1,353			—			—			1,353
Write-off of ABG finance receivable		—			—		28,900			—			(28,900	)		—
Escrow shares released from downstream merger		(7,659	)		—		(151	)		—			—			(151	)
Shares issued for common stock at-the-market, net of issuance costs		2,265,115			—		27,027			—			—			27,027
Shares issued for investments		6,934			—		—			—			—			—
Shares issued under stock-based compensation plans		597,868			—		1,079			—			—			1,079
Stock-based compensation expenses		—			—		7,677			—			—			7,677
Shares issued under registered offering, net of issuance costs		7,250,000			1		19,827			—			—			19,828
Shares issued for exercise of pre-funded warrants		11,750,000			1		49,053			—			—			49,054
Other comprehensive loss		—			—		—			(16,707	)		—			(16,707	)
Net loss		—			—		—			—			(184,123	)		(184,123	)
Balance at March 31, 2020		124,643,483		$	13	$	840,436		$	(6,988	)	$	(643,153	)	$	190,308
Escrow shares released from downstream merger		(42,785	)		—		(378	)		—			—			(378	)
Shares issued for common stock at-the-market, net of issuance costs		447,289			—		3,842			—			—			3,842
Shares issued under stock-based compensation plans		883,425			—		4,536			—			—			4,536
Stock-based compensation expenses		—			—		7,647			—			—			7,647
Other comprehensive income		—			—		—			7,219			—			7,219
Net loss		—			—		—			—			(81,687	)		(81,687	)
Balance at June 30, 2020		125,931,412			13		856,083			231			(724,840	)		131,487
Shares issued for common stock at-the-market, net of issuance costs		6,781,090			—		45,230			—			—			45,230
Shares issued under stock-based compensation plans		375,218			—		286			—			—			286
Stock-based compensation expenses		—			—		8,080			—			—			8,080
Shares issued for contract settlement		202,224			—		1,492			—			—			1,492
Other comprehensive income		—			—		—			2,458			—			2,458
Net loss		—			—		��			—			(2,316	)		(2,316	)
Balance at September 30, 2020		133,289,944			13		911,171			2,689			(727,156	)		186,717

	Three months ended September 30, 2019						Nine months ended September 30, 2019
	Net loss			Other comprehensive (loss) income			Net (loss) income			Other comprehensive (loss) income
Unadjusted	$	(35,678	)	$	(5,164	)	$	(101,032	)	$	(2,069	)
Impact of adoption of accounting standards:
ASU 2016-01		(312	)		312			265			(265	)
ASC 842		(32	)		—			(157	)		—
ASU 2018-07		(329	)		—			(1,097	)		—
ASC 606		—			—			—			—
Adjusted	$	(36,351	)	$	(4,852	)	$	(102,021	)	$	(2,334	)

													Intellectual
	Customer												property,
	relationships				Licenses,				Non-				trademarks,				Total
	& distribution				permits &				compete				know how				intangible
	channel				applications				agreements				& brands				assets
Cost
At May 31, 2021	$	239,810				414,930				12,453				990,917			$	1,658,110
Additions		—				182				—				856				1,038
Effect of foreign exchange		(9,300	)			(17,346	)			(659	)			(51,738	)			(79,043	)
At August 31, 2021	$	230,510				397,766				11,794				940,035			$	1,580,105
Additions		—				26				—				97				123
Effect of foreign exchange		(6,240	)			(11,776	)			—				(10,099	)			(28,115	)
At November 30, 2021	$	224,270				386,016				11,794				930,033			$	1,552,113
Accumulated amortization
At May 31, 2021	$	18,302				1,167				4,299				28,424			$	52,192
Amortization		9,466				116				833				14,684				25,099
At August 31, 2021	$	27,768				1,283				5,132				43,108			$	77,291
Amortization		10,904				122				1,188				12,593				24,807
At November 30, 2021	$	38,672				1,405				6,320				55,701			$	102,098
Net book value at May 31, 2021	$	221,508		0	$	413,763		0	$	8,154		0	$	962,493		0	$	1,605,918
Net book value at August 31, 2021	$	202,742			$	396,483			$	6,662			$	896,927			$	1,502,814
Net book value at November 30, 2021	$	185,598		0	$	384,611		0	$	5,474		0	$	874,332		0	$	1,450,015

	Amortization
2022 (remaining six months)	$	35,746
2023		63,770
2024		57,094
2025		56,091
2026		56,091
Thereafter		797,778
Total	$	1,066,570

	As of September 30, 2020
Assets classified as held for sale
Land and buildings	$	6,797
Cultivation license		—
Total assets held for sale	$	6,797

	September 30, 2020		December 31, 2019
Raw materials	$	15,338	$	15,926
Work-in-process		59,863		53,973
Finished goods		14,716		17,962
Total	$	89,917	$	87,861

	September 30, 2020		December 31, 2019
Deposits	$	15,325	$	25,490
Prepayments		6,854		5,847
Taxes receivable		5,975		6,165
ABG finance receivable - current		—		671
Total	$	28,154	$	38,173

	September 30, 2020		December 31, 2019
Equity investments at fair value	$	2,207	$	4,183
Equity investments under measurement alternative		14,738		14,954
Debt securities classified under available-for-sale method		5,765		5,047
Total other investments	$	22,710	$	24,184

	November 30,		May 31,
	2021		2021
Assets
Cash and cash equivalents	$	375,673	$	375,673
Accounts receivable		28,054		28,054
Inventory		68,547		76,547
Prepaids and other current assets		2,960		8,960
Capital assets		136,637		136,637
Right-of-use assets, operating leases		12,606		12,606
Definite-lived intangible assets (estimated useful life)
Distribution channel (15 years)		404,000		404,000
Customer relationships (15 years)		59,000		59,000
Know how (5 years)		115,000		115,000
Brands (10 to 25 years)		301,000		301,000
Indefinite-lived intangible assets
Licenses		200,000		200,000
Goodwill-provisional		2,232,941		2,221,613
Other assets		22,879		22,879
Total assets		3,959,297		3,961,969
Liabilities
Accounts payable		62,292		62,292
Accrued expenses and other current liabilities		85,120		85,120
Accrued lease obligations		21,962		21,962
Warrant liability		79,402		79,402
Deferred tax liability		233,719		236,391
Convertible notes		267,862		267,862
Other liabilities		4,034		4,034
Total liabilities		754,391		757,063
Net assets acquired	$	3,204,906	$	3,204,906

	Approximate	Carrying value		(Loss) gain from equity method investments for the nine months ended
	ownership %	September 30, 2020		September 30, 2020
Investment in Fluent	50%	$	5,147	$	(4,725	)
Investment in Cannfections	50%		3,764		230
Total equity method investments		$	8,911	$	(4,495	)


Allowance for credit losses, January 1, 2020	$	615
Provision for expected credit losses ⁽¹⁾		288
Write-offs charged against allowance		(74	)
Recoveries of amounts previously written off		—
Foreign currency translation adjustment		(3	)
Allowance for credit losses, September 30, 2020	$	826
Accounts receivable balance before allowance for credit losses and provision for sales returns, September 30, 2020	$	26,843

Expected term	0.4 to 6.7 years
Expected volatility		70	%
Effective interest rate		20.4	%
Expected dividend yield		0.0	%
Probability of conversion	0% to 60%
Strike price	$0.15 to $4.29
Fair value of common stock	$	0.22

	September 30, 2020		December 31, 2019
Fair value	$	1,124	$	945
Unrealized loss	$	148	$	302

	Hemp			Cannabis			Total
Balance as of December 31, 2019	$	133,314		$	29,937		$	163,251
Foreign currency translation adjustment		(2,971	)		(685	)		(3,656	)
Balance as of September 30, 2020	$	130,343		$	29,252		$	159,595

	September 30,								December 31,
	2020								2019
	Cost		Accumulated Amortization		Impairment		Net		Cost		Accumulated Amortization		Impairment		Net
Definite-lived intangible assets:
Patent	$	669	$	131	$	538	$	—	$	716	$	99	$	—	$	617
Customer relationships		132,837		13,241		—		119,596		135,953		7,132		—		128,821
Developed technology		6,912		1,094		—		5,818		7,074		590		—		6,484
Websites		5,126		3,921		—		1,205		5,157		3,331		—		1,826
Trademarks and licenses		9,052		1,293		7,650		109		9,135		925		—		8,210
Total		154,596		19,680		8,188		126,728		158,035		12,077		—		145,958
Indefinite-lived intangible assets:
Cultivation license		10,239		—		10,239		—		10,689		—		—		10,689
Alef license		—		—		—		—		4,086		—		4,086		—
Trademarks		54,125		—		—		54,125		55,416		—		—		55,416
Rights under ABG Profit Participation Arrangement		16,765		—		16,765		—		119,366		—		102,601		16,765
Total		81,129		—		27,004		54,125		189,557		—		106,687		82,870
Total intangible assets		235,725		19,680		35,192		180,853	$	347,592	$	12,077	$	106,687	$	228,828

Year ending December 31,	Amortization
2020 (remaining three months)	$	2,522
2021		9,801
2022		9,306
2023		9,078
2024		9,078
Thereafter		86,943
Total	$	126,728

	September 30, 2020		December 31, 2019
Accrued interest on convertible notes	$	11,875	$	5,938
Accrued payroll and employment related withholding taxes		10,709		24,765
Other accrued expenses and current liabilities		8,031		17,032
ABG finance liability - current		1,125		1,500
Accrued interest on Senior Facility		422		—
Accrued legal and professional fees		364		1,174
Contingent consideration for acquisitions		—		420
Total accrued expenses and other current liabilities	$	32,526	$	50,829


Opening Balance as of January 1, 2020	$	—
Additional charges		3,575
Less payments made to employees		(3,393	)
Closing Balance as of September 30, 2020	$	182

	September 30, 2020			December 31, 2019
5.00% Convertible Notes	$	475,000		$	475,000
Unamortized discount		(28,133	)		(34,219	)
Unamortized transaction costs		(8,713	)		(10,571	)
Net carrying amount	$	438,154		$	430,210

	September 30, 2020
Senior Facility	$	48,299
Unamortized transaction costs		(2,355	)
Net carrying amount	$	45,944
Less: current portion of Senior Facility		—
Total noncurrent portion of Senior Facility	$	45,944

	Three months ended September 30, 2020		Nine months ended September 30, 2020
Contractual interest at Canadian prime plus 8.05%	$	1,260	$	2,970
Amortization of transaction costs		407		943
Total	$	1,667	$	3,913

Description	Classification	Exercise price		Expiration date	Balance December 31, 2019		Issued		Exercised			Balance September 30, 2020
Pre-Funded Warrants	Liability	$	0.0001	March 17, 2025		—		11,750,000		(11,750,000	)		—
Warrants	Liability	$	5.95	March 17, 2025		—		19,000,000		—			19,000,000
				Total		—		30,750,000		(11,750,000	)		19,000,000

Risk-free interest rate		0.35	%
Expected volatility		100	%
Expected term	5 years
Expected dividend yield		0	%
Strike price	$	5.95
Fair value of common stock	$	4.85

Risk-free interest rate		1.43	%
Expected volatility		70	%
Expected term	2.5 years
Expected dividend yield		0.0	%

	Par Value		Authorized		Voting Rights
Class 1 common stock	$	0.0001		233,333,333	10 votes for each share
Class 2 common stock	$	0.0001		500,000,000	1 vote for each share
Preferred stock	$	0.0001		10,000,000	N/A

	Stock options			Weighted- average exercise price		Weighted- average remaining contractual term (years)		Aggregate intrinsic value
Balance December 31, 2019		3,014,004		$	3.04		5.8	$	44,108
Exercised		(528,261	)		1.15
Forfeited		(62,153	)		4.44
Cancelled		(125,999	)		3.30
Balance September 30, 2020		2,297,591		$	3.38		3.8	$	32,717
Vested and expected to vest, September 30, 2020		2,299,283		$	3.37		3.8	$	32,742
Vested and exercisable, September 30, 2020		2,198,632		$	3.22		3.7	$	31,750

			Balance							Balance
	Classification	Exercise Price	May 31, 2021		Issued		Exercised/Expired			November 30, 2021
Expiration date – September 26, 2021	Equity	3.08		166,000		—		(166,000	)		—
Expiration date – January 30, 2022	Equity	9.08		5,828,651		—		—			5,828,651
Expiration date – March 17, 2025	Liability	5.95		6,209,000		—		—			6,209,000
				12,203,651		—		(166,000	)		12,037,651

	November 30, 2021					November 30, 2020
				Weighted				Weighted
	Number of			average		Number of		average
	warrants			price		warrants		price
Outstanding, opening		12,203,651		$	7.41		5,994,651	$	8.91
Exercised during the period		0			0		0		0
Issued during the period		0			0		0		0
Cancelled during the period		0			0		0		0
Expired during the period		(166,000	)	$	3.08		0		0
Outstanding, ending		12,037,651		$	7.47		5,994,651	$	8.91